Processing 00000000.tx.1: Localization of Structural Elements of Bee Venom Phospholipase A2 Involved in N-type Receptor Binding and Neurotoxicity* (Received for publication, October 4,1996, and in revised form, December 2,1996) Jean-Paul Nicolas , Ying Lin , Grard Lambeau **, Farideh Ghomashchi , Michel Lazdunski and Michael H. 

Phrase: "Localization of Structural Elements of Bee Venom Phospholipase A2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0475264:Localisation [Functional Concept]
   742   C1744691:localisation [Biologic Function]

Phrase: "Involved in N-type Receptor Binding"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0597358:Receptor Binding [Molecular Function]
   753   C0243122:binding [Functional Concept]
   753   C0332307:Type [Qualitative Concept]
   753   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]
   753   C1314939:Involved [Functional Concept]
   753   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "Neurotoxicity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0235032:Neurotoxicity [Injury or Poisoning]

Phrase: "*"

Phrase: "("

Phrase: "Received for publication,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0034036:Publication [Intellectual Product,Manufactured Object]
   790   C0034037:Publication [Occupational Activity]
   790   C1514756:Received [Qualitative Concept]
   790   C1704324:Publication [Intellectual Product]

Phrase: "October 4,"

Phrase: "1996,"

Phrase: "and in revised form,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0348078:Form [Qualitative Concept]
   770   C0376315:Form [Manufactured Object]
   770   C1515981:And [Idea or Concept]
   770   C1522492:Form [Functional Concept]
   770   C1527075:Revised [Therapeutic or Preventive Procedure]

Phrase: "December 2,"

Phrase: "1996"

Phrase: ")"

Phrase: "Jean-Paul Nicolas ,"

Phrase: "Ying Lin ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0861352:LIN [Neoplastic Process]

Phrase: "Grard Lambeau"

Phrase: "*"

Phrase: "*,"

Phrase: "Farideh Ghomashchi ,"

Phrase: "Michel Lazdunski"

Phrase: "and"

Phrase: "Michael H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.2: Gelb ** From the Institut de Pharmacologie Molculaire et Cellulaire, CNRS, 660Route des Lucioles, Sophia Antipolis, 06560Valbonne, France and the Departments of Chemistry and Biochemistry, University of Washington, Seattle,Washington98195-1700 ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION FOOTNOTES Acknowledgments REFERENCES ABSTRACT We have shown previously that neurotoxic venom secretory phospholipases A2 (sPLA2s) have specific receptors in brain membranes called N-type receptors that are likely to play a role in the molecular events leading to neurotoxicity of these proteins. 

Phrase: "Gelb"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0165519:GELB [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1334523:GELB [Gene or Genome]
  1000   C1708832:GELB [Gene or Genome]

Phrase: "*"

Phrase: "*"

Phrase: "From the Institut de Pharmacologie Molculaire et Cellulaire,"

Phrase: "CNRS,"

Phrase: "660Route des Lucioles,"

Phrase: "Sophia Antipolis,"

Phrase: "06560Valbonne,"

Phrase: "France"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016674:France [Geographic Area]

Phrase: "and"

Phrase: "the Departments of Chemistry"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C1704729:Department [Organization]

Phrase: "and"

Phrase: "Biochemistry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005477:Biochemistry [Occupation or Discipline]

Phrase: "University of Washington,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0041740:University [Manufactured Object,Organization]
   827   C0043038:Washington [Geographic Area]

Phrase: "Seattle,"

Phrase: "Washington98195-1700 ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION FOOTNOTES Acknowledgments"

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "ABSTRACT"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "We"

Phrase: "have"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "previously"

Phrase: "that neurotoxic venom secretory phospholipases A2 (sPLA2s)"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   884   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   840   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "have"

Phrase: "specific receptors in brain membranes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   781   C0230664:membrane receptors [Receptor]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "called"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0679006:Call [Mental Process]
   966   C1947967:Call [Functional Concept]

Phrase: "N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "that"

Phrase: "are"

Phrase: "likely to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332148:Likely [Qualitative Concept]
   861   C0750492:Likely [Idea or Concept]

Phrase: "play"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:play [Finding]

Phrase: "a role in the molecular events"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "leading to neurotoxicity of these proteins."
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   753   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C0235032:Neurotoxicity [Injury or Poisoning]
   753   C0332152:Leading [Temporal Concept]
   753   C1522538:Leading [Functional Concept]
   719 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   719 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   719 E C2348269:Lead [Element, Ion, or Isotope]
   719 E C3275067:LEAD [Therapeutic or Preventive Procedure]
Processing 00000000.tx.3: The sPLA2 found in honey bee venom is neurotoxic and binds to this receptor with high affinity. 

Phrase: "The sPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1418616:SPLA2 [Gene or Genome]
  1000   C1706169:sPLA2 [Gene or Genome]

Phrase: "found in honey bee venom"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   862   C0440459:Honey bee venom [Hazardous or Poisonous Substance,Organic Chemical]
   806   C0004920:Bee Venom [Biologically Active Substance,Hazardous or Poisonous Substance]
   806   C0323351:Honey bee [Eukaryote]
   806   C0939871:honey bee [Organic Chemical,Pharmacologic Substance]
   760   C0004923:Bee [Eukaryote]
   760   C0019906:Honey [Food]
   760   C0042479:Venom [Hazardous or Poisonous Substance]
   760   C0150312:Found [Quantitative Concept]
   760   C1365952:HONEY [Food]
   726 E C0243095:Find [Finding]

Phrase: "is"

Phrase: "neurotoxic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0235032:Neurotoxicity [Injury or Poisoning]

Phrase: "and"

Phrase: "binds to this receptor"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   770   C1145667:Bind [Activity]
   770   C1167622:bind [Molecular Function]

Phrase: "with high affinity."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0205250:High [Qualitative Concept]
   861   C1299351:High [Qualitative Concept]
   861   C1510827:Affinity [Natural Phenomenon or Process]
   861   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.4: In this paper, we have used a number of mutants of bee venom sPLA2 produced in Escherichia coli to determine the structural elements of this protein that are involved in its binding to N-type receptors. 

Phrase: "In this paper,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0030351:Paper [Manufactured Object]
  1000   C1547566:Paper [Idea or Concept]

Phrase: "we"

Phrase: "have"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a number of mutants of bee venom sPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0237753:*Number [Quantitative Concept]
   744   C0449788:Number [Quantitative Concept]

Phrase: "produced in Escherichia coli to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0014834:Escherichia coli [Bacterium]
   760   C0014833:Escherichia [Bacterium]

Phrase: "determine"

Phrase: "the structural elements of this protein"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0013879:Elements [Element, Ion, or Isotope]
   719 E C1705248:Element [Conceptual Entity]

Phrase: "that"

Phrase: "are"

Phrase: "involved in its binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]
   770   C1314939:Involved [Functional Concept]

Phrase: "to N-type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.5: Mutations in the interfacial binding surface, in the Ca2+-binding loop and in the hydrophobic channel lead to a dramatic decrease in binding to N-type receptors, whereas mutations of surface residues localized in other parts of the sPLA2 structure do not significantly modify the binding properties. 

Phrase: "Mutations in the interfacial binding surface,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0026882:Mutations [Genetic Function]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "in the Ca2+-binding loop"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0243122:binding [Functional Concept]
   827   C0419518:Loop [Medical Device]
   827   C0445022:Loop [Spatial Concept]
   827   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1145667:Binding [Activity]
   827   C1167622:Binding [Molecular Function]

Phrase: "and in the hydrophobic channel"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0439799:Channel [Spatial Concept]
   760   C0598629:Hydrophobic [Qualitative Concept]
   760   C1515981:And [Idea or Concept]
   760   C1706095:Channel [Conceptual Entity]

Phrase: "lead to a dramatic decrease"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0392756:Decrease [Qualitative Concept]
   760   C0547047:Decrease [Quantitative Concept]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "in binding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0243122:binding [Functional Concept]
  1000   C1145667:Binding [Activity]
  1000   C1167622:Binding [Molecular Function]

Phrase: "to N-type receptors,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "whereas"

Phrase: "mutations of surface residues"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0026882:Mutations [Genetic Function]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "localized in other parts of the sPLA2 structure"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   754   C1292711:Part of [Spatial Concept]
   750   C0442052:Part structure [Spatial Concept]
   744   C0392752:Localized [Spatial Concept]
   744   C0449719:parts [Spatial Concept]
   744   C0678594:Structure [Spatial Concept]
   744   C1418616:SPLA2 [Gene or Genome]
   744   C1706169:sPLA2 [Gene or Genome]
   744   C1709471:PARTS [Quantitative Concept]

Phrase: "do"

Phrase: "not significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "modify"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392747:MODIFY [Functional Concept]

Phrase: "the binding properties."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0871161:properties [Qualitative Concept]
   861   C1292721:properties [Functional Concept]
   827 E C1882134:Property [Conceptual Entity]
   827 E C2347695:Property [Entity]
Processing 00000000.tx.6: Neurotoxicity experiments show that mutants with low affinity for N-type receptors are devoid of neurotoxic properties, even though some of them retain high enzymatic activity. 

Phrase: "Neurotoxicity experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "that mutants with low affinity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "for N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "are"

Phrase: "devoid of neurotoxic properties,"

Phrase: "even"

Phrase: "though"

Phrase: "some of them"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205392:Some [Quantitative Concept]
   790   C3540770:Some [Intellectual Product]

Phrase: "retain"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333118:Retain [Functional Concept]

Phrase: "high enzymatic activity."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]
Processing 00000000.tx.7: These results provide further evidence for the involvement of N-type receptors in neurotoxic processes associated with venom sPLA2s and identify the surface region surrounding the hydrophobic channel of bee venom sPLA2 as the N-type receptor recognition domain. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "further evidence for the involvement of N-type receptors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   762   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "in neurotoxic processes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1184743:Process [Body Part, Organ, or Organ Component]
   827   C1522240:Process [Phenomenon or Process]

Phrase: "associated with venom sPLA2s"
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   833   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0332281:Associated with [Qualitative Concept]
           Associated
   756 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   756 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0042479:Venom [Hazardous or Poisonous Substance]
   753   C1327616:Secretory [Cell Function]
   719 E C0750490:Associate [Idea or Concept]
   719 E C1706221:Associate [Professional or Occupational Group]

Phrase: "and"

Phrase: "identify"

Phrase: "the surface region"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C1268222:Surface region [Body Location or Region]
   861   C0017446:Region [Geographic Area]
   861   C0205147:Region [Spatial Concept]
   789 E C0205276:Regional [Spatial Concept]
   789 E C1947913:Regional [Spatial Concept]

Phrase: "surrounding"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1282914:Surrounding [Spatial Concept]

Phrase: "the hydrophobic channel of bee venom sPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0439799:Channel [Spatial Concept]
   748   C1706095:Channel [Conceptual Entity]

Phrase: "as the N-type receptor recognition domain."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   897   C1513868:N Domain [Amino Acid Sequence]
   804   C1880389:Domain [Functional Concept]
   804   C1883221:Domain [Conceptual Entity]
   804   C3541951:Domain [Intellectual Product]
Processing 00000000.tx.8: INTRODUCTION Secretory phospholipases A2 (sPLA2s,1 14kDa) catalyze the hydrolysis of the sn-2 position of glycerophospholipids to yield fatty acids and lysophospholipids (1-3). 

Phrase: "INTRODUCTION Secretory phospholipases A2"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   923   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(sPLA2s,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   867 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   867 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "1 14kDa"

Phrase: ")"

Phrase: "catalyze"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0007382:catalyse [Natural Phenomenon or Process]

Phrase: "the hydrolysis of the sn-2 position of glycerophospholipids to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0020291:Hydrolysis [Natural Phenomenon or Process]

Phrase: "yield"

Phrase: "fatty acids"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0015684:Fatty Acids [Lipid]
   861   C0001128:Acids [Chemical]
   827 E C0202406:Acid [Laboratory Procedure]

Phrase: "and"

Phrase: "lysophospholipids"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0024367:Lysophospholipids [Lipid]
  1000   C0066772:lysophospholipids [Lipid]

Phrase: "(1-3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2827734:1+ [Quantitative Concept]
   861   C2981698:1+ [Classification]

Phrase: ")."
Processing 00000000.tx.9: They are found in mammalian tissues and in the venoms of a wide range of organisms (insects, reptiles, amphibians, arachnids, coelenterates). 

Phrase: "They"

Phrase: "are"

Phrase: "found in mammalian tissues"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0024660:Mammalian [Mammal]
   770   C0040300:Tissues [Tissue]
   770   C0150312:Found [Quantitative Concept]
   737 E C0243095:Find [Finding]
   737 E C1547928:Tissue [Intellectual Product]

Phrase: "and in the venoms of a wide range of organisms"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   739   C0029235:Organisms [Organism]
   739   C0042479:Venoms [Hazardous or Poisonous Substance]
   739   C0332464:Wide [Spatial Concept]
   739   C1514721:Range [Quantitative Concept]
   739   C1515981:And [Idea or Concept]
   739   C1692334:venoms [Intellectual Product]
   739   C2348147:Range [Quantitative Concept]
   739   C3542016:Range [Intellectual Product]

Phrase: "(insects,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0021585:Insects [Eukaryote]
   966 E C0770740:INSECT [Pharmacologic Substance]
   966 E C1546678:Insect [Intellectual Product]

Phrase: "reptiles,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035161:Reptiles [Reptile]

Phrase: "amphibians,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0002668:Amphibians [Amphibian]

Phrase: "arachnids,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003704:Arachnids [Eukaryote]

Phrase: "coelenterates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0009222:Coelenterates [Eukaryote]

Phrase: ")."
Processing 00000000.tx.10: Most sPLA2s require millimolar concentrations of Ca2+ as a catalytic cofactor and show broad specificity for phospholipids with different polar head groups and fatty acyl chains (2, 3). 

Phrase: "Most sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   923   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "require"

Phrase: "millimolar concentrations of Ca2+"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0086045:Concentrations [Mental Process]
   737 E C1446561:Concentration [Quantitative Concept]

Phrase: "as a catalytic cofactor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0178555:Cofactor [Biologically Active Substance]

Phrase: "and"

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "broad specificity for phospholipids"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0037791:Specificity [Quantitative Concept]
   770   C1511884:Specificity [Quantitative Concept]

Phrase: "with different polar head groups"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   812   C0018670:Head [Body Location or Region]
   812   C0441833:Group [Idea or Concept]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1281590:Head [Body Part, Organ, or Organ Component]
   812   C1552516:Group [Health Care Related Organization]
   812   C1552839:groups [Idea or Concept]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
   812   C1706305:Head [Manufactured Object]
   756 E C0205096:Cephalic [Spatial Concept]

Phrase: "and"

Phrase: "fatty acyl chains"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0337112:chains [Manufactured Object]
   827   C1524075:Chains [Idea or Concept]

Phrase: "(2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")."
Processing 00000000.tx.11: sPLA2s have been classified into three main groups according to their primary structure, including the location of their disulfide bridges (2, 4, 5). 

Phrase: "sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   867 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   867 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "have"

Phrase: "been"

Phrase: "classified into three main groups"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   760   C0008902:Classified [Classification]
   760   C0205225:Main [Qualitative Concept]
   760   C0205449:Three [Quantitative Concept]
   760   C0441833:Group [Idea or Concept]
   760   C0687744:group [Population Group]
   760   C1257890:Group [Population Group]
   760   C1542147:Main [Qualitative Concept]
   760   C1552516:Group [Health Care Related Organization]
   760   C1552839:groups [Idea or Concept]
   760   C1705428:Group [Conceptual Entity]
   760   C1705429:Group [Population Group]

Phrase: "according to their primary structure,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205225:Primary [Qualitative Concept]
   861   C0439631:Primary [Therapeutic or Preventive Procedure]
   861   C0678594:Structure [Spatial Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "the location of their disulfide bridges"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0450429:Location [Spatial Concept]
   753   C1515974:Location [Body Location or Region]

Phrase: "(2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "4,"

Phrase: "5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.12: The mammalian pancreatic sPLA2, the mammalian non-pancreatic inflammatory sPLA2, and the sPLA2 purified from honey bee venom (denoted bvPLA2) are prototypes of group I, II, and III sPLA2s, respectively. 

Phrase: "The mammalian pancreatic sPLA2,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1418616:SPLA2 [Gene or Genome]
   827   C1706169:sPLA2 [Gene or Genome]

Phrase: "the mammalian non-pancreatic inflammatory sPLA2,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C1418616:SPLA2 [Gene or Genome]
   804   C1706169:sPLA2 [Gene or Genome]

Phrase: "and"

Phrase: "the sPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1418616:SPLA2 [Gene or Genome]
  1000   C1706169:sPLA2 [Gene or Genome]

Phrase: "purified from honey bee venom"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   862   C0440459:Honey bee venom [Hazardous or Poisonous Substance,Organic Chemical]
   806   C0004920:Bee Venom [Biologically Active Substance,Hazardous or Poisonous Substance]
   806   C0323351:Honey bee [Eukaryote]
   806   C0939871:honey bee [Organic Chemical,Pharmacologic Substance]
   760   C0004923:Bee [Eukaryote]
   760   C0019906:Honey [Food]
   760   C0042479:Venom [Hazardous or Poisonous Substance]
   760   C1365952:HONEY [Food]
   760   C1998793:Purified [Functional Concept]

Phrase: "(denoted bvPLA2"

Phrase: ")"

Phrase: "are"

Phrase: "prototypes of group I,"

Phrase: "II,"

Phrase: "and"

Phrase: "III sPLA2s,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   923   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "respectively."
Processing 00000000.tx.13: The structures of type I and II enzymes are very similar, but the structure of bvPLA2 is similar to those of the other sPLA2 only in its active site (6). 

Phrase: "The structures of type I"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0678594:structures [Spatial Concept]

Phrase: "and"

Phrase: "II enzymes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014442:Enzymes [Enzyme,Organic Chemical]
   861   C0014445:enzymes [Functional Concept]

Phrase: "are"

Phrase: "very similar,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2348205:Similar [Qualitative Concept]

Phrase: "but"

Phrase: "the structure of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0678594:Structure [Spatial Concept]

Phrase: "is"

Phrase: "similar to those of the"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C2348205:Similar [Qualitative Concept]

Phrase: "other sPLA2 only in its active site"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1418616:SPLA2 [Gene or Genome]
   748   C1706169:sPLA2 [Gene or Genome]

Phrase: "(6"

Phrase: ")."
Processing 00000000.tx.14: sPLA2s are implicated in a diversity of biological functions. 

Phrase: "sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   867 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   867 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "are"

Phrase: "implicated in a diversity of biological functions."
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   774   C0282469:Biological Diversity [Qualitative Concept]
   748   C0005532:Biological [Biomedical Occupation or Discipline]
   748   C0205460:biological [Qualitative Concept]
   748   C0542341:Functions [Functional Concept]
   748   C1880371:Diversity [Qualitative Concept]
   745   C0031845:Biological function, NOS [Physiologic Function]
   714 E C0031843:function [Physiologic Function]
   714 E C0700205:FUNCTION [Classification]
   714 E C1705273:Function [Intellectual Product]
Processing 00000000.tx.15: Mammalian group II sPLA2 is involved in inflammatory processes (7-11), while pancreatic group I sPLA2 is involved not only in digestion but is also endowed with other cellular functions such as the induction of cell proliferation (12) and smooth muscle contraction (13, 14). 

Phrase: "Mammalian group II sPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1418616:SPLA2 [Gene or Genome]
   812   C1706169:sPLA2 [Gene or Genome]

Phrase: "is"

Phrase: "involved in inflammatory processes"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0333348:Inflammatory [Functional Concept]
   770   C1314939:Involved [Functional Concept]
   737   C1184743:Process [Body Part, Organ, or Organ Component]
   737   C1522240:Process [Phenomenon or Process]

Phrase: "(7-11"

Phrase: ")"

Phrase: ","

Phrase: "while"

Phrase: "pancreatic group I sPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1418616:SPLA2 [Gene or Genome]
   812   C1706169:sPLA2 [Gene or Genome]

Phrase: "is"

Phrase: "involved"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1314939:Involved [Functional Concept]

Phrase: "not only in digestion"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   770   C0012238:Digestion [Organism Function]
   770   C0205171:Only [Quantitative Concept]
   770   C1518422:Not [Functional Concept]
   770   C1720467:Only [Intellectual Product]
   770   C2349986:Digestion [Research Activity]
   715 E C0443277:Peptic [Functional Concept]

Phrase: "but"

Phrase: "is"

Phrase: "also"

Phrase: "endowed with other cellular functions"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   790   C0007613:Cellular Function [Cell Function]
   760   C0007634:Cellular [Cell]
   760   C0178539:Cellular [Functional Concept]
   760   C0542341:Functions [Functional Concept]
   726 E C0031843:function [Physiologic Function]
   726 E C0700205:FUNCTION [Classification]
   726 E C1705273:Function [Intellectual Product]

Phrase: "such as the induction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205263:Induction [Functional Concept]
  1000   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "of cell proliferation"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0596290:Cell Proliferation [Cell Function]
   861   C0007634:Cell [Cell]
   861   C0334094:Proliferation [Pathologic Function]
   861   C1269647:Cell [Cell]
   861   C1514485:Proliferation [Functional Concept]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]

Phrase: "(12"

Phrase: ")"

Phrase: "and"

Phrase: "smooth muscle contraction"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1155937:smooth muscle contraction [Organ or Tissue Function]
   901   C0026820:Muscle Contraction [Physiologic Function]
   827   C1140999:Contraction [Pathologic Function]
   734   C1267092:Muscle, Smooth [Tissue]

Phrase: "(13,"

Phrase: "14"

Phrase: ")."
Processing 00000000.tx.16: On the other hand, most sPLA2s from venom are toxic enzymes: they can act as neurotoxins, myotoxins, anticoagulants, and they can also cause inflammation (15-18). 

Phrase: "On the"

Phrase: "other hand,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0018563:Hand [Body Part, Organ, or Organ Component]
  1000   C1281583:Hand [Body Part, Organ, or Organ Component]
  1000   C1552914:hand [Quantitative Concept]
   944 E C0024763:Manual [Intellectual Product,Manufactured Object]
   944 E C0175674:Manual [Functional Concept]

Phrase: "most sPLA2s from venom"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   833   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   756 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   756 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "are"

Phrase: "toxic enzymes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014442:Enzymes [Enzyme,Organic Chemical]
   861   C0014445:enzymes [Functional Concept]

Phrase: ":"

Phrase: "they"

Phrase: "can"

Phrase: "act as neurotoxins,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0027934:Neurotoxins [Hazardous or Poisonous Substance]
   790   C0079613:ACT [Therapeutic or Preventive Procedure]

Phrase: "myotoxins,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0067064:myotoxins [Amino Acid, Peptide, or Protein,Hazardous or Poisonous Substance]

Phrase: "anticoagulants,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0003280:Anticoagulants [Pharmacologic Substance]
   966 E C3536711:Anticoagulant [Pharmacologic Substance]

Phrase: "and"

Phrase: "they"

Phrase: "can"

Phrase: "also"

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "inflammation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021368:Inflammation [Pathologic Function]

Phrase: "(15-18"

Phrase: ")."
Processing 00000000.tx.17: The existence of specific receptors for sPLA2s has been demonstrated recently (19, 20). 

Phrase: "The existence of specific receptors"

Phrase: "for sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   867 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   867 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "has"

Phrase: "been"

Phrase: "demonstrated"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "(19,"

Phrase: "20"

Phrase: ")."
Processing 00000000.tx.18: Using OS1 and OS2, two sPLA2s purified from Taipan snake Oxyuranus scutellatus scutellatus venom, two types of receptors have been characterized. 

Phrase: "Using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "OS1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0029408:OS1 [Disease or Syndrome]

Phrase: "and"

Phrase: "OS2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0409957:OS2 [Disease or Syndrome]

Phrase: "two sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   923   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "purified from Taipan snake Oxyuranus scutellatus scutellatus venom,"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   770   C0327460:Oxyuranus scutellatus [Reptile]
           Taipan
   767   C0037380:Snake Venom [Biologically Active Substance,Hazardous or Poisonous Substance]
   767   C0580771:Taipan venom [Biologically Active Substance,Hazardous or Poisonous Substance]
   744   C0037382:Snake, NOS [Reptile]
   744   C0042479:Venom [Hazardous or Poisonous Substance]
   744   C0327459:Oxyuranus [Reptile]
   744   C1998793:Purified [Functional Concept]
   731 E C0037381:Venomous snake [Reptile]

Phrase: "two types of receptors"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0332307:Types [Qualitative Concept]
   737 E C1547052:*Type [Quantitative Concept]

Phrase: "have"

Phrase: "been"

Phrase: "characterized."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1880022:Characterized [Activity]
Processing 00000000.tx.19: The M-type receptor is a 180-kDa protein that was first characterized in rabbit skeletal muscle (20, 21). 

Phrase: "The"

Phrase: "M-"

Phrase: "type receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "is"

Phrase: "a 180-kDa protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "that"

Phrase: "was"

Phrase: "first"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205435:First [Quantitative Concept]
  1000   C1279901:First [Qualitative Concept]

Phrase: "characterized in rabbit skeletal muscle"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   806   C0242692:Muscle, Skeletal [Tissue]
   806   C1280260:Skeletal muscle [Body Part, Organ, or Organ Component]
   760   C0026845:Muscle [Tissue]
   760   C0034493:Rabbit [Mammal]
   760   C0037253:skeletal [Body System]
   760   C0521324:Skeletal [Spatial Concept]
   760   C1880022:Characterized [Activity]

Phrase: "(20,"

Phrase: "21"

Phrase: ")."
Processing 00000000.tx.20: This receptor binds various venom sPLA2s, including OS1 and OS2, but does not bind bvPLA2. 

Phrase: "This receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "binds"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "various venom sPLA2s,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   884   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   840   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "OS1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0029408:OS1 [Disease or Syndrome]

Phrase: "and"

Phrase: "OS2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0409957:OS2 [Disease or Syndrome]

Phrase: "but"

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "bind"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "bvPLA2."
Processing 00000000.tx.21: It also binds pancreatic type and inflammatory type sPLA2s with high affinities (1-10 nM), suggesting that these sPLA2s are probably the endogenous ligands of this sPLA2 receptor (21). 

Phrase: "It also"

Phrase: "binds"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "pancreatic type"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332307:Type [Qualitative Concept]
   861   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "inflammatory type sPLA2s with high affinities"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   800   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   770   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]
   737 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   737 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(1-10 nM),"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0312860:NM [Cell Function]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "these sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   867 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   867 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "are"

Phrase: "probably"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750492:Probably [Idea or Concept]

Phrase: "the endogenous ligands of this sPLA2 receptor"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   757   C1621296:receptor ligand [Molecular Function]
   748   C0023688:Ligands [Chemical]

Phrase: "(21"

Phrase: ")."
Processing 00000000.tx.22: The M-type receptor has been cloned recently from various animal species (21-24), and its molecular properties have been analyzed in detail (23, 25-29). 

Phrase: "The"

Phrase: "M-"

Phrase: "type receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "has"

Phrase: "been"

Phrase: "cloned"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0009013:cloned [Cell]
   966 E C1522642:Clone [Tissue]

Phrase: "recently from various animal species"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0003062:Animal [Animal]
   760   C0332185:Recently [Temporal Concept]
   760   C0440102:Various [Indicator, Reagent, or Diagnostic Aid]
   760   C1705920:Species [Conceptual Entity]

Phrase: "(21-24"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "its molecular properties"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0871161:properties [Qualitative Concept]
   861   C1292721:properties [Functional Concept]
   827 E C1882134:Property [Conceptual Entity]
   827 E C2347695:Property [Entity]

Phrase: "have"

Phrase: "been"

Phrase: "analyzed in detail"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0936012:Analyzed [Research Activity]
   790   C1522508:Detail [Qualitative Concept]
   790   C1561567:detail [Functional Concept]

Phrase: "(23,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: "25-29"

Phrase: ")."
Processing 00000000.tx.23: Notably, the interaction between the M-type receptor and sPLA2 has been studied both from the receptor side (25, 29) and from the sPLA2 side to show that the Ca2+-binding loop of the sPLA2 ligand plays a central role in binding to M-type receptor (28). 

Phrase: "Notably,"

Phrase: "the interaction between the"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1704675:Interaction [Functional Concept]

Phrase: "M-"

Phrase: "type receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "and"

Phrase: "sPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1418616:SPLA2 [Gene or Genome]
  1000   C1706169:sPLA2 [Gene or Genome]

Phrase: "has"

Phrase: "been"

Phrase: "studied"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0557651:Study [Manufactured Object]
   966   C2603343:Study [Research Activity]

Phrase: "both from the receptor side"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0238767:Both [Spatial Concept]
   760   C0441987:Side [Spatial Concept]
   760   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   760   C1706086:Both [Qualitative Concept]

Phrase: "(25,"

Phrase: "29"

Phrase: ")"

Phrase: "and from the sPLA2 side to"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0441987:Side [Spatial Concept]
   753   C1418616:SPLA2 [Gene or Genome]
   753   C1515981:And [Idea or Concept]
   753   C1706169:sPLA2 [Gene or Genome]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "that"

Phrase: "the Ca2+-binding loop of the sPLA2 ligand"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   767   C1517880:Ligand Binding [Molecular Function]
   744   C0243122:binding [Functional Concept]
   744   C0419518:Loop [Medical Device]
   744   C0445022:Loop [Spatial Concept]
   744   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   744   C1145667:Binding [Activity]
   744   C1167622:Binding [Molecular Function]

Phrase: "plays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:Plays [Finding]

Phrase: "a central role in binding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0035820:Role [Social Behavior]
   760   C1705810:Role [Conceptual Entity]

Phrase: "to"

Phrase: "M-"

Phrase: "type receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "(28"

Phrase: ")."
Processing 00000000.tx.24: Although the biological role of the M-type receptors remains to be clearly elucidated, this receptor has been proposed to be involved in many biological effects of the pancreatic sPLA2 (30). 

Phrase: "Although"

Phrase: "the biological role of the"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0035820:Role [Social Behavior]
   760   C1705810:Role [Conceptual Entity]

Phrase: "M-"

Phrase: "type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "remains"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "clearly"

Phrase: "elucidated"

Phrase: ","

Phrase: "this receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "has"

Phrase: "been"

Phrase: "proposed"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1441414:PROPOSED [Idea or Concept]
  1000   C1553874:Proposed [Qualitative Concept]
  1000   C1578820:Proposed [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "involved in many biological effects of the pancreatic sPLA2 (30"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   739   C0005532:Biological [Biomedical Occupation or Discipline]
   739   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   739   C0205460:biological [Qualitative Concept]
   739   C1280500:effects [Qualitative Concept]
   739   C1314939:Involved [Functional Concept]
   739   C1418616:SPLA2 [Gene or Genome]
   739   C1706169:sPLA2 [Gene or Genome]
   706 E C2348382:Effect [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.25: Another type of PLA2 receptor has been identified in rat brain using OS2 as a ligand and called the N (for neuronal)-type sPLA2 receptor (19). 

Phrase: "Another type of PLA2 receptor"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0332307:Type [Qualitative Concept]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "has"

Phrase: "been"

Phrase: "identified in rat brain"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   833   C1882598:Rat Brain [Body Part, Organ, or Organ Component]
   770   C0006104:Brain [Body Part, Organ, or Organ Component]
   770   C0034693:Rat, NOS [Mammal]
   770   C0034721:Rat [Mammal]
   770   C0205396:Identified [Qualitative Concept]
   770   C1269537:Brain [Body Part, Organ, or Organ Component]
   770   C1550043:Identified [Finding]
   770   C1551388:Identified [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "OS2 as a ligand"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0409957:OS2 [Disease or Syndrome]

Phrase: "and"

Phrase: "called"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0679006:Call [Mental Process]
   966   C1947967:Call [Functional Concept]

Phrase: "the N (for neuronal"

Phrase: ")-"

Phrase: "type sPLA2 receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "(19"

Phrase: ")."
Processing 00000000.tx.26: N-type receptors are highly expressed in brain, but are also present in heart, skeletal muscle, kidney, lung, liver, pancreas, and smooth muscle (31). 

Phrase: "N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "are"

Phrase: "highly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205250:Highly [Qualitative Concept]

Phrase: "expressed in brain,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0006104:Brain [Body Part, Organ, or Organ Component]
   790   C1269537:Brain [Body Part, Organ, or Organ Component]

Phrase: "but"

Phrase: "are"

Phrase: "also"

Phrase: "present in heart,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0018787:Heart [Body Part, Organ, or Organ Component]
   790   C0150312:Present [Quantitative Concept]
   790   C0449450:Present [Idea or Concept]
   790   C1281570:Heart [Body Part, Organ, or Organ Component]

Phrase: "skeletal muscle,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0242692:Muscle, Skeletal [Tissue]
  1000   C1280260:Skeletal muscle [Body Part, Organ, or Organ Component]
   861   C0026845:Muscle [Tissue]
   861   C0037253:skeletal [Body System]
   861   C0521324:Skeletal [Spatial Concept]
   789 E C0442025:Muscular [Spatial Concept]

Phrase: "kidney,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0022646:Kidney [Body Part, Organ, or Organ Component]
  1000   C0227665:kidney [Body Part, Organ, or Organ Component]
  1000   C1278978:Kidney [Body Part, Organ, or Organ Component]
  1000   C1514845:KIDNEY [Tissue]
   907 E C0027697:Nephritides [Disease or Syndrome]

Phrase: "lung,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0024109:Lung [Body Part, Organ, or Organ Component]
  1000   C0819757:LUNG [Tissue]
  1000   C1278908:Lung [Body Part, Organ, or Organ Component]
   944 E C2707265:Pulmonary [Clinical Attribute]
   944 E C2709248:Pulmonary [Qualitative Concept]
   907 E C0032285:Pneumonia [Disease or Syndrome]

Phrase: "liver,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0023884:Liver [Body Part, Organ, or Organ Component]
  1000   C0736268:LIVER [Body Part, Organ, or Organ Component]
  1000   C1278929:Liver [Body Part, Organ, or Organ Component]
  1000   C2346688:LIVER [Food]
   944 E C0205054:Hepatic [Body Location or Region]

Phrase: "pancreas,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0030274:Pancreas [Body Part, Organ, or Organ Component]
  1000   C1278931:Pancreas [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "smooth muscle"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1267092:Muscle, Smooth [Tissue]
   861   C0026845:Muscle [Tissue]
   861   C0205357:Smooth [Qualitative Concept]
   789 E C0442025:Muscular [Spatial Concept]

Phrase: "(31"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.27: They have been shown to consist of proteins of 36-51 and 85kDa (19). 

Phrase: "They"

Phrase: "have"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "consist of proteins of 36-51"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C0332529:CONSIST [Qualitative Concept]

Phrase: "and"

Phrase: "85kDa"

Phrase: "(19"

Phrase: ")."
Processing 00000000.tx.28: N-type receptors have a pharmacological binding profile distinct from that of M-type receptors. 

Phrase: "N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "have"

Phrase: "a pharmacological binding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0243122:binding [Functional Concept]
   861   C1145667:Binding [Activity]
   861   C1167622:Binding [Molecular Function]

Phrase: "profile"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1979963:Profile [Laboratory Procedure]
  1000   C2003903:Profile [Functional Concept]

Phrase: "distinct from that of"

Phrase: "M-"

Phrase: "type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.29: They bind several neurotoxic sPLA2s, including OS2 and bvPLA2, with high affinity, but unlike M-type receptors they do not bind pancreatic and inflammatory type sPLA2s (19, 32). 

Phrase: "They"

Phrase: "bind"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "several neurotoxic sPLA2s,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   884   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   840   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "OS2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0409957:OS2 [Disease or Syndrome]

Phrase: "and"

Phrase: "bvPLA2,"

Phrase: "with high affinity,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0205250:High [Qualitative Concept]
   861   C1299351:High [Qualitative Concept]
   861   C1510827:Affinity [Natural Phenomenon or Process]
   861   C2700149:HIGH [Intellectual Product]

Phrase: "but unlike"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C0233535:but [Mental or Behavioral Dysfunction]

Phrase: "M-"

Phrase: "type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "they"

Phrase: "do"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "bind"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "pancreatic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030274:Pancreatic [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "inflammatory type sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   884   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   840   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(19,"

Phrase: "32"

Phrase: ")."
Processing 00000000.tx.30: These N-type receptors are thought to mediate some of the physiological, pathophysiological, and toxic effects of sPLA2s. 

Phrase: "These N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "are"

Phrase: "thought"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039869:Thought [Mental Process]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "mediate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086597:Mediate [Social Behavior]

Phrase: "some of the physiological, pathophysiological,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0205392:Some [Quantitative Concept]
   760   C0205463:Physiological [Functional Concept]
   760   C3540770:Some [Intellectual Product]

Phrase: "and"

Phrase: "toxic effects of sPLA2s."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   756   C0600688:Toxic effect [Injury or Poisoning]
           toxic
   753   C1280500:effects [Qualitative Concept]
   753   C1407029:Toxic [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.31: The normal biological role(s) of N-type receptors is presently unknown. 

Phrase: "The normal biological role"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0035820:Role [Social Behavior]
   827   C1705810:Role [Conceptual Entity]

Phrase: "("

Phrase: "s) of N-type receptors"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1547052:*Type [Quantitative Concept]
   760   C2603362:S' [Clinical Attribute]

Phrase: "is"

Phrase: "presently unknown."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439673:Unknown [Qualitative Concept]
Processing 00000000.tx.32: Based on the fact that these latter receptors bind neurotoxic sPLA2s but not non neurotoxic sPLA2s with very high affinities, we have suggested that N-type receptors are involved in the neurotoxicity of venom sPLA2s after intracerebroventricular injection (19, 33). 

Phrase: "Based on the fact"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C1527178:Based [Functional Concept]
   770   C1705938:Based [Idea or Concept]
   737 E C0002055:base [Inorganic Chemical]
   737 E C0178499:Base [Chemical Viewed Functionally]
   737 E C1880279:Base [Biomedical or Dental Material]

Phrase: "that"

Phrase: "these latter receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "bind"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "neurotoxic sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   923   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "but"

Phrase: "not non neurotoxic sPLA2s with very high affinities,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   782   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   739   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]
   726 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   726 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "we"

Phrase: "have"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "are"

Phrase: "involved in the neurotoxicity of venom sPLA2s"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   790   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   764   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   742   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]
   742   C0042479:Venom [Hazardous or Poisonous Substance]
   742   C0235032:Neurotoxicity [Injury or Poisoning]
   742   C1314939:Involved [Functional Concept]
   742   C1327616:Secretory [Cell Function]
   731 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   731 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "after intracerebroventricular injection"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0021485:injection [Therapeutic or Preventive Procedure]
   861   C1272883:Injection [Biomedical or Dental Material]
   861   C1533685:Injection [Therapeutic or Preventive Procedure]
   861   C1828121:Injection [Functional Concept]

Phrase: "(19,"

Phrase: "33"

Phrase: ")."
Processing 00000000.tx.33: The purpose of this study is to identify the region of sPLA2s that is responsible for both their interaction with N-type receptors and their neurotoxicity. 

Phrase: "The purpose of this study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   844   C0681832:purpose of study [Research Activity]
   760   C1285529:Purpose [Functional Concept]

Phrase: "is"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "identify"

Phrase: "the region of sPLA2s"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0017446:Region [Geographic Area]
   753   C0205147:Region [Spatial Concept]

Phrase: "that"

Phrase: "is"

Phrase: "responsible for both"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1273518:Responsible [Finding]

Phrase: "their interaction with N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1704675:Interaction [Functional Concept]

Phrase: "and"

Phrase: "their neurotoxicity."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0235032:Neurotoxicity [Injury or Poisoning]
Processing 00000000.tx.34: These studies were carried out using a series of mutants of the neurotoxic bvPLA2, a very specific ligand of the N-type receptors (32-34) and one in which its tridimensional structure has been obtained at high resolution (35). 

Phrase: "These studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "were"

Phrase: "carried"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:carried [Activity]
  1000   C0699809:carried [Finding]

Phrase: "out"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439787:Out [Spatial Concept]
  1000   C0849355:Out [Qualitative Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a series of mutants of the neurotoxic bvPLA2,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0205549:Series [Quantitative Concept]
   744   C2348044:Series [Intellectual Product]

Phrase: "a very specific ligand of the N-type receptors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   745   C1621296:receptor ligand [Molecular Function]
   742   C0023688:Ligand [Chemical]

Phrase: "(32-34"

Phrase: ")"

Phrase: "and"

Phrase: "one in which"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205447:One [Quantitative Concept]

Phrase: "its tridimensional structure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0678594:Structure [Spatial Concept]

Phrase: "has"

Phrase: "been"

Phrase: "obtained at high resolution"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   833   C1719039:High resolution [Laboratory Procedure]
   770   C0205250:High [Qualitative Concept]
   770   C1299351:High [Qualitative Concept]
   770   C1301820:Obtained [Functional Concept]
   770   C1514893:Resolution [Idea or Concept]
   770   C1706463:Resolution [Quantitative Concept]
   770   C2699488:Resolution [Conceptual Entity]
   770   C2700149:HIGH [Intellectual Product]
   737 E C1706701:Obtain [Activity]

Phrase: "(35"

Phrase: ")."
Processing 00000000.tx.35: EXPERIMENTAL PROCEDURES Materials OS2 was purified and iodinated as described previously (19). 

Phrase: "EXPERIMENTAL PROCEDURES Materials OS2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0409957:OS2 [Disease or Syndrome]

Phrase: "was"

Phrase: "purified"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1998793:Purified [Functional Concept]
   907 E C1947930:Cleanse [Activity]

Phrase: "and"

Phrase: "iodinated"

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "previously"

Phrase: "(19"

Phrase: ")."
Processing 00000000.tx.36: Pa2 and Pa5, two sPLA2s from Heloderma suspectum were a generous gift from Prof. 

Phrase: "Pa2"

Phrase: "and"

Phrase: "Pa5,"

Phrase: "two sPLA2s from Heloderma suspectum"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   814   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   778   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   748   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]
   745 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   745 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "were"

Phrase: "a generous gift from Prof."
Processing 00000000.tx.37: Andr Vandermeers (Universit Libre de Bruxelles, Brussels, Belgium). 

Phrase: "Andr Vandermeers"

Phrase: "(Universit Libre de Bruxelles,"

Phrase: "Brussels,"

Phrase: "Belgium"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0004950:Belgium [Geographic Area]

Phrase: ")."
Processing 00000000.tx.38: The bvPLA2 expression plasmid p6xHis-Kall-BV-PLA2-#2 has been described previously (36). 

Phrase: "The bvPLA2 expression plasmid p6xHis-Kall-BV-PLA2-#2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C0032136:Plasmid [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   793   C0185117:Expression [Therapeutic or Preventive Procedure]
   793   C3540622:PLA2 [Gene or Genome]

Phrase: "has"

Phrase: "been"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "previously"

Phrase: "(36"

Phrase: ")."
Processing 00000000.tx.39: Technical grade guanidine hydrochloride and USP grade urea were purchased from AMRESCO (Solon, OH). 

Phrase: "Technical grade guanidine hydrochloride"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0120447:Guanidine Hydrochloride [Organic Chemical,Pharmacologic Substance]
   812   C0018320:guanidine [Organic Chemical]
   812   C0120446:Guanidine [Biologically Active Substance,Organic Chemical,Pharmacologic Substance]
   812   C1512523:hydrochloride [Inorganic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "USP grade urea"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0041942:Urea [Biologically Active Substance,Organic Chemical,Pharmacologic Substance]
   771 E C0728794:Ureaphil [Organic Chemical,Pharmacologic Substance]

Phrase: "were"

Phrase: "purchased from AMRESCO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0869011:purchased [Activity]

Phrase: "(Solon,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0142991:Solon [Organic Chemical,Pharmacologic Substance]

Phrase: "OH"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0220853:OH- [Element, Ion, or Isotope]

Phrase: ")."
Processing 00000000.tx.40: The following commercial kits, Geneclean kit (BIO 101,Inc., Vista, CA), QIAGEN plasmid mini-kit (Qiagen Inc., Chatsworth, CA), and Taq DyeDeoxy terminator cycle sequencing kit (Applied Biosystems Inc., Foster City, CA), were used according to the manufacturer's instructions. 

Phrase: "The following commercial kits,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   827   C1690540:Kits [Qualitative Concept]
   793 E C0812225:KIT [Medical Device]
   793 E C1150635:KIT [Molecular Function]
   793 E C1705212:Kit [Medical Device]
   793 E C1705213:KIT [Medical Device]
   793 E C3273202:Kit [Manufactured Object]

Phrase: "Geneclean kit (BIO 101,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   812   C0812225:KIT [Medical Device]
   812   C1150635:KIT [Molecular Function]
   812   C1705212:Kit [Medical Device]
   812   C1705213:KIT [Medical Device]
   812   C3273202:Kit [Manufactured Object]

Phrase: "Inc.,"

Phrase: "Vista,"

Phrase: "CA),"

Phrase: "QIAGEN plasmid mini-kit (Qiagen Inc.,"

Phrase: "Chatsworth,"

Phrase: "CA),"

Phrase: "and"

Phrase: "Taq DyeDeoxy terminator cycle sequencing kit (Applied Biosystems Inc.,"

Phrase: "Foster City,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0008848:City [Geographic Area]
   861   C0242298:foster [Daily or Recreational Activity]
   861   C0344349:foster [Family Group]
   861   C3262831:City [Clinical Attribute]

Phrase: "CA),"

Phrase: "were"

Phrase: "used according to the manufacturer's instructions."
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   753   C0302828:instructions [Intellectual Product]
   753   C0680240:according [Social Behavior]
   753   C0947322:Manufacturer [Intellectual Product]
   753   C1273517:used [Finding]
   753   C1442085:Instructions [Idea or Concept]
   753   C1705426:Manufacturer [Population Group]
   753   C3263700:Instructions [Clinical Attribute]
   719 E C0039401:Instruction [Educational Activity]
   719 E C0042153:use [Functional Concept]
   719 E C0457083:Use [Functional Concept]
   719 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.41: Ni2+-nitrilotriacetic acid-agarose is from Qiagen. 

Phrase: "Ni2+-nitrilotriacetic acid-agarose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0036681:Agarose [Carbohydrate]

Phrase: "is from Qiagen."
Processing 00000000.tx.42: 1-Palmitoyl-2[10-(1-pyrene)decanoyl]-sn-glycerol-3-phosphomethanol lithium salt was prepared as described elsewhere (37) or purchased from Molecular Probes (Eugene, OR). 

Phrase: "1-Palmitoyl-2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0580272:1/2 [Intellectual Product]
   913   C1519043:1-2 [Research Activity]
   827   C2827734:1+ [Quantitative Concept]
   827   C2981698:1+ [Classification]

Phrase: "[10-"

Phrase: "(1-pyrene"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0034243:pyrene [Hazardous or Poisonous Substance,Organic Chemical]
   861   C0072667:pyrene [Organic Chemical]

Phrase: ")"

Phrase: "decanoyl"

Phrase: "]-sn-glycerol-3-phosphomethanol lithium salt"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   827   C0302213:Lithium salt [Inorganic Chemical,Pharmacologic Substance]
   799   C0023870:Lithium [Element, Ion, or Isotope,Pharmacologic Substance]
   799   C0036140:Salt [Chemical Viewed Structurally]
   799   C0037494:Salt [Biologically Active Substance,Inorganic Chemical,Pharmacologic Substance]
   799   C0206136:Salt [Food,Inorganic Chemical]
   727 E C1537053:salty [Qualitative Concept]

Phrase: "was"

Phrase: "prepared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1521827:Prepare [Functional Concept]

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "elsewhere"

Phrase: "(37"

Phrase: ")"

Phrase: "or"

Phrase: "purchased from Molecular Probes"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   833   C0026381:Molecular Probes [Indicator, Reagent, or Diagnostic Aid]
   770   C0182400:Probes [Medical Device]
   770   C0869011:purchased [Activity]
   770   C1521991:Molecular [Qualitative Concept]
   737 E C1704681:Probe [Gene or Genome]
   737 E C2347609:Probe [Chemical Viewed Functionally]
   737 E C3536729:Probe [Manufactured Object]

Phrase: "(Eugene,"

Phrase: "OR"

Phrase: ")."
Processing 00000000.tx.43: The GRASP program was obtained from Dr. 

Phrase: "The GRASP program"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1709697:Program [Conceptual Entity]
   861   C2728259:Program [Pharmacologic Substance]
   861   C3484370:Program [Functional Concept]

Phrase: "was"

Phrase: "obtained from Dr."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   790   C0031831:DR [Professional or Occupational Group]
   790   C1301820:Obtained [Functional Concept]
   790   C1707664:DR [Biomedical or Dental Material]
   790   C2348314:Dr. [Conceptual Entity]
   790   C3540849:DR [Idea or Concept]
   756 E C1706701:Obtain [Activity]
   718 E C1517378:Gain [Quantitative Concept]
Processing 00000000.tx.44: Anthony Nicholls, Department of Biochemistry, Columbia University. 

Phrase: "Anthony Nicholls,"

Phrase: "Department of Biochemistry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1704729:Department [Organization]

Phrase: "Columbia University."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0041740:University [Manufactured Object,Organization]
   861   C1551442:Columbia [Population Group]
   861   C3245499:Columbia [Health Care Related Organization]
   789 E C1551955:Columbian [Language]
Processing 00000000.tx.45: Construction of the Recombinant bvPLA2 Mutants All mutants were made using a PCR-based method. 

Phrase: "Construction of the Recombinant bvPLA2 Mutants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0441513:Construction [Therapeutic or Preventive Procedure]

Phrase: "All mutants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "were"

Phrase: "made"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1881534:Make [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a PCR-based method."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025663:Method [Intellectual Product]
   827   C0449851:Method [Functional Concept]
   827   C0871511:METHOD [Intellectual Product]
Processing 00000000.tx.46: All primers used for mutagenesis are listed in Table I. 

Phrase: "All primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "used for mutagenesis"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   790   C0079866:Mutagenesis [Molecular Function]
   790   C1273517:used [Finding]
   790   C3146302:Mutagenesis [Laboratory Procedure]
   756 E C0042153:use [Functional Concept]
   756 E C0457083:Use [Functional Concept]
   756 E C1947944:Use [Intellectual Product]

Phrase: "are"

Phrase: "listed in Table I."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0021966:I- [Inorganic Chemical]
   770   C0039224:Table [Manufactured Object]
   770   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C1706073:Table [Medical Device]
   770   C1706074:Table [Intellectual Product]
   737   C0745732:List [Conceptual Entity]
   737   C3272378:LIST [Intellectual Product]
Processing 00000000.tx.47: Some of the primers contain a mixture of nucleotides so that several mutations at a single site were introduced in a single mutagenesis experiment. 

Phrase: "Some of the primers"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205392:Some [Quantitative Concept]
   770   C3540770:Some [Intellectual Product]
   737   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "contain"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:contain [Functional Concept]
  1000   C2700400:Contain [Activity]

Phrase: "a mixture of nucleotides"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0439962:Mixture [Substance]

Phrase: "so"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0037640:SO [Geographic Area]

Phrase: "that several mutations at a single site"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C0026882:Mutations [Genetic Function]
   714 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "were"

Phrase: "introduced in a single mutagenesis experiment."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   753   C0037179:Single [Population Group]
   753   C0079866:Mutagenesis [Molecular Function]
   753   C0087136:single [Finding]
   753   C0205171:Single [Quantitative Concept]
   753   C0681814:Experiment [Research Activity]
   753   C1706386:Experiment [Conceptual Entity]
   753   C3146302:Mutagenesis [Laboratory Procedure]
   719   C1292748:introduce [Functional Concept]
Processing 00000000.tx.48: One-hundred l of PCR reactions consist of 1ng of template p6xHis-Kall-BV-PLA2-#2 (36), 20pmol of mutant primer, 20pmol of T7 primer (Stratagene, La Jolla, CA), 0.2mM of each deoxyribonucleotide triphosphate, 0.1g of bovine serum albumin (New England Biolabs), 1-4 units of either Vent DNA polymerase (New England Biolabs or Boehringer Mannheim) or Taq DNA polymerase (New England Biolabs or Boehringer Mannheim) and the appropriate polymerase buffer as supplied by the manufacturer. 

Phrase: "One-hundred l of PCR reactions"

Phrase: "consist of 1ng"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0332529:CONSIST [Qualitative Concept]

Phrase: "of template p6xHis-Kall-BV-PLA2-#2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   799   C0728990:TEMPLATE [Medical Device]
   799   C1514575:Template [Conceptual Entity]
   799   C1705542:Template [Idea or Concept]
   799   C3540622:PLA2 [Gene or Genome]

Phrase: "(36"

Phrase: ")"

Phrase: ","

Phrase: "20pmol of mutant primer,"

Phrase: "20pmol of T7 primer"

Phrase: "(Stratagene,"

Phrase: "La Jolla,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1555265:La Jolla [Population Group]

Phrase: "CA),"

Phrase: "0.2mM of each deoxyribonucleotide triphosphate,"

Phrase: "0.1g of bovine serum albumin"

Phrase: "(New England Biolabs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C0027965:New England [Geographic Area]

Phrase: ")"

Phrase: ","

Phrase: "1-4 units of either Vent DNA polymerase"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   744   C0439148:Units [Quantitative Concept]
   744   C1519795:Units [Quantitative Concept]
   711 E C1704753:Unit [Manufactured Object]
   711 E C1880519:Unit [Quantitative Concept]

Phrase: "(New England Biolabs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C0027965:New England [Geographic Area]

Phrase: "or"

Phrase: "Boehringer Mannheim"

Phrase: ")"

Phrase: "or"

Phrase: "Taq DNA polymerase"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0075813:Taq DNA Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
           Taq Polymerase
  1000   C2257065:Taq DNA polymerase [Genetic Function]
   901   C0012892:DNA Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(New England Biolabs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C0027965:New England [Geographic Area]

Phrase: "or"

Phrase: "Boehringer Mannheim"

Phrase: ")"

Phrase: "and"

Phrase: "the appropriate polymerase buffer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "as"

Phrase: "supplied by the manufacturer."
Meta Candidates (Total=8; Excluded=5; Pruned=0; Remaining=3)
   770   C0947322:Manufacturer [Intellectual Product]
   770   C1705426:Manufacturer [Population Group]
   770   C1999230:Supplied [Activity]
   737 E C0243163:supply [Idea or Concept]
   737 E C0699914:supply [Quantitative Concept]
   737 E C1314650:SUPPLY, NOT OTHERWISE SPECIFIED [Medical Device]
   737 E C1561604:supply [Functional Concept]
   737 E C1875802:SUPPLY [Medical Device]
Processing 00000000.tx.49: PCR reaction conditions were set at 96C for 30s, 45C for 30s (if no PCR product is detected, the annealing temperature was varied in the range 37-55C), 2min primer extension at 72C, and this cycle was repeated 35times. 

Phrase: "PCR reaction conditions"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   793   C0012634:condition [Disease or Syndrome]
   793   C0348080:Condition [Qualitative Concept]
   793   C1705253:Condition [Conceptual Entity]
   743 E C0009647:Conditioned [Mental Process]
   743 E C1701901:Conditional [Qualitative Concept]
   743 E C1963686:Conditional [Functional Concept]
   721 E C1519605:Conditionality [Conceptual Entity]

Phrase: "were"

Phrase: "set at 96C"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0036849:Set [Mental Process]
   790   C1442518:Set [Functional Concept]
   790   C1705195:Set [Conceptual Entity]

Phrase: "for 30s,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0227073:30S [Body Part, Organ, or Organ Component]

Phrase: "45C for 30s"

Phrase: "("

Phrase: "if"

Phrase: "no PCR product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]

Phrase: "is"

Phrase: "detected"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0442726:Detected [Finding]
  1000   C1511790:Detected [Therapeutic or Preventive Procedure]

Phrase: ","

Phrase: "the annealing temperature"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0005903:temperature [Organism Attribute]
   861   C0039476:*Temperature [Quantitative Concept]

Phrase: "was"

Phrase: "varied in the range 37-55C"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1514721:Range [Quantitative Concept]
   753   C2348147:Range [Quantitative Concept]
   753   C3542016:Range [Intellectual Product]

Phrase: ")"

Phrase: ","

Phrase: "2min primer extension at 72C,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C1514433:Primer Extension [Molecular Biology Research Technique]
   760   C0231448:Extension [Functional Concept]
   760   C1880641:Extension [Conceptual Entity]

Phrase: "and"

Phrase: "this cycle"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1511572:Cycle [Temporal Concept]

Phrase: "was"

Phrase: "repeated"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205341:Repeated [Functional Concept]
   966 E C1547730:Repeat [Temporal Concept]
   966 E C1705914:Repeat [Conceptual Entity]

Phrase: "35times."
Processing 00000000.tx.50: At the end of the 35th cycle, 10min of extension at 72C was used. 

Phrase: "At the end"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0444930:End [Spatial Concept]
  1000   C2746065:End [Temporal Concept]
   944 E C0205088:Terminal [Temporal Concept]
   944 E C1705314:Terminal [Manufactured Object]
   944 E C1705315:Terminal [Spatial Concept]

Phrase: "of the 35th cycle,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1511572:Cycle [Temporal Concept]

Phrase: "10min of extension"

Phrase: "at 72C"

Phrase: "was"

Phrase: "used."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.51: PCR products were analyzed and purified by gel electrophoresis (1% agarose) to remove the unreacted primers and the template. 

Phrase: "PCR products"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1514468:Products [Entity]
   827 E C1704444:Product [Quantitative Concept]

Phrase: "were"

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: "and"

Phrase: "purified by gel electrophoresis"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   833   C0596607:Gel Electrophoresis [Laboratory Procedure]
   819 E C0972569:Electrophoresis Gel [Indicator, Reagent, or Diagnostic Aid]
   770   C0013855:Electrophoresis [Laboratory Procedure]
   770   C0017243:Gel [Biomedical or Dental Material]
   770   C1382104:Gel [Substance]
   770   C1998793:Purified [Functional Concept]

Phrase: "(1% agarose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036681:Agarose [Carbohydrate]

Phrase: ")"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "remove"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0849355:remove [Qualitative Concept]
  1000   C1883720:Remove [Activity]
  1000   C3244314:remove [Functional Concept]

Phrase: "the unreacted primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and"

Phrase: "the template."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0728990:TEMPLATE [Medical Device]
  1000   C1514575:Template [Conceptual Entity]
  1000   C1705542:Template [Idea or Concept]
Processing 00000000.tx.52: The PCR product band was cut from the gel, and the DNA was recovered using the Geneclean kit. 

Phrase: "The PCR product band"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0175723:Band [Medical Device]
   827   C0439645:Band [Spatial Concept]
   827   C1521913:band [Cell Component]

Phrase: "was"

Phrase: "cut from the gel,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0000925:Cut [Injury or Poisoning]
   770   C0017243:Gel [Biomedical or Dental Material]
   770   C1382104:Gel [Substance]
   770   C1883724:CUT [Phenomenon or Process]

Phrase: "and"

Phrase: "the DNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "recovered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0521108:recovered [Qualitative Concept]
   966 E C2004454:recover [Organism Function]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the Geneclean kit."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0812225:KIT [Medical Device]
   861   C1150635:KIT [Molecular Function]
   861   C1705212:Kit [Medical Device]
   861   C1705213:KIT [Medical Device]
   861   C3273202:Kit [Manufactured Object]
Processing 00000000.tx.53: After restriction digestion, the PCR fragment was ligated into p6xHis-Kall-BV-PLA2-#1 (36) that had been digested previously with the appropriate restriction enzymes. 

Phrase: "After restriction digestion,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0012238:Digestion [Organism Function]
   861   C2349986:Digestion [Research Activity]
   805 E C0443277:Peptic [Functional Concept]

Phrase: "the PCR fragment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332255:fragment [Functional Concept]
   861   C1708096:Fragment [Qualitative Concept]

Phrase: "was"

Phrase: "ligated into p6xHis-Kall-BV-PLA2-#1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C3540622:PLA2 [Gene or Genome]

Phrase: "(36"

Phrase: ")"

Phrase: "that"

Phrase: "had"

Phrase: "been"

Phrase: "digested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0868946:digested [Physiologic Function]

Phrase: "previously with the appropriate restriction enzymes."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   756   C0012906:Restriction Enzyme [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0014442:Enzymes [Enzyme,Organic Chemical]
   753   C0014445:enzymes [Functional Concept]
   753   C0443288:Restriction [Functional Concept]
   753   C1548787:Appropriate [Qualitative Concept]
Processing 00000000.tx.54: The constructs were used to transform XL1-Blue (Stratagene). 

Phrase: "The constructs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2827421:Construct [Classification]

Phrase: "were"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "transform"

Phrase: "XL1-Blue"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1260957:Blue [Qualitative Concept]

Phrase: "(Stratagene"

Phrase: ")."
Processing 00000000.tx.55: The insert in p6xHis-Kall-BV-PLA2-#1 lacks the BamHI site that is present in the PCR product (36), and restriction analysis with BamHI was used to identify the recombinant p6xHis-Kall-BV-PLA2-#1 that contains the PCR fragment. 

Phrase: "The insert in p6xHis-Kall-BV-PLA2-#1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0441587:Insert [Health Care Activity]
   744   C1743766:Insert [Medical Device]
   744   C1883719:Insert [Functional Concept]

Phrase: "lacks"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332268:lack [Qualitative Concept]

Phrase: "the BamHI site"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205145:Site [Spatial Concept]
   861   C1515974:Site [Body Location or Region]
   861   C2825164:Site [Spatial Concept]

Phrase: "that"

Phrase: "is"

Phrase: "present in the PCR product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0150312:Present [Quantitative Concept]
   760   C0449450:Present [Idea or Concept]

Phrase: "(36"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "restriction analysis with BamHI"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0002778:Analysis [Laboratory Procedure]
   770   C0936012:Analysis [Research Activity]
   770   C1524024:analysis [Functional Concept]

Phrase: "was"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "identify"

Phrase: "the recombinant p6xHis-Kall-BV-PLA2-#1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C1514798:recombinant [Organism]
   799   C3540622:PLA2 [Gene or Genome]

Phrase: "that"

Phrase: "contains"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:contain [Functional Concept]
  1000   C2700400:Contain [Activity]

Phrase: "the PCR fragment."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332255:fragment [Functional Concept]
   861   C1708096:Fragment [Qualitative Concept]
Processing 00000000.tx.56: In many cases, the PCR mutagenesis primers also contain a second mutation that either adds or eliminates a restriction site to facilitate the identification of recombinant clones. 

Phrase: "In many cases,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0868928:Cases [Functional Concept]
  1000   C1533148:Cases [Quantitative Concept]
   966 E C1706255:CASE [Medical Device]
   966 E C1706256:Case [Conceptual Entity]

Phrase: "the PCR mutagenesis primers also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   779   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "contain"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:contain [Functional Concept]
  1000   C2700400:Contain [Activity]

Phrase: "a second mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that either adds"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1883712:Add [Functional Concept]

Phrase: "or"

Phrase: "eliminates"

Phrase: "a restriction site to"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1882940:Restriction Site [Nucleotide Sequence]
   827   C0205145:Site [Spatial Concept]
   827   C0443288:Restriction [Functional Concept]
   827   C1515974:Site [Body Location or Region]
   827   C2825164:Site [Spatial Concept]

Phrase: "facilitate"

Phrase: "the identification of recombinant clones."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0020792:Identification [Mental Process]
   760   C0205396:Identification [Qualitative Concept]
Processing 00000000.tx.57: After restriction mapping, plasmids from candidate clones were purified using the QIAGEN plasmid mini-kit, and the DNA was sequenced using the DyeDeoxy terminator sequencing kit on a model 373A DNA Sequencer (Applied Biosystems, Foster City, CA) using the primers described previously (36). 

Phrase: "After restriction mapping,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0035269:Restriction Mapping [Laboratory Procedure,Molecular Biology Research Technique]
   861   C0443288:Restriction [Functional Concept]
   861   C1283195:Mapping [Activity]
   827 E C0024779:Map [Manufactured Object]
   827 E C1706473:Map [Conceptual Entity]

Phrase: "plasmids from candidate clones"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0032136:Plasmids [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "were"

Phrase: "purified"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1998793:Purified [Functional Concept]
   907 E C1947930:Cleanse [Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the QIAGEN plasmid mini-kit,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   812   C0812225:KIT [Medical Device]
   812   C1150635:KIT [Molecular Function]
   812   C1705212:Kit [Medical Device]
   812   C1705213:KIT [Medical Device]
   812   C3273202:Kit [Manufactured Object]

Phrase: "and"

Phrase: "the DNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "sequenced"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   966   C0004793:Sequence [Nucleotide Sequence]
   966   C0162326:Sequence [Nucleotide Sequence]
   966   C0162327:Sequence [Nucleotide Sequence]
   966   C1519249:Sequence [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the DyeDeoxy terminator sequencing kit on a model 373A DNA Sequencer"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   738   C0812225:KIT [Medical Device]
   738   C1150635:KIT [Molecular Function]
   738   C1705212:Kit [Medical Device]
   738   C1705213:KIT [Medical Device]
   738   C3273202:Kit [Manufactured Object]

Phrase: "(Applied Biosystems,"

Phrase: "Foster City,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0008848:City [Geographic Area]
   861   C0242298:foster [Daily or Recreational Activity]
   861   C0344349:foster [Family Group]
   861   C3262831:City [Clinical Attribute]

Phrase: "CA)"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "previously"

Phrase: "(36"

Phrase: ")."
Processing 00000000.tx.58: Finally, the plasmid was transferred into M15/pRep4 cell line (36) for protein expression. 

Phrase: "Finally,"

Phrase: "the plasmid"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0032136:Plasmid [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "transferred into M15/pRep4 cell line"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   790   C0007600:Cell Line [Cell]
   753   C0007634:Cell [Cell]
   753   C0168944:M15 [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   753   C0205132:Line [Spatial Concept]
   753   C0348011:transferred [Functional Concept]
   753   C1269647:Cell [Cell]
   753   C1549811:M15 [Intellectual Product]
   753   C1550648:Line [Substance]
   753   C1552960:Line [Quantitative Concept]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]
   719 E C0040671:Transfer [Mental Process]
   719 E C1705822:Transfer [Activity]

Phrase: "(36"

Phrase: ")"

Phrase: "for protein expression."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1171362:protein expression [Genetic Function]
   861   C0185117:Expression [Therapeutic or Preventive Procedure]
Processing 00000000.tx.59: Table I. 

Phrase: "Table I."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.60: PCR primers used to construct the bvPLA2 mutants Mutant PCR primer I1C 5-ATC ACA GAT CTC CGT TCC GCT GCA TCT AC I2C 5-ATC ACA GAT CTC ACT TCC GCA TCT GCT ATC CG I2C/H34R/V40Fa Same I2C G12X (X=A, C)b 5-TCT ACC CGG GGA CTC TGT GGT GTG GTC ACK SCA ACA G12S/K14Ra Same as G12X N13C 5-AAG CGG CCG AGT TCG TTC GGA CCA GCC GAT TTG CAG CCG K14C 5-AAG CGG CCG AGT TCG TTC GGA CCA CTC GAG CAG TTG CC K14E 5-AAA GCG GCC GAG TTC GTT CGG ACC AGA AGA TTC GTT G S15C 5-AAG CGG CCG AGT TCG TTC GGA CCA SAASAT TTG TTG S16C 5-AAG CGG CCG AGT TCG TTC GGA CCA SAASAT TTG TTG R23C 5-GAC AGC ATG CGT CGG TGT GTT TAM AGC RGC CG R23E 5-GGG GGG GCA TGC GTC GGT GTG TTT AAA TTC GCC G F24C 5-GAC AGC ATG CGT CGG TGT GTT TAM AGC RGC CG T51C 5-GAG ACG CGT GTG AGA AGC GGT GTT ACA TAA CCC T53C 5-GAG ACG CGT GTG AGA AGC GCA GTT AGT CAA CCC T57X (X=D, E, F, L, V) 5-CAC GGG TTA ACT AAC ACC GCT TCT CAC KWM CGT R58A 5-CGG CGC TGA GCT GCG ACT GC K66C 5-CAC ACG CGT CTG AGC TGC GAC TGC GAC GAC TGC TTC TAC 178X (X=C, Y) 5-CTG CCT TAA GAA CTC CGC CGA TAC GTTR TTC TTC F82C 5-GAT ACGATA TCT TCT TAC TGC GTT GG K85C 5-TAC GAT ATC TTC TTA CTT CGT TGG TTG CAT GTA T K94E 5-GTT ACC GGG TGC TCG AGT TTG TAA CAT TCG GTA T I91F 5-GCC GGT TAC CGG GTG CTC CAG TTT GTA ACA TTT GTT ATC GAA CAG G D92C 5-GCC GGT TAC CGG GTG CTC CAG TTT GTA ACA TTT GGT ACA GAT CAG K133E CTA ATT AAG CTT CAG TAT TCG CGC AG a The mutations H34R and V40F of 12C/H34R/V40F and K14R of G12S/K14R were introduced unintentionally during PCR. 

Phrase: "PCR primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "construct"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2827421:Construct [Classification]

Phrase: "the bvPLA2 mutants Mutant PCR primer I1C 5-ATC ACA GAT CTC CGT TCC GCT GCA TCT AC I2C 5-ATC ACA GAT CTC"

Phrase: "ACT"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0079613:ACT [Therapeutic or Preventive Procedure]

Phrase: "TCC GCA TCT GCT ATC CG I2C/H34R/V40Fa Same I2C G12X"

Phrase: "(X=A,"

Phrase: "C)b 5-TCT ACC CGG GGA CTC TGT GGT GTG GTC ACK SCA ACA G12S/K14Ra"

Phrase: "Same"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0445247:Same [Qualitative Concept]

Phrase: "as G12X N13C 5-AAG CGG CCG AGT TCG TTC GGA CCA GCC GAT TTG CAG CCG K14C 5-AAG CGG CCG AGT TCG TTC GGA CCA CTC GAG CAG TTG CC K14E 5-AAA GCG GCC GAG TTC GTT CGG ACC AGA AGA TTC GTT G S15C 5-AAG CGG CCG AGT TCG TTC GGA CCA SAASAT TTG TTG S16C 5-AAG CGG CCG AGT TCG TTC GGA CCA SAASAT TTG TTG R23C 5-GAC AGC ATG CGT CGG TGT GTT TAM AGC RGC CG R23E 5-GGG GGG GCA TGC GTC GGT GTG TTT AAA TTC GCC G F24C 5-GAC AGC ATG CGT CGG TGT GTT TAM AGC RGC CG T51C 5-GAG ACG CGT GTG AGA AGC GGT GTT ACA TAA CCC T53C 5-GAG ACG CGT GTG AGA AGC GCA GTT AGT CAA CCC T57X"

Phrase: "(X=D,"

Phrase: "E,"

Phrase: "F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "L,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "V) 5-CAC GGG TTA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C1627773:TTA [Finding]

Phrase: "ACT"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0079613:ACT [Therapeutic or Preventive Procedure]

Phrase: "AAC ACC GCT TCT CAC KWM CGT R58A 5-CGG CGC TGA GCT GCG"

Phrase: "ACT"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0079613:ACT [Therapeutic or Preventive Procedure]

Phrase: "GC K66C 5-CAC ACG CGT CTG AGC TGC GAC TGC GAC GAC TGC TTC TAC 178X"

Phrase: "(X=C, Y) 5-CTG CCT TAA GAA CTC CGC CGA TAC GTTR TTC TTC F82C 5-GAT ACGATA TCT TCT TAC TGC GTT GG K85C 5-TAC GAT ATC TTC TTA CTT CGT TGG TTG CAT GTA T K94E 5-GTT ACC GGG TGC TCG AGT TTG TAA CAT TCG GTA T I91F 5-GCC GGT TAC CGG GTG CTC CAG TTT GTA ACA TTT GTT ATC GAA CAG G D92C 5-GCC GGT TAC CGG GTG CTC CAG TTT GTA ACA TTT GGT ACA GAT CAG K133E CTA ATT AAG CTT CAG TAT TCG CGC AG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   809   C0369248:G Ag [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "a The mutations H34R"

Phrase: "and"

Phrase: "V40F of 12C/H34R/V40F"

Phrase: "and"

Phrase: "K14R of G12S/K14R"

Phrase: "were"

Phrase: "introduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1292748:introduce [Functional Concept]

Phrase: "unintentionally during PCR."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   790   C0677874:pCR [Finding]
Processing 00000000.tx.61: b The symbols used for mixed primers are as follows: K=(G, T), M=(A, C), R=(A, G), S=(C, G), Y=(C, T), W=(A, T). 

Phrase: "b"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "The symbols"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0679214:symbols [Idea or Concept]
   966 E C1698987:symbol [Intellectual Product]

Phrase: "used for mixed primers"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0205430:Mixed [Functional Concept]
   770   C1273517:used [Finding]
   770   C3160715:Mixed [Finding]
   737 E C0042153:use [Functional Concept]
   737   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]

Phrase: "are"

Phrase: "as"

Phrase: "follows"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332283:follow [Temporal Concept]
  1000   C1719822:Follow [Intellectual Product]

Phrase: ":"

Phrase: "K=(G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "T"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: ")"

Phrase: ","

Phrase: "M=(A,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "C),"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "R=(A,"

Phrase: "G"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "S=(C,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2603362:S' [Clinical Attribute]

Phrase: "G"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "Y=(C,"

Phrase: "T"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: ")"

Phrase: ","

Phrase: "W=(A,"

Phrase: "T"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.62: Preparation of Recombinant bvPLA2 Mutant Proteins and Analysis of Their Enzymatic Activities For the production of recombinant bvPLA2 mutants, cells were grown and induced as described (36). 

Phrase: "Preparation of Recombinant bvPLA2 Mutant Proteins"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0455052:Preparation [Health Care Activity]
   753   C1521827:Preparation [Functional Concept]

Phrase: "and"

Phrase: "Analysis of Their Enzymatic Activities"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   781   C0556570:Activity analysis [Therapeutic or Preventive Procedure]
   760   C0002778:Analysis [Laboratory Procedure]
   760   C0936012:Analysis [Research Activity]
   760   C1524024:analysis [Functional Concept]

Phrase: "For the production"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033268:production [Occupational Activity]

Phrase: "of recombinant bvPLA2 mutants,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "grown"

Phrase: "and"

Phrase: "induced as described"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205263:Induced [Functional Concept]
   790   C1552738:described [Idea or Concept]

Phrase: "(36"

Phrase: ")."
Processing 00000000.tx.63: The fusion proteins were obtained by chromatography on Ni2+-nitrilotriacetic acid-agarose as described (36) except that the sample before application to the column was clarified by centrifugation at 100,000g for 40min at 4C instead of by filtration. 

Phrase: "The fusion proteins"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   966   C0162768:Fusion protein [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
   861   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0332466:Fusion [Functional Concept]
   861   C1293131:Fusion [Therapeutic or Preventive Procedure]

Phrase: "were"

Phrase: "obtained by chromatography"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0008550:Chromatography [Laboratory Procedure]
   790   C1301820:Obtained [Functional Concept]
   756 E C1706701:Obtain [Activity]
   718 E C1517378:Gain [Quantitative Concept]

Phrase: "on Ni2+-nitrilotriacetic acid-agarose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0036681:Agarose [Carbohydrate]

Phrase: "as described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "(36"

Phrase: ")"

Phrase: "except"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332300:except [Functional Concept]

Phrase: "that"

Phrase: "the sample before application"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0370003:Sample [Substance]
   770   C2347026:Sample [Conceptual Entity]

Phrase: "to the column"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1185738:Column [Body Part, Organ, or Organ Component]
  1000   C1706132:Column [Idea or Concept]

Phrase: "was"

Phrase: "clarified by centrifugation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0007703:Centrifugation [Laboratory Procedure]
   790   C2986669:Clarified [Activity]

Phrase: "at 100,"

Phrase: "000g for 40min"

Phrase: "at 4C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450376:4c [Intellectual Product]

Phrase: "instead of"

Phrase: "by filtration."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016107:filtration [Laboratory Procedure]
Processing 00000000.tx.64: The denatured fusion protein was refolded as described, and the protein was purified by chromatography on SP-Sephadex C-25 (Pharmacia Biotech Inc.) as described (36) except that the column was equilibrated and washed in 50mM Tris, pH 7.5,and eluted with a linear gradient from 50mM Tris, pH 7.5,to 1M Tris, pH 9.0.

Phrase: "The denatured fusion protein"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0162768:Fusion protein [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0332466:Fusion [Functional Concept]
   827   C1293131:Fusion [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "refolded"

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: ","

Phrase: "and"

Phrase: "the protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "was"

Phrase: "purified by chromatography"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0008550:Chromatography [Laboratory Procedure]
   790   C1998793:Purified [Functional Concept]

Phrase: "on SP-Sephadex C-25"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   875   C1442758:SP-C [Gene or Genome]
   812   C0074343:sephadex [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "(Pharmacia Biotech"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0331955:Pharmacia [Health Care Related Organization]

Phrase: "Inc.)"

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "(36"

Phrase: ")"

Phrase: "except"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332300:except [Functional Concept]

Phrase: "that"

Phrase: "the column"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1185738:Column [Body Part, Organ, or Organ Component]
  1000   C1706132:Column [Idea or Concept]

Phrase: "was"

Phrase: "equilibrated"

Phrase: "and"

Phrase: "washed in 50mM Tris,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   770   C0041175:TRIS [Organic Chemical,Pharmacologic Substance]
   770   C0077281:Tris [Hazardous or Poisonous Substance,Organophosphorus Compound]
   770   C0450400:50mm [Quantitative Concept]
   770   C0814229:TRI [Intellectual Product]
   770   C1548982:Washed [Idea or Concept]
   737 E C0441648:Wash [Activity]

Phrase: "pH 7.5,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: "and"

Phrase: "eluted with a linear gradient"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0205132:Linear [Spatial Concept]
   760   C0439182:% gradient [Quantitative Concept]
   760   C0812409:Gradient [Quantitative Concept]

Phrase: "from 50mM Tris,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0041175:TRIS [Organic Chemical,Pharmacologic Substance]
   861   C0077281:Tris [Hazardous or Poisonous Substance,Organophosphorus Compound]
   861   C0814229:TRI [Intellectual Product]

Phrase: "pH 7.5,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: "to 1M Tris,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0041175:TRIS [Organic Chemical,Pharmacologic Substance]
   861   C0077281:Tris [Hazardous or Poisonous Substance,Organophosphorus Compound]
   861   C0814229:TRI [Intellectual Product]

Phrase: "pH 9.0."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]
Processing 00000000.tx.65: The fractions containing protein were pooled and dialyzed against 5mM Tris, pH 7.5.

Phrase: "The fractions"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1264633:Fractions [Quantitative Concept]
   966 E C1554103:Fraction [Idea or Concept]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "were"

Phrase: "pooled"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C1709595:Pooled [Conceptual Entity]
  1000   C2349200:Pooled [Functional Concept]
   966 E C0337051:Pool [Geographic Area]
   966 E C1509144:pool [Clinical Attribute]

Phrase: "and"

Phrase: "dialyzed against 5mM Tris,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0041175:TRIS [Organic Chemical,Pharmacologic Substance]
   770   C0077281:Tris [Hazardous or Poisonous Substance,Organophosphorus Compound]
   770   C0814229:TRI [Intellectual Product]

Phrase: "pH 7.5."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]
Processing 00000000.tx.66: After dialysis, the solution was concentrated up to 4mg of protein/ml in a Speed-Vac concentrator (Savant Instruments, Farmidale, NY). 

Phrase: "After dialysis,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0011945:Dialysis [Natural Phenomenon or Process]
  1000   C0011946:dialysis [Therapeutic or Preventive Procedure]
  1000   C0917873:dialysis [Therapeutic or Preventive Procedure]
  1000   C1059964:Dialysis [Eukaryote]

Phrase: "the solution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0037633:Solution [Substance]
  1000   C0525069:Solution [Biomedical or Dental Material]

Phrase: "was"

Phrase: "concentrated up to 4mg of protein/ml"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   748   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0439526:/mL [Quantitative Concept]
   748   C1880165:Concentrated [Biomedical or Dental Material]
   714 E C1880310:Concentrate [Manufactured Object]
   714 E C2003864:Concentrate [Substance]

Phrase: "in a Speed-Vac concentrator"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1707469:Concentrator [Manufactured Object]

Phrase: "(Savant Instruments,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0348000:instruments [Medical Device]

Phrase: "Farmidale,"

Phrase: "NY"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027976:NY [Geographic Area]
  1000   C1879958:NY [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.67: Mutant proteins were stored at 80C. 

Phrase: "Mutant proteins"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1564139:Mutant Proteins [Amino Acid, Peptide, or Protein]
   861   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "were"

Phrase: "stored at 80C."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1698986:Store [Functional Concept]
Processing 00000000.tx.68: The protein concentrations of recombinant bvPLA2 solutions were obtained from the absorbance at 280nm (38) and by the Bradford assay (Bio-Rad) using commercial bvPLA2 (Boehringer Mannheim) as a standard (both methods gave similar results). 

Phrase: "The protein concentrations of recombinant bvPLA2 solutions"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   762   C0427716:Protein concentration [Laboratory Procedure]
   762   C1304757:Protein concentration [Laboratory or Test Result]
   748   C0086045:Concentrations [Mental Process]
   716   C1707468:Concentrated Solution [Biomedical or Dental Material]
   714 E C1446561:Concentration [Quantitative Concept]

Phrase: "were"

Phrase: "obtained from the absorbance"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C1268822:Absorbance [Clinical Attribute]
   770   C1301820:Obtained [Functional Concept]
   770   C2825050:Absorbance [Phenomenon or Process]
   737 E C1706701:Obtain [Activity]

Phrase: "at 280nm"

Phrase: "(38"

Phrase: ")"

Phrase: "and by the Bradford assay"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0005507:Assay [Laboratory Procedure]
   760   C0243073:assay [Qualitative Concept]
   760   C1510438:Assay [Laboratory Procedure]
   760   C1515981:And [Idea or Concept]

Phrase: "(Bio-Rad)"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "commercial bvPLA2"

Phrase: "(Boehringer Mannheim"

Phrase: ")"

Phrase: "as a standard"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1442989:Standard [Qualitative Concept]
  1000   C2828392:Standard [Intellectual Product]

Phrase: "("

Phrase: "both methods"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "gave"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1947971:Give [Functional Concept]

Phrase: "similar results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: ")."
Processing 00000000.tx.69: The enzymatic activities of the mutants were assayed using a spectrofluorimeter (Jasco 821-FP) with the fluorescent substrate 1-palmitoyl-2[10-(1-pyrene)decanoyl]-sn-glycerol-3-phosphomethanol lithium salt (39). 

Phrase: "The enzymatic activities of the mutants"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   773   C2267219:Enzymatic Activity [Molecular Function]
   753   C0441655:Activities [Activity]
   719 E C0205177:Activity [Functional Concept]
   719 E C0439167:% activity [Quantitative Concept]
   719 E C1561536:*Activity [Idea or Concept]

Phrase: "were"

Phrase: "assayed"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0005507:Assay [Laboratory Procedure]
   966   C0243073:assay [Qualitative Concept]
   966   C1510438:Assay [Laboratory Procedure]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a spectrofluorimeter"

Phrase: "(Jasco 821-FP)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1419068:FP [Gene or Genome]
   827   C1419906:FP [Gene or Genome]
   827   C3541238:Fp [Amino Acid, Peptide, or Protein,Enzyme]
   827   C3541412:FP [Gene or Genome]

Phrase: "with the fluorescent substrate 1-palmitoyl-2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   804   C1710236:Substrate [Manufactured Object]

Phrase: "[10-"

Phrase: "(1-pyrene"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0034243:pyrene [Hazardous or Poisonous Substance,Organic Chemical]
   861   C0072667:pyrene [Organic Chemical]

Phrase: ")"

Phrase: "decanoyl"

Phrase: "]-sn-glycerol-3-phosphomethanol lithium salt"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   827   C0302213:Lithium salt [Inorganic Chemical,Pharmacologic Substance]
   799   C0023870:Lithium [Element, Ion, or Isotope,Pharmacologic Substance]
   799   C0036140:Salt [Chemical Viewed Structurally]
   799   C0037494:Salt [Biologically Active Substance,Inorganic Chemical,Pharmacologic Substance]
   799   C0206136:Salt [Food,Inorganic Chemical]
   727 E C1537053:salty [Qualitative Concept]

Phrase: "(39"

Phrase: ")."
Processing 00000000.tx.70: Mutants in which a bvPLA2 residue was changed to cysteine require special comment. 

Phrase: "Mutants in which"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "a bvPLA2 residue"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C1709915:Residue [Conceptual Entity]
   861   C1882936:RESIDUE [Phenomenon or Process]
   789 E C1609982:Residual [Qualitative Concept]

Phrase: "was"

Phrase: "changed to cysteine"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   790   C0392747:Changed [Functional Concept]
   790   C0443172:Changed [Quantitative Concept]
   756 E C1705241:Change [Quantitative Concept]

Phrase: "require"

Phrase: "special comment."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0282411:Comment [Intellectual Product]
   861   C0947611:Comment [Intellectual Product]
Processing 00000000.tx.71: Analysis of these mutants with Ellman's reagent after refolding them in the presence of the cysteine/cystine redox couple buffer showed that in all cases these proteins lack free SH groups. 

Phrase: "Analysis of these mutants"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0002778:Analysis [Laboratory Procedure]
   770   C0936012:Analysis [Research Activity]
   770   C1524024:analysis [Functional Concept]

Phrase: "with Ellman's reagent"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0012788:Ellman's Reagent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   861   C0034760:Reagent [Indicator, Reagent, or Diagnostic Aid]

Phrase: "after refolding"

Phrase: "them in the presence of the cysteine/cystine redox couple buffer"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   754   C0369077:Cystine+Cysteine [Organic Chemical]
   738   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   738   C0010222:couple [Family Group]
   738   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   738   C0010682:Cystine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   738   C0030012:Redox [Molecular Function]
   738   C0392148:Presence [Therapeutic or Preventive Procedure]
   738   C0546634:CYSTINE [Laboratory Procedure]
   738   C1948027:Couple [Functional Concept]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that in all cases"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0868928:Cases [Functional Concept]
   770   C1533148:Cases [Quantitative Concept]
   737 E C1706255:CASE [Medical Device]
   737 E C1706256:Case [Conceptual Entity]

Phrase: "these proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "lack"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332268:lack [Qualitative Concept]

Phrase: "free SH groups."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   827   C0441833:Group [Idea or Concept]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1552516:Group [Health Care Related Organization]
   827   C1552839:groups [Idea or Concept]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]
Processing 00000000.tx.72: This suggests that not only have all the 10cysteines of wild-type bvPLA2 formed disulfides, but the added cysteines is engaged in a disulfide bond with free cysteine from the buffer. 

Phrase: "This"

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "not only"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205171:Only [Quantitative Concept]
   861   C1518422:Not [Functional Concept]
   861   C1720467:Only [Intellectual Product]

Phrase: "have"

Phrase: "all the 10cysteines of wild-type bvPLA2 formed disulfides,"

Phrase: "but"

Phrase: "the added cysteines"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0010654:cysteines [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "is"

Phrase: "engaged in a disulfide bond"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C1511997:Disulfide Bond [Amino Acid Sequence]
   760   C0012771:disulfide [Chemical Viewed Structurally]
   760   C0425152:Engaged [Finding]

Phrase: "with free cysteine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "from the buffer."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
Processing 00000000.tx.73: This result was confirmed by analysis of of the mutants by mass spectrometry and by the fact that treatment of these mutants with DTT under conditions that do not cleave the disulfide of wild-type enzyme results in the appearance of 0.7-1.0 equivalents of SH/mol of enzyme. 

Phrase: "This result"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1274040:Result [Functional Concept]
  1000   C1546471:Result [Idea or Concept]
  1000   C2825142:Result [Finding]

Phrase: "was"

Phrase: "confirmed by analysis of of the mutants"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   778   C0521093:Confirmed by [Qualitative Concept]
           confirmed
   748   C0002778:Analysis [Laboratory Procedure]
   748   C0596988:mutants [Cell or Molecular Dysfunction]
   748   C0750484:Confirmed [Idea or Concept]
   748   C0936012:Analysis [Research Activity]
   748   C1524024:analysis [Functional Concept]
   714 E C1456348:Confirm [Qualitative Concept]

Phrase: "by mass spectrometry"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0037813:Mass Spectrometry [Laboratory Procedure]
   861   C0436196:Spectrometry [Laboratory Procedure]
   861   C0577559:Mass [Finding]
   861   C1306372:*Mass [Quantitative Concept]
   861   C3152252:Mass [Quantitative Concept]

Phrase: "and by the fact"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1515981:And [Idea or Concept]

Phrase: "that treatment of these mutants"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "with DTT"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012789:DTT [Carbohydrate,Pharmacologic Substance]

Phrase: "under conditions"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   966   C0012634:condition [Disease or Syndrome]
   966   C0348080:Condition [Qualitative Concept]
   966   C1705253:Condition [Conceptual Entity]
   916 E C0009647:Conditioned [Mental Process]
   916 E C1701901:Conditional [Qualitative Concept]
   916 E C1963686:Conditional [Functional Concept]
   893 E C1519605:Conditionality [Conceptual Entity]

Phrase: "that"

Phrase: "do"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "cleave"

Phrase: "the disulfide of wild-type enzyme"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0012771:disulfide [Chemical Viewed Structurally]

Phrase: "results in the appearance of 0.7-1.0 equivalents"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   739   C0233426:Appearance [Organism Attribute]
   739   C0439185:Equivalents [Quantitative Concept]
   739   C0700364:Appearance [Qualitative Concept]
   739   C1274040:Result [Functional Concept]
   739   C1546471:Result [Idea or Concept]
   739   C2825142:Result [Finding]
   706 E C0205163:Equivalent [Qualitative Concept]

Phrase: "of SH/mol"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   861   C0027960:Mole [Neoplastic Process]
   861   C0324740:Mole [Mammal]
   861   C0439189:Mole [Quantitative Concept]
   861   C1456781:mole [Neoplastic Process]
   861   C1824986:mol [Gene or Genome]
   777 E C0026367:Molar [Body Part, Organ, or Organ Component]
   761 E C0027962:moles [Neoplastic Process]

Phrase: "of enzyme."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0014442:Enzyme [Enzyme,Organic Chemical]
   916 E C0014445:enzymes [Functional Concept]
Processing 00000000.tx.74: The full details of these analyses will be reported elsewhere. 

Phrase: "The full details of these analyses"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1522508:Details [Qualitative Concept]
   719 E C1561567:detail [Functional Concept]

Phrase: "will"

Phrase: "be"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "elsewhere."
Processing 00000000.tx.75: Preparation of Deglycosylated bvPLA2 Natural purified bvPLA2 (300g) was incubated with or without 1unit N-glycosidase F (Boehringer Mannheim, catalog number 913782) in 100mM sodium phosphate buffer (pH 7.4) containing 10mM EDTA for 18h at 37C. 

Phrase: "Preparation of Deglycosylated bvPLA2 Natural purified bvPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0455052:Preparation [Health Care Activity]
   748   C1521827:Preparation [Functional Concept]

Phrase: "(300g"

Phrase: ")"

Phrase: "was"

Phrase: "incubated with"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C1439852:Incubated [Laboratory Procedure]

Phrase: "or without 1unit N-glycosidase F (Boehringer Mannheim,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   744   C0017976:Glycosidase [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   744   C0439133:(f) [Intellectual Product]
   744   C1553038:[f] [Quantitative Concept]

Phrase: "catalog number 913782"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C3274660:Catalog Number [Intellectual Product]
   827   C0237753:*Number [Quantitative Concept]
   827   C0376658:Catalog [Intellectual Product]
   827   C0449788:Number [Quantitative Concept]

Phrase: ")"

Phrase: "in 100mM sodium phosphate buffer"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   923   C3256935:sodium phosphate buffer [Pharmacologic Substance]
   861   C0991865:Phosphate Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   812   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "(pH 7.4"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C2678549:PH-4 [Gene or Genome]
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: ")"

Phrase: "containing 10mM EDTA for 18h"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0013618:EDTA [Organic Chemical,Pharmacologic Substance]

Phrase: "at 37C."
Processing 00000000.tx.76: After digestion, the mixtures were chromatographed on a C18 Waters column (4.6250mm) prewarmed at 30C with a Beckman system gold apparatus. 

Phrase: "After digestion,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0012238:Digestion [Organism Function]
  1000   C2349986:Digestion [Research Activity]
   944 E C0443277:Peptic [Functional Concept]

Phrase: "the mixtures"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439962:mixtures [Substance]

Phrase: "were"

Phrase: "chromatographed on a C18 Waters column"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   753   C0043047:Waters [Inorganic Chemical,Pharmacologic Substance]
   753   C1185738:Column [Body Part, Organ, or Organ Component]
   753   C1706132:Column [Idea or Concept]
   719   C0302647:chromatograph [Medical Device]
   719 E C0599638:WATER [Substance]
   719 E C1550678:Water [Inorganic Chemical]

Phrase: "(4.6250mm"

Phrase: ")"

Phrase: "prewarmed at 30C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1441704:Prewarmed [Laboratory Procedure]

Phrase: "with a Beckman system gold apparatus."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0243111:apparatus [Manufactured Object]
   812   C1947951:Apparatus [Anatomical Structure]
Processing 00000000.tx.77: Elution was performed using an acetonitrile linear gradient in 0.5% trifluoroacetic acid, 0.9% triethylamine, 0.001% -mercaptoethanol, 27-40% acetonitrile for 35min at 1.4ml/min. 

Phrase: "Elution"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441565:Elution [Laboratory Procedure]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "an acetonitrile linear gradient in 0.5% trifluoroacetic acid,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0439182:% gradient [Quantitative Concept]
   742   C0812409:Gradient [Quantitative Concept]

Phrase: "0.9% triethylamine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0077096:triethylamine [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]

Phrase: "0.001% -mercaptoethanol,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0025402:Mercaptoethanol [Organic Chemical]

Phrase: "27-40% acetonitrile for 35min at 1.4ml/min."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0050456:acetonitrile [Organic Chemical]
Processing 00000000.tx.78: The eluted fractions were lyophilized, resuspended in water, and assayed for protein concentration by measurement of the absorbance at 280nm. 

Phrase: "The eluted fractions"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1264633:Fractions [Quantitative Concept]
   827 E C1554103:Fraction [Idea or Concept]

Phrase: "were"

Phrase: "lyophilized"

Phrase: ","

Phrase: "resuspended in water,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   790   C0599638:WATER [Substance]
   790   C1550678:Water [Inorganic Chemical]
   718 E C0443350:Watery [Qualitative Concept]

Phrase: "and"

Phrase: "assayed for protein concentration"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   833   C0427716:Protein concentration [Laboratory Procedure]
   833   C1304757:Protein concentration [Laboratory or Test Result]
   770   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C0086045:Concentration [Mental Process]
   770   C1446561:Concentration [Quantitative Concept]
   737   C0005507:Assay [Laboratory Procedure]
   737   C0243073:assay [Qualitative Concept]
   737   C1510438:Assay [Laboratory Procedure]

Phrase: "by measurement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0242485:Measurement [Functional Concept]

Phrase: "of the absorbance"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1268822:Absorbance [Clinical Attribute]
  1000   C2825050:Absorbance [Phenomenon or Process]

Phrase: "at 280nm."
Processing 00000000.tx.79: 1.5g of the samples were then analyzed by high resolution SDS/Tris/Tricine gels (16.5%) under reducing conditions followed by Coomassie Blue staining. 

Phrase: "1.5g of the samples"

Phrase: "were"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "analyzed by high resolution SDS/Tris/Tricine gels"
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   770   C1719039:High resolution [Laboratory Procedure]
   744   C0017243:Gels [Biomedical or Dental Material]
   744   C0041175:TRIS [Organic Chemical,Pharmacologic Substance]
   744   C0077068:tricine [Organic Chemical]
   744   C0077281:Tris [Hazardous or Poisonous Substance,Organophosphorus Compound]
   744   C0205250:High [Qualitative Concept]
   744   C0814229:TRI [Intellectual Product]
   744   C0936012:Analyzed [Research Activity]
   744   C1299351:High [Qualitative Concept]
   744   C1514893:Resolution [Idea or Concept]
   744   C1706463:Resolution [Quantitative Concept]
   744   C2699488:Resolution [Conceptual Entity]
   744   C2700149:HIGH [Intellectual Product]
   711 E C1382104:Gel [Substance]

Phrase: "(16.5%"

Phrase: ")"

Phrase: "under reducing conditions"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0012634:condition [Disease or Syndrome]
   827   C0348080:Condition [Qualitative Concept]
   827   C1705253:Condition [Conceptual Entity]
   777 E C0009647:Conditioned [Mental Process]
   777 E C1701901:Conditional [Qualitative Concept]
   777 E C1963686:Conditional [Functional Concept]
   755 E C1519605:Conditionality [Conceptual Entity]

Phrase: "followed by Coomassie Blue staining."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0056269:Coomassie blue [Organic Chemical,Pharmacologic Substance]
   806   C0332283:Followed by [Temporal Concept]
           followed
   760   C0487602:Staining [Laboratory Procedure]
   760   C1260957:Blue [Qualitative Concept]
   760   C1704680:Staining [Finding]
   726 E C1719822:Follow [Intellectual Product]
Processing 00000000.tx.80: Protein molecular mass markers were from Promega. 

Phrase: "Protein molecular mass markers"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   875   C0005516:molecular markers [Clinical Attribute]
           Marker

Phrase: "were from Promega."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0072149:Promega [Lipid]
Processing 00000000.tx.81: Binding Experiments All N-type receptor binding experiments were performed as described (19). 

Phrase: "Binding Experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]

Phrase: "All N-type receptor binding experiments"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   804   C0681814:Experiments [Research Activity]
   771 E C1706386:Experiment [Conceptual Entity]
   721 E C1517586:Experimental [Qualitative Concept]
   708   C1149510:N binding [Molecular Function]

Phrase: "were"

Phrase: "performed as described"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0884358:Performed [Functional Concept]
   790   C1552738:described [Idea or Concept]
   756 E C2947996:Perform [Pharmacologic Substance]

Phrase: "(19"

Phrase: ")."
Processing 00000000.tx.82: Briefly, membranes, 125I-OS2, and competitors were incubated at 20C in 0.5or 1ml of buffer (140mM NaCl, 0.1mM CaCl2, 20mM Tris, pH 7.4,and 0.1% bovine serum albumin). 

Phrase: "Briefly,"

Phrase: "membranes,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0025255:Membranes [Tissue]
   966 E C0596901:Membrane [Cell Component]
   966 E C1706182:Membrane [Manufactured Object]
   916 E C0205287:Membranous [Qualitative Concept]

Phrase: "125I-OS2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0409957:OS2 [Disease or Syndrome]

Phrase: "and"

Phrase: "competitors"

Phrase: "were"

Phrase: "incubated at 20C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1439852:Incubated [Laboratory Procedure]

Phrase: "in 0.5or 1ml"

Phrase: "of buffer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "(140mM NaCl,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0037494:NaCl [Biologically Active Substance,Inorganic Chemical,Pharmacologic Substance]
   861   C1959973:% NaCl [Quantitative Concept]

Phrase: "0.1mM CaCl2,"

Phrase: "20mM Tris,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0041175:TRIS [Organic Chemical,Pharmacologic Substance]
   861   C0077281:Tris [Hazardous or Poisonous Substance,Organophosphorus Compound]
   861   C0814229:TRI [Intellectual Product]

Phrase: "pH 7.4,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C2678549:PH-4 [Gene or Genome]
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: "and"

Phrase: "0.1% bovine serum albumin"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   884   C0036774:Serum Albumin, Bovine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   840   C0036773:Serum Albumin [Amino Acid, Peptide, or Protein]
   840   C0728877:serum albumin [Laboratory or Test Result]
   804   C0001924:Albumin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0007452:Bovine [Mammal]
   804   C0229671:Serum [Body Substance]
   804   C1140701:bovine [Mammal]
   804   C1546774:Serum [Intellectual Product]
   804   C1550100:Serum [Body Substance]

Phrase: ")."
Processing 00000000.tx.83: Incubations were started by addition of rat brain membranes and filtered after 90min of incubation through GF/C glass fiber filters presoaked in 0.5% polyethyleneimine. 

Phrase: "Incubations"

Phrase: "were"

Phrase: "started by addition of rat brain membranes"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   778   C1882598:Rat Brain [Body Part, Organ, or Organ Component]
   748   C0006104:Brain [Body Part, Organ, or Organ Component]
   748   C0025255:Membranes [Tissue]
   748   C0034693:Rat, NOS [Mammal]
   748   C0034721:Rat [Mammal]
   748   C1269537:Brain [Body Part, Organ, or Organ Component]
   748   C1272689:Started [Qualitative Concept]
   748   C1883712:Addition [Functional Concept]
   714 E C0439659:Start [Temporal Concept]
   714 E C0596901:Membrane [Cell Component]
   714 E C1706182:Membrane [Manufactured Object]

Phrase: "and"

Phrase: "filtered after 90min of incubation"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   726   C0180860:Filter [Manufactured Object]
   726   C0581406:Filter [Medical Device]
   726   C1522664:Filter [Intellectual Product]
   726   C1704449:Filter [Conceptual Entity]
   726   C1704684:Filter [Medical Device]
   726   C1875155:FILTER [Medical Device]

Phrase: "through GF/C glass fiber filters"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   804   C0180860:Filters [Manufactured Object]
   771 E C0581406:Filter [Medical Device]
   771 E C1522664:Filter [Intellectual Product]
   771 E C1704449:Filter [Conceptual Entity]
   771 E C1704684:Filter [Medical Device]
   771 E C1875155:FILTER [Medical Device]

Phrase: "presoaked in 0.5% polyethyleneimine."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0444499:0/5 [Quantitative Concept]
   760   C0032486:Polyethyleneimine [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
Processing 00000000.tx.84: Toxicity Experiments Neurotoxic properties of the various recombinant sPLA2s have been determined by intracerebroventricular injections in adult male Balb/C mice (average weight, 20g). 

Phrase: "Toxicity Experiments Neurotoxic properties of the various recombinant sPLA2s"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   738   C0871161:properties [Qualitative Concept]
   738   C1292721:properties [Functional Concept]
   704 E C1882134:Property [Conceptual Entity]
   704 E C2347695:Property [Entity]

Phrase: "have"

Phrase: "been"

Phrase: "determined by intracerebroventricular injections"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0021485:injections [Therapeutic or Preventive Procedure]
   770   C1533685:INJECTIONS [Therapeutic or Preventive Procedure]
   770   C1828121:Injections [Functional Concept]
   737 E C1272883:Injection [Biomedical or Dental Material]

Phrase: "in adult male Balb/C mice"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   884   C0025919:Mice, BALB C [Mammal]
           BALB/C
   804   C0025914:Mice [Mammal]
   804   C0025929:mice [Mammal]
   804   C0026809:Mice [Mammal]

Phrase: "(average weight,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0005910:weight [Organism Attribute]
   861   C0043100:Weight [Quantitative Concept]
   861   C1305866:weight [Diagnostic Procedure]
   861   C1705104:Weight [Idea or Concept]

Phrase: "20g"

Phrase: ")."
Processing 00000000.tx.85: Animals were anesthetized using a mixture of ketamine hydrochloride (100mg/kg, Rhne Mrieux) and xylazine hydrochloride (12mg/kg, Bayer Pharma). 

Phrase: "Animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]

Phrase: "were"

Phrase: "anesthetized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1720436:Anesthetized [Finding]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a mixture of ketamine hydrochloride"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0439962:Mixture [Substance]

Phrase: "(100mg/kg,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0022718:KG [Geographic Area]
   861   C0439209:kg [Quantitative Concept]

Phrase: "Rhne Mrieux"

Phrase: ")"

Phrase: "and"

Phrase: "xylazine hydrochloride"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0242544:Xylazine Hydrochloride [Organic Chemical,Pharmacologic Substance]
   861   C0043366:Xylazin [Organic Chemical,Pharmacologic Substance]
   861   C1512523:hydrochloride [Inorganic Chemical,Pharmacologic Substance]

Phrase: "(12mg/kg,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0022718:KG [Geographic Area]
   861   C0439209:kg [Quantitative Concept]

Phrase: "Bayer Pharma"

Phrase: ")."
Processing 00000000.tx.86: Injections of sPLA2s in a volume of 5l of saline solution were made into the right ventricle according to stereotaxic coordinates (40). 

Phrase: "Injections of sPLA2s"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   760   C0021485:injections [Therapeutic or Preventive Procedure]
   760   C1533685:INJECTIONS [Therapeutic or Preventive Procedure]
   760   C1828121:Injections [Functional Concept]
   726 E C1272883:Injection [Biomedical or Dental Material]

Phrase: "in a volume"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0449468:*Volume [Quantitative Concept]
  1000   C1690016:% volume [Qualitative Concept]
  1000   C1705102:Volume [Intellectual Product]
  1000   C2700258:Volume [Laboratory Procedure]

Phrase: "of 5l"

Phrase: "of saline solution"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0036082:Saline Solution [Substance]
           Saline
   861   C0037633:Solution [Substance]
   861   C0525069:Solution [Biomedical or Dental Material]

Phrase: "were"

Phrase: "made into the right ventricle"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0225883:Right Ventricle [Body Part, Organ, or Organ Component]
   806   C1269891:Right ventricle [Body Part, Organ, or Organ Component]
   760   C0018827:Ventricle [Body Part, Organ, or Organ Component]
   760   C0205090:Right [Spatial Concept]
   760   C2355627:Ventricle [Body Part, Organ, or Organ Component]
   726   C1881534:Make [Functional Concept]

Phrase: "according to stereotaxic coordinates"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0427184:coordinates [Finding]
   861   C0700114:coordinates [Functional Concept]
   861   C1707511:Coordinates [Spatial Concept]

Phrase: "(40"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439509:/40 [Temporal Concept]

Phrase: ")."
Processing 00000000.tx.87: Lethality was checked 24h after injection. 

Phrase: "Lethality"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C3151529:Lethal [Finding]

Phrase: "was"

Phrase: "checked"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1283174:Checked [Activity]

Phrase: "24h after injection."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0456696:/24h [Temporal Concept]
   790   C1442770:24H [Temporal Concept]
Processing 00000000.tx.88: RESULTS Binding of Recombinant bvPLA2 to N-type Receptors A panel of mutants of recombinant bvPLA2 have been used to identify the region of the enzyme that is involved in binding to N-type receptors. 

Phrase: "RESULTS"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "Binding of Recombinant bvPLA2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]
   770   C1514798:recombinant [Organism]

Phrase: "to N-type Receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "A panel of mutants of recombinant bvPLA2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0441833:Panel [Idea or Concept]
   748   C1999270:Panel [Intellectual Product]
   748   C3537156:Panel [Manufactured Object]

Phrase: "have"

Phrase: "been"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "identify"

Phrase: "the region of the enzyme"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0017446:Region [Geographic Area]
   760   C0205147:Region [Spatial Concept]

Phrase: "that"

Phrase: "is"

Phrase: "involved in binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]
   790   C1314939:Involved [Functional Concept]

Phrase: "to N-type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.89: Binding properties of these mutants and of wild-type bvPLA2 have been determined by competition binding experiments with 125I-OS2, which is the canonical labeled ligand for N-type receptors (19). 

Phrase: "Binding properties of these mutants"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   760   C0871161:properties [Qualitative Concept]
   760   C1292721:properties [Functional Concept]
   726 E C1882134:Property [Conceptual Entity]
   726 E C2347695:Property [Entity]

Phrase: "and of wild-type bvPLA2"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C1883559:Wild Type [Organism Attribute]
   760   C0332307:Type [Qualitative Concept]
   760   C0445392:Wild [Intellectual Product]
   760   C1515981:And [Idea or Concept]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "have"

Phrase: "been"

Phrase: "determined by competition binding experiments"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   760   C0243122:binding [Functional Concept]
   760   C0679932:competition [Social Behavior]
   760   C0681814:Experiments [Research Activity]
   760   C1145667:Binding [Activity]
   760   C1167622:Binding [Molecular Function]
   726 E C1706386:Experiment [Conceptual Entity]

Phrase: "with 125I-OS2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0409957:OS2 [Disease or Syndrome]

Phrase: "which"

Phrase: "is"

Phrase: "the canonical labeled ligand for N-type receptors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   750   C1621296:receptor ligand [Molecular Function]
   744   C0023688:Ligand [Chemical]

Phrase: "(19"

Phrase: ")."
Processing 00000000.tx.90: As a first step toward the identification of the binding domain of sPLA2 involved in the interaction with N-type receptors, we have analyzed the binding properties of recombinant bvPLA2 expressed either as a fusion protein or after the removal of the N-terminal His-tag fusion peptide and compared their binding properties with those of the natural bvPLA2. 

Phrase: "As a first step"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1722730:First Step [Biomedical or Dental Material]
   861   C1261552:Step [Conceptual Entity]
   861   C1704379:Step [Functional Concept]
   861   C1705117:Step [Quantitative Concept]
   861   C2825408:Step [Manufactured Object]

Phrase: "toward the identification"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020792:Identification [Mental Process]
  1000   C0205396:Identification [Qualitative Concept]

Phrase: "of the binding domain"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1880389:Domain [Functional Concept]
   861   C1883221:Domain [Conceptual Entity]
   861   C3541951:Domain [Intellectual Product]

Phrase: "of sPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1418616:SPLA2 [Gene or Genome]
  1000   C1706169:sPLA2 [Gene or Genome]

Phrase: "involved in the interaction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1314939:Involved [Functional Concept]
   770   C1704675:Interaction [Functional Concept]

Phrase: "with N-type receptors,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "we"

Phrase: "have"

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: "the binding properties of recombinant bvPLA2"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   753   C0871161:properties [Qualitative Concept]
   753   C1292721:properties [Functional Concept]
   719 E C1882134:Property [Conceptual Entity]
   719 E C2347695:Property [Entity]

Phrase: "expressed"

Phrase: "either as a fusion protein"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0162768:Fusion protein [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
   797   C0038164:Protein A [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   760   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0332466:Fusion [Functional Concept]
   760   C1293131:Fusion [Therapeutic or Preventive Procedure]

Phrase: "or after the removal of the N-terminal"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   744   C0015252:Removal [Therapeutic or Preventive Procedure]
   744   C0205088:Terminal [Temporal Concept]
   744   C0728940:Removal [Therapeutic or Preventive Procedure]
   744   C1705314:Terminal [Manufactured Object]
   744   C1705315:Terminal [Spatial Concept]

Phrase: "His-tag fusion peptide"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   913   C0244435:TAG peptide [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0030956:Peptide [Amino Acid, Peptide, or Protein]

Phrase: "and"

Phrase: "compared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]

Phrase: "their binding properties with those of the natural bvPLA2."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   742   C0871161:properties [Qualitative Concept]
   742   C1292721:properties [Functional Concept]
   708 E C1882134:Property [Conceptual Entity]
   708 E C2347695:Property [Entity]
Processing 00000000.tx.91: As shown in Fig. 

Phrase: "As"

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.92: 1 and Table II, the K0.5 values obtained for the recombinant forms of bvPLA2 (4.6and 2.0nM for recombinant cleaved bvPLA2 and recombinant fusion protein bvPLA2, respectively) are close to the K0.5 value measured for the natural purified bvPLA2 protein (0.79nM). 

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "and"

Phrase: "Table II,"

Phrase: "the K0.5 values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0042295:Values [Qualitative Concept]
   793 E C1522609:Value [Quantitative Concept]

Phrase: "obtained for the recombinant forms of bvPLA2"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   748   C0348078:forms [Qualitative Concept]
   748   C0376315:Forms [Manufactured Object]
   748   C1301820:Obtained [Functional Concept]
   748   C1514798:recombinant [Organism]
   714 E C1522492:Form [Functional Concept]
   714 E C1706701:Obtain [Activity]

Phrase: "(4.6and 2.0nM for recombinant cleaved bvPLA2"

Phrase: "and"

Phrase: "recombinant fusion protein bvPLA2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   708   C0034861:Recombinant protein [Amino Acid, Peptide, or Protein]

Phrase: "respectively"

Phrase: ")"

Phrase: "are"

Phrase: "close to the K0.5 value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0587267:Close [Functional Concept]

Phrase: "measured for the natural purified bvPLA2 protein"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   748   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0205296:Natural [Functional Concept]
   748   C0444706:Measured [Qualitative Concept]
   748   C1998793:Purified [Functional Concept]
   748   C3541902:MEASURED [Diagnostic Procedure]
   714 E C0079809:Measure [Quantitative Concept]
   714 E C0242485:Measure [Functional Concept]

Phrase: "(0.79nM"

Phrase: ")."
Processing 00000000.tx.93: These results establish that recombinant forms of bvPLA2 expressed either as a fusion protein or as a free protein are good tools for the study of the molecular determinants of sPLA2 that are implicated in binding to N-type receptors. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "establish"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443211:establish [Qualitative Concept]

Phrase: "that recombinant forms of bvPLA2"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0348078:forms [Qualitative Concept]
   760   C0376315:Forms [Manufactured Object]
   726 E C1522492:Form [Functional Concept]

Phrase: "expressed"

Phrase: "either as a fusion protein"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0162768:Fusion protein [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
   797   C0038164:Protein A [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   760   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0332466:Fusion [Functional Concept]
   760   C1293131:Fusion [Therapeutic or Preventive Procedure]

Phrase: "or as a free protein"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   797   C0038164:Protein A [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   760   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0332296:free [Functional Concept]
   760   C1880497:Free [Qualitative Concept]
   760   C1996904:Free [Qualitative Concept]

Phrase: "are"

Phrase: "good tools for the study of the molecular determinants of sPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   704   C0336791:Tool [Manufactured Object]
   704   C2827396:Tool [Manufactured Object]

Phrase: "that"

Phrase: "are"

Phrase: "implicated in binding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]

Phrase: "to N-type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.94: Furthermore, as both uncleaved fusion protein and cleaved recombinant bvPLA2 bind nearly equally well to N-type receptors, the different mutants have been used as recombinant proteins containing the N-terminal peptide extension. 

Phrase: "Furthermore,"

Phrase: "as"

Phrase: "both uncleaved fusion protein"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0162768:Fusion protein [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0332466:Fusion [Functional Concept]
   827   C1293131:Fusion [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "cleaved recombinant bvPLA2"

Phrase: "bind"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "nearly equally well to N-type receptors,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0205170:Well [Qualitative Concept]
   748   C0332307:Type [Qualitative Concept]
   748   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   748   C1547052:*Type [Quantitative Concept]
   748   C3146287:Well [Manufactured Object]

Phrase: "the different mutants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "have"

Phrase: "been"

Phrase: "used as recombinant proteins"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   833   C0034861:Recombinant Proteins [Amino Acid, Peptide, or Protein]
   770   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C1273517:used [Finding]
   770   C1514798:recombinant [Organism]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "the N-terminal peptide extension."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0231448:Extension [Functional Concept]
   812   C1880641:Extension [Conceptual Entity]
Processing 00000000.tx.95: Fig. 

Phrase: "Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.96: 1. 

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.97: Inhibition of 125I-OS2 binding to N-type receptors by recombinant bvPLA2s produced in E.coli. 

Phrase: "Inhibition of 125I-OS2 binding"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   844   C2259198:inhibition of binding [Molecular Function]
   760   C0021467:Inhibition [Mental Process]
   760   C0021469:Inhibition [Molecular Function]
   760   C1628982:% inhibition [Quantitative Concept]
   760   C3463820:Inhibition [Activity]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "by recombinant bvPLA2s"

Phrase: "produced in E.coli."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C0014834:E coli [Bacterium]
Processing 00000000.tx.98: Binding experiments were performed as described under "Experimental Procedures." 

Phrase: "Binding experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "as"

Phrase: "described under ""Experimental Procedures."""
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   770   C0025664:procedures [Intellectual Product]
   770   C0184661:Procedures [Diagnostic Procedure,Therapeutic or Preventive Procedure]
   770   C1517586:Experimental [Qualitative Concept]
   770   C1552738:described [Idea or Concept]
   770   C2700391:procedures [Activity]
   737 E C1948041:Procedure [Therapeutic or Preventive Procedure]
   737 E C3274430:PROCEDURE [Health Care Activity]
   737 E C3538935:Procedure [Idea or Concept]
   737 E C3539779:Procedure [Intellectual Product]
Processing 00000000.tx.99: Results are expressed as the percentage of control that corresponds to 125I-OS2-specific binding measured in the absence of competitor. 

Phrase: "Results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "expressed as the percentage of control"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   753   C0243148:control [Qualitative Concept]
   753   C0439165:Percentage [Quantitative Concept]
   753   C1549488:Percentage [Idea or Concept]
   753   C1550141:Control [Substance]
   753   C1561533:Percentage [Idea or Concept]
   753   C1882979:Control [Conceptual Entity]
   753   C2587213:Control [Functional Concept]
   753   C3274648:Control [Qualitative Concept]

Phrase: "that"

Phrase: "corresponds to 125I-OS2-specific binding"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0205369:Specific [Qualitative Concept]
   753   C0243122:binding [Functional Concept]
   753   C0409957:OS2 [Disease or Syndrome]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]
   753   C1552740:specific [Intellectual Product]

Phrase: "measured in the absence of competitor."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   753   C0332197:absence [Quantitative Concept]
   753   C0444706:Measured [Qualitative Concept]
   753   C1689985:Absence [Anatomical Abnormality]
   753   C3541902:MEASURED [Diagnostic Procedure]
   719 E C0079809:Measure [Quantitative Concept]
   719 E C0242485:Measure [Functional Concept]
Processing 00000000.tx.100: K0.5 values measured for natural bvPLA2 (BV), for the recombinant bvPLA2 expressed as a fusion protein (rBVfp), and for the cleaved recombinant bvPLA2 (rBV) are indicated in the figure. 

Phrase: "K0.5 values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0042295:Values [Qualitative Concept]
   793 E C1522609:Value [Quantitative Concept]

Phrase: "measured for natural bvPLA2 (BV),"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0205296:Natural [Functional Concept]
   770   C0444706:Measured [Qualitative Concept]
   770   C3541902:MEASURED [Diagnostic Procedure]
   737 E C0079809:Measure [Quantitative Concept]
   737 E C0242485:Measure [Functional Concept]

Phrase: "for the recombinant bvPLA2 expressed as a fusion protein (rBVfp),"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   866   C0034861:Recombinant protein [Amino Acid, Peptide, or Protein]
   807   C0162768:Fusion protein [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
   791   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   791   C0332466:Fusion [Functional Concept]
   791   C0521125:For [Qualitative Concept]
   791   C1293131:Fusion [Therapeutic or Preventive Procedure]
   791   C1514798:recombinant [Organism]

Phrase: "and for the cleaved recombinant bvPLA2 (rBV)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0205242:Cleaved [Spatial Concept]
   753   C0333853:Cleaved [Cell]
   753   C1514798:recombinant [Organism]
   753   C1515981:And [Idea or Concept]

Phrase: "are"

Phrase: "indicated in the figure."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1444656:Indicated [Finding]
Processing 00000000.tx.101: [View Larger Version of this Image (25K GIF file)] Table II. 

Phrase: "[View Larger Version of this Image"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0333052:Version [Functional Concept]
   753   C2607870:Version [Spatial Concept]

Phrase: "(25K GIF file"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0016094:File [Occupational Activity]
   827   C0180853:File [Medical Device]
   827   C1522646:File [Functional Concept]

Phrase: ")"

Phrase: "] Table II."
Processing 00000000.tx.102: Binding properties and enzymatic activity of recombinant wild-type and mutant bee venom sPLA2s K0.5 values are expressed as mean values of at least two independent determinations. 

Phrase: "Binding properties"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0871161:properties [Qualitative Concept]
   861   C1292721:properties [Functional Concept]
   827 E C1882134:Property [Conceptual Entity]
   827 E C2347695:Property [Entity]

Phrase: "and"

Phrase: "enzymatic activity of recombinant wild-type"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   814   C0459205:Type of activity [Intellectual Product]
   790   C2267219:Enzymatic Activity [Molecular Function]
   753   C0205177:Activity [Functional Concept]
   753   C0439167:% activity [Quantitative Concept]
   753   C0441655:Activity [Activity]
   753   C1561536:*Activity [Idea or Concept]

Phrase: "and"

Phrase: "mutant bee venom sPLA2s K0.5 values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   791   C0042295:Values [Qualitative Concept]
   758 E C1522609:Value [Quantitative Concept]

Phrase: "are"

Phrase: "expressed as mean values of"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0042295:Values [Qualitative Concept]
   760   C0444504:Mean [Quantitative Concept]
   760   C2347634:Mean [Quantitative Concept]
   760   C2348143:Mean [Quantitative Concept]
   726 E C1522609:Value [Quantitative Concept]

Phrase: "at least two independent determinations."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0680730:determinations [Governmental or Regulatory Activity]
   779 E C1148554:determination [Laboratory Procedure]
Processing 00000000.tx.103: Data obtained for various mutations at the same position are indicated on the same line separated by "/" signs. 

Phrase: "Data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "obtained for various mutations"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0026882:Mutations [Genetic Function]
   770   C0440102:Various [Indicator, Reagent, or Diagnostic Aid]
   770   C1301820:Obtained [Functional Concept]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]
   737 E C1706701:Obtain [Activity]

Phrase: "at the same position"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0733755:Position [Spatial Concept]
   789 E C0240795:POSITIONAL [Finding]

Phrase: "are"

Phrase: "indicated on the same line"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0205132:Line [Spatial Concept]
   760   C0445247:Same [Qualitative Concept]
   760   C1444656:Indicated [Finding]
   760   C1550648:Line [Substance]
   760   C1552960:Line [Quantitative Concept]

Phrase: "separated by ""/"" signs."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   790   C0086972:Separated [Finding]
   790   C0220912:signs [Functional Concept]
   790   C0220913:signs [Manufactured Object]
   790   C0311392:SIGNS [Finding]
   790   C0443299:separated [Spatial Concept]
   790   C0687118:Separated [Functional Concept]
   756 E C1547188:Sign [Idea or Concept]
Processing 00000000.tx.104: sPLA2 Binding activity, K0.5 value PLA2 activitya nM % of rBV rbvPLA2fp 2.0 100 rbvPLA2 4.6 170 bvPLA2 (purified) 0.8 183 Interfacial binding surface I1C 52 15 I2C 37 5 I78C/Y 490/4.2 7/117 F82C 280 7 K85C/E 69/82 42/104 K85E/K133E 360 69 K85E/K94E/K133E >103 0.22 R23E/K85E/K133E >103 18 Y87F 2.6 152 I91F 98 20 D92C 14 33 Ca2+-binding loop G12A/C >103/35 37/17 G12S/K14R 5.3 100 N13C 12 43 N14C/E 42/16 29/62 K14E/R23E 580 10 S15C 14 58 Hydrophobic channel and active site T57F/V 131/550 0.7/0.2 T57D/E >103/>103 0.8/0.4 T57L 103 0.04 D64A/N >103/13 1.2/5 D64E/K66C 2.7 85 Other mutations R23C/E 10/20 32/165 R23E/R58A >103 7.6 F24C 42 102 K25Q 2.7 80 T51C 8.9 33 T53C 6.2 28 R58A 73 80 K66C/E 2.5/1.7 97/100 K72E 5.5 100 K94E 40 100 K122Q 0.6 110 K133E 9.4 80 99-118 7.6 >20 a All of the mutants were also assayed using the well established pH-stat method with vesicles of the anionic phospholipid 1,2-dimyristoylphosphatidylmethanol (36). 

Phrase: "sPLA2 Binding activity,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2266866:Binding Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "K0.5 value PLA2 activitya nM %"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0312860:NM [Cell Function]

Phrase: "of rBV rbvPLA2fp 2.0 100 rbvPLA2 4.6 170 bvPLA2"

Phrase: "(purified"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1998793:Purified [Functional Concept]
   907 E C1947930:Cleanse [Activity]

Phrase: ")"

Phrase: "0.8 183 Interfacial binding surface I1C 52 15 I2C 37 5 I78C/Y 490/4.2 7/117 F82C 280 7 K85C/E 69/82 42/104 K85E/K133E 360 69 K85E/K94E/K133E"

Phrase: ">103 0.22 R23E/K85E/K133E"

Phrase: ">103 18 Y87F 2.6 152 I91F 98 20 D92C 14 33 Ca2+-binding loop G12A/C >103/35 37/17 G12S/K14R 5.3 100 N13C 12 43 N14C/E 42/16 29/62 K14E/R23E 580 10 S15C 14 58 Hydrophobic channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   780   C0439799:Channel [Spatial Concept]
   780   C1706095:Channel [Conceptual Entity]

Phrase: "and"

Phrase: "active site T57F/V 131/550 0.7/0.2 T57D/E >103/"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   856   C0231963:V E [Laboratory or Test Result]
   839   C0445364:V 7/2 [Intellectual Product]
   838   C0445362:V 2 [Intellectual Product]
   797   C0205681:Active Site [Functional Concept]
   786   C0205145:Site [Spatial Concept]
   786   C0205177:Active [Functional Concept]
   786   C1515974:Site [Body Location or Region]
   786   C2825164:Site [Spatial Concept]

Phrase: ">103 0.8/0.4 T57L 103 0.04 D64A/N >103/13 1.2/5 D64E/K66C 2.7 85"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   857   C0444499:0/5 [Quantitative Concept]

Phrase: "Other mutations R23C/E 10/20 32/165 R23E/R58A"

Phrase: ">103 7.6 F24C 42 102 K25Q 2.7 80 T51C 8.9 33 T53C 6.2 28 R58A 73 80 K66C/E 2.5/1.7 97/100 K72E 5.5 100 K94E 40 100 K122Q 0.6 110 K133E 9.4 80 99-118 7.6"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   780   C0439073:97 [Intellectual Product]
   780   C0439082:>97 [Quantitative Concept]
   780   C0439509:/40 [Temporal Concept]

Phrase: ">20"

Phrase: "a All of the mutants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "were"

Phrase: "also"

Phrase: "assayed"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0005507:Assay [Laboratory Procedure]
   966   C0243073:assay [Qualitative Concept]
   966   C1510438:Assay [Laboratory Procedure]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the well established pH-stat method with vesicles"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0025663:Method [Intellectual Product]
   744   C0449851:Method [Functional Concept]
   744   C0871511:METHOD [Intellectual Product]

Phrase: "of the anionic phospholipid 1,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0031676:Phospholipid [Biologically Active Substance,Lipid]
   827   C0202177:Phospholipid [Laboratory Procedure]
   755   C0003075:Anion [Element, Ion, or Isotope]

Phrase: "2-dimyristoylphosphatidylmethanol"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0058288:dimyristoylphosphatidylmethanol [Indicator, Reagent, or Diagnostic Aid,Lipid]

Phrase: "(36"

Phrase: ")."
Processing 00000000.tx.105: The results are essentially the same, within 20%, as those obtained with the fluorimetric assay. 

Phrase: "The results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "essentially"

Phrase: "the same,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0445247:Same [Qualitative Concept]

Phrase: "within 20%,"

Phrase: "as"

Phrase: "those"

Phrase: "obtained with the fluorimetric assay."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0005507:Assay [Laboratory Procedure]
   760   C0243073:assay [Qualitative Concept]
   760   C1301820:Obtained [Functional Concept]
   760   C1510438:Assay [Laboratory Procedure]
   726 E C1706701:Obtain [Activity]
Processing 00000000.tx.106: In both assays, all of the mutants are tightly bound to vesicles, and thus the decrease in catalytic turnover is due to an increase in the interfacial Km, a decrease in the interfacial kcat, or a combination of both. 

Phrase: "In both assays,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0005507:Assay [Laboratory Procedure]
   966   C0243073:assay [Qualitative Concept]
   966   C1510438:Assay [Laboratory Procedure]

Phrase: "all of the mutants"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0444868:All [Quantitative Concept]
   770   C0596988:mutants [Cell or Molecular Dysfunction]
   770   C3539085:All [Idea or Concept]

Phrase: "are"

Phrase: "tightly"

Phrase: "bound to vesicles,"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   790   C0332297:bound [Spatial Concept]
   790   C0333262:VESICLES [Acquired Abnormality]
   790   C1145667:Bound [Activity]
   790   C1167622:Bound [Molecular Function]
   790   C1689898:% bound [Quantitative Concept]
   790   C2349209:Bound [Conceptual Entity]
   756 E C1622418:vesicle [Cell Component]
   706 E C0205378:Vesicular [Qualitative Concept]

Phrase: "and"

Phrase: "thus"

Phrase: "the decrease in catalytic turnover"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0392756:Decrease [Qualitative Concept]
   760   C0547047:Decrease [Quantitative Concept]

Phrase: "is due to an increase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C0678226:Due to [Functional Concept]
           due
   760   C0442805:Increase [Functional Concept]
   760   C3146286:Due [Idea or Concept]

Phrase: "in the interfacial Km,"

Phrase: "a decrease in the interfacial kcat,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0392756:Decrease [Qualitative Concept]
   753   C0547047:Decrease [Quantitative Concept]

Phrase: "or"

Phrase: "a combination of both."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205195:Combination [Qualitative Concept]
   770   C1947911:Combination [Physical Object]
Processing 00000000.tx.107: Fig. 

Phrase: "Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.108: 1 indicates a 3-6-fold difference in affinity between recombinant and natural bvPLA2. 

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "indicates"

Phrase: "a 3-6-fold difference in affinity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1705241:*Difference [Quantitative Concept]
   748   C1705242:Difference [Qualitative Concept]

Phrase: "between recombinant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514798:recombinant [Organism]

Phrase: "and"

Phrase: "natural bvPLA2."
Processing 00000000.tx.109: Natural bvPLA2 is heavily glycosylated on Asn-13 (41, 42), but the recombinant forms of bvPLA2 have been produced in Escherichia coli where glycosylation does not occur. 

Phrase: "Natural bvPLA2"

Phrase: "is"

Phrase: "heavily"

Phrase: "glycosylated on Asn-13"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0003995:Asn [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(41,"

Phrase: "42"

Phrase: ")"

Phrase: ","

Phrase: "but"

Phrase: "the recombinant forms of bvPLA2"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0348078:forms [Qualitative Concept]
   760   C0376315:Forms [Manufactured Object]
   726 E C1522492:Form [Functional Concept]

Phrase: "have"

Phrase: "been"

Phrase: "produced in Escherichia coli where glycosylation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0014834:Escherichia coli [Bacterium]
   753   C0014833:Escherichia [Bacterium]
   753   C0017982:glycosylation [Natural Phenomenon or Process]
   753   C0376322:Glycosylation [Molecular Function]

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "occur."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1709305:Occur [Activity]
  1000   C2745955:OCCUR [Temporal Concept]
Processing 00000000.tx.110: This suggests that differences in affinity between recombinant and natural bvPLA2 could be due to the presence of the carbohydrate moiety in the native enzyme. 

Phrase: "This"

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that differences in affinity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   737   C1705241:*Difference [Quantitative Concept]
   737   C1705242:Difference [Qualitative Concept]

Phrase: "between recombinant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514798:recombinant [Organism]

Phrase: "and"

Phrase: "natural bvPLA2"

Phrase: "could"

Phrase: "be due to the presence of the carbohydrate moiety"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   764   C0678226:Due to [Functional Concept]
           due
   742   C0007004:Carbohydrate [Carbohydrate]
   742   C0392148:Presence [Therapeutic or Preventive Procedure]
   742   C2987476:Be [Conceptual Entity]
   742   C3146286:Due [Idea or Concept]

Phrase: "in the native enzyme."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0014442:Enzyme [Enzyme,Organic Chemical]
   777 E C0014445:enzymes [Functional Concept]
Processing 00000000.tx.111: To address this point, we have enzymatically deglycosylated the natural bvPLA2 with N-glycosidase F and analyzed the binding properties of the purified deglycosylated enzyme. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "address"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0376649:Address [Intellectual Product]
  1000   C1442065:Address [Spatial Concept]

Phrase: "this point,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1552961:Point [Quantitative Concept]
  1000   C2347617:point [Quantitative Concept]

Phrase: "we"

Phrase: "have"

Phrase: "enzymatically"

Phrase: "deglycosylated"

Phrase: "the natural bvPLA2 with N-glycosidase F"

Phrase: "and"

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: "the binding properties of the purified deglycosylated enzyme."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   744   C0871161:properties [Qualitative Concept]
   744   C1292721:properties [Functional Concept]
   711 E C1882134:Property [Conceptual Entity]
   711 E C2347695:Property [Entity]
Processing 00000000.tx.112: After treatment with N-glycosidase F, deglycosylated bvPLA2 was purified by reverse phase high performance liquid chromatography (Fig. 2A), and the resulting peaks were analyzed by SDS-Tricine gel electrophoresis (Fig. 2B). 

Phrase: "After treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "with N-glycosidase F,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0377091:N-Glycosidase F [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   827   C0439133:(f) [Intellectual Product]
   827   C1553038:[f] [Quantitative Concept]
   734   C0597005:N glycosidase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "deglycosylated bvPLA2"

Phrase: "was"

Phrase: "purified by reverse phase high performance liquid chromatography"
Meta Candidates (Total=19; Excluded=0; Pruned=0; Remaining=19)
   833   C0008562:Chromatography, High Performance Liquid [Laboratory Procedure]
   833   C0687276:LIQUID CHROMATOGRAPHY, HIGH PERFORMANCE [Medical Device]
   833   C1579831:High performance liquid chromatography [Functional Concept]
   819   C2717789:Reverse-Phase Liquid Chromatography [Laboratory Procedure]
   793   C0597410:Chromatography, Reverse-Phase [Laboratory Procedure]
   770   C0008565:Liquid Chromatography [Laboratory Procedure]
   744   C0008550:Chromatography [Laboratory Procedure]
   744   C0205250:High [Qualitative Concept]
   744   C0205390:Phase [Temporal Concept]
   744   C0302908:Liquid [Substance]
   744   C0597198:Performance [Individual Behavior]
   744   C1299351:High [Qualitative Concept]
   744   C1304698:Liquid [Finding]
   744   C1546699:Liquid NOS [Intellectual Product]
   744   C1555029:Reverse [Idea or Concept]
   744   C1561501:Liquid NOS [Substance]
   744   C1882330:Performance [Activity]
   744   C1998793:Purified [Functional Concept]
   744   C2700149:HIGH [Intellectual Product]

Phrase: "(Fig. 2A"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "the resulting peaks"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0444505:peaks [Quantitative Concept]

Phrase: "were"

Phrase: "analyzed by SDS-Tricine gel electrophoresis"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   790   C0596607:Gel Electrophoresis [Laboratory Procedure]
   783 E C0972569:Electrophoresis Gel [Indicator, Reagent, or Diagnostic Aid]
   753   C0013855:Electrophoresis [Laboratory Procedure]
   753   C0017243:Gel [Biomedical or Dental Material]
   753   C0077068:tricine [Organic Chemical]
   753   C0936012:Analyzed [Research Activity]
   753   C1382104:Gel [Substance]

Phrase: "(Fig. 2B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450354:2b [Intellectual Product]
   861   C1706096:2B [Research Activity]

Phrase: ")."
Processing 00000000.tx.113: A shift in mobility of about 3 kDa was observed between the two main peaks that is consistent with the molecular mass of the carbohydrate moiety of bvPLA2 made of 14N-glycans (42). 

Phrase: "A shift in mobility of about 3 kDa"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0333051:Shift [Functional Concept]
   744   C2347509:Shift [Phenomenon or Process]

Phrase: "was"

Phrase: "observed between the two main peaks"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0205225:Main [Qualitative Concept]
   753   C0205448:Two [Quantitative Concept]
   753   C0444505:peaks [Quantitative Concept]
   753   C1441672:Observed [Functional Concept]
   753   C1542147:Main [Qualitative Concept]

Phrase: "that"

Phrase: "is"

Phrase: "consistent with the molecular mass of the carbohydrate moiety of bvPLA2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   756   C0332290:Consistent with [Idea or Concept]
           Consistent
   718   C2983632:Mass Consistency [Qualitative Concept]

Phrase: "made of 14N-glycans"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0032594:Glycans [Carbohydrate,Pharmacologic Substance]
   737   C1881534:Make [Functional Concept]

Phrase: "(42"

Phrase: ")."
Processing 00000000.tx.114: This suggests the major peak (peak B) effectively corresponds to deglycosylated bvPLA2. 

Phrase: "This"

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "the major peak"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0444505:Peak [Quantitative Concept]

Phrase: "(peak B) effectively"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0444505:Peak [Quantitative Concept]

Phrase: "corresponds to deglycosylated bvPLA2."
Processing 00000000.tx.115: Furthermore, the migration position of the faster moving protein is identical to that of the non-glycosylated fraction that is present in natural bee venom (36). 

Phrase: "Furthermore,"

Phrase: "the migration position of the faster moving protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0733755:Position [Spatial Concept]

Phrase: "is"

Phrase: "identical to that of the non-glycosylated fraction"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0205280:Identical [Qualitative Concept]

Phrase: "that"

Phrase: "is"

Phrase: "present in natural bee venom"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0150312:Present [Quantitative Concept]
   760   C0449450:Present [Idea or Concept]

Phrase: "(36"

Phrase: ")."
Processing 00000000.tx.116: The identification of peak B as deglycosylated bvPLA2 was further confirmed by N-terminal protein sequencing, indicating that Asn-13 has been fully deglycosylated (not shown). 

Phrase: "The identification of peak B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0020792:Identification [Mental Process]
   760   C0205396:Identification [Qualitative Concept]

Phrase: "as deglycosylated bvPLA2"

Phrase: "was"

Phrase: "further"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "confirmed by N-terminal protein sequencing,"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   790   C0002518:protein sequencing [Amino Acid Sequence]
   790   C0521093:Confirmed by [Qualitative Concept]
           confirmed
   790   C0751971:Protein Sequencing [Laboratory Procedure,Molecular Biology Research Technique]
   753   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C0205088:Terminal [Temporal Concept]
   753   C0750484:Confirmed [Idea or Concept]
   753   C1553778:Sequencing [Intellectual Product]
   753   C1561491:Sequencing [Functional Concept]
   753   C1705314:Terminal [Manufactured Object]
   753   C1705315:Terminal [Spatial Concept]
   719 E C1456348:Confirm [Qualitative Concept]

Phrase: "indicating"

Phrase: "that Asn-13"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0003995:Asn [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "has"

Phrase: "been"

Phrase: "fully"

Phrase: "deglycosylated"

Phrase: "("

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.117: Results from competition binding experiments with deglycosylated bvPLA2 for binding to N-type receptors are shown in Fig. 

Phrase: "Results from competition binding experiments"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   739   C2825142:Experimental Result [Finding]
           Result
   726   C1274040:Result [Functional Concept]
   726   C1546471:Result [Idea or Concept]

Phrase: "with deglycosylated bvPLA2"

Phrase: "for binding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0243122:binding [Functional Concept]
  1000   C1145667:Binding [Activity]
  1000   C1167622:Binding [Molecular Function]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "are"

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.118: 2C. 

Phrase: "2C."
Processing 00000000.tx.119: Interestingly, deglycosylated bvPLA2 displays a K0.5 value nearly identical to that of the cleaved recombinant bvPLA2 (Fig. 1). 

Phrase: "Interestingly,"

Phrase: "deglycosylated bvPLA2"

Phrase: "displays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0870432:displays [Functional Concept]
  1000   C1705417:Display [Manufactured Object]

Phrase: "a K0.5 value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1522609:Value [Quantitative Concept]

Phrase: "nearly identical to that of the cleaved recombinant bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0205280:Identical [Qualitative Concept]

Phrase: "(Fig. 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.120: This K0.5 value is about five times higher than that of the natural glycosylated bvPLA2. 

Phrase: "This K0.5 value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1522609:Value [Quantitative Concept]

Phrase: "is"

Phrase: "about five times"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0040223:times [Temporal Concept]
   827   C1632851:Times [Quantitative Concept]
   793 E C3541383:Time [Temporal Concept]
   755 E C0442043:Temporal [Spatial Concept]
   755 E C2362314:Temporal [Temporal Concept]

Phrase: "higher than that of the natural glycosylated bvPLA2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   711   C0205250:High [Qualitative Concept]
   711   C1299351:High [Qualitative Concept]
   711   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.121: Taken together, these results indicate that the carbohydrate moiety of bvPLA2, although not crucially involved in the interaction of bvPLA2 with N-type receptors, increases the affinity by a factor of about 5. 

Phrase: "Taken"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883727:Taken [Conceptual Entity]
   966 E C1515187:Take [Health Care Activity]

Phrase: "together,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883357:Together [Qualitative Concept]

Phrase: "these results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "indicate"

Phrase: "that"

Phrase: "the carbohydrate moiety of bvPLA2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0007004:Carbohydrate [Carbohydrate]

Phrase: "although"

Phrase: "not crucially"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "involved in the interaction of bvPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1314939:Involved [Functional Concept]
   753   C1704675:Interaction [Functional Concept]

Phrase: "with N-type receptors,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "the affinity by a factor of about 5."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1510827:Affinity [Natural Phenomenon or Process]
Processing 00000000.tx.122: Fig. 

Phrase: "Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.123: 2. 

Phrase: "2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]
Processing 00000000.tx.124: Preparation and binding properties of deglycosylated bvPLA2. 

Phrase: "Preparation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0455052:Preparation [Health Care Activity]
  1000   C1521827:Preparation [Functional Concept]

Phrase: "and"

Phrase: "binding properties of deglycosylated bvPLA2."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   760   C0871161:properties [Qualitative Concept]
   760   C1292721:properties [Functional Concept]
   726 E C1882134:Property [Conceptual Entity]
   726 E C2347695:Property [Entity]
Processing 00000000.tx.125: A, elution profile of natural bvPLA2 treated with N-glycopeptidase F on C18 reverse phase column. 

Phrase: "A,"

Phrase: "elution profile of natural bvPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1979963:Profile [Laboratory Procedure]
   760   C2003903:Profile [Functional Concept]

Phrase: "treated with N-glycopeptidase F"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   806   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   806   C0377091:Glycopeptidase F [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   760   C0061642:Glycopeptidase [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0439133:(f) [Intellectual Product]
   760   C1522326:Treated [Functional Concept]
   760   C1553038:[f] [Quantitative Concept]
   726 E C1292734:TREAT [Functional Concept]

Phrase: "on C18 reverse phase column."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1185738:Column [Body Part, Organ, or Organ Component]
   812   C1706132:Column [Idea or Concept]
Processing 00000000.tx.126: Retention time for bvPLA2 treated without N-glycopeptidase F corresponds to peak A (not shown). 

Phrase: "Retention time for bvPLA2"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   770   C0035280:Retention [Mental Process]
   770   C0040223:Time [Temporal Concept]
   770   C0333117:Retention [Functional Concept]
   770   C1753315:retention [Cell Function]
   770   C3541383:Time [Temporal Concept]
   715 E C0442043:Temporal [Spatial Concept]
   715 E C2362314:Temporal [Temporal Concept]

Phrase: "treated without N-glycopeptidase F"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   806   C0377091:Glycopeptidase F [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   760   C0061642:Glycopeptidase [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0332293:treated [Therapeutic or Preventive Procedure]
   760   C0439133:(f) [Intellectual Product]
   760   C1522326:Treated [Functional Concept]
   760   C1553038:[f] [Quantitative Concept]
   726 E C1292734:TREAT [Functional Concept]

Phrase: "corresponds to peak A ("
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0444505:Peak [Quantitative Concept]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.127: B, gel analysis of untreated bvPLA2, N-glycopeptidase F/bvPLA2 reaction mixture, and peaks A and B.C, comparison of binding properties to N-type receptors for natural glycosylated bvPLA2 () and purified deglycosylated bvPLA2 (). 

Phrase: "B,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "gel analysis of untreated bvPLA2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0002778:Analysis [Laboratory Procedure]
   760   C0936012:Analysis [Research Activity]
   760   C1524024:analysis [Functional Concept]

Phrase: "N-glycopeptidase F/bvPLA2 reaction mixture,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0439962:Mixture [Substance]

Phrase: "and"

Phrase: "peaks"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0444505:Peak [Quantitative Concept]

Phrase: "A"

Phrase: "and"

Phrase: "B.C,"

Phrase: "comparison of binding properties"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1707455:Comparison [Activity]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "for natural glycosylated bvPLA2"

Phrase: "("

Phrase: ")"

Phrase: "and"

Phrase: "purified"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1998793:Purified [Functional Concept]
   907 E C1947930:Cleanse [Activity]

Phrase: "deglycosylated bvPLA2"

Phrase: "("

Phrase: ")."
Processing 00000000.tx.128: Binding conditions are as indicated in the legend to Fig. 

Phrase: "Binding conditions"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0012634:condition [Disease or Syndrome]
   827   C0348080:Condition [Qualitative Concept]
   827   C1705253:Condition [Conceptual Entity]
   777 E C0009647:Conditioned [Mental Process]
   777 E C1701901:Conditional [Qualitative Concept]
   777 E C1963686:Conditional [Functional Concept]
   755 E C1519605:Conditionality [Conceptual Entity]

Phrase: "are"

Phrase: "as"

Phrase: "indicated in the legend"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1444656:Indicated [Finding]
   770   C2729544:Legend [Pharmacologic Substance]

Phrase: "to Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.129: 1. 

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.130: [View Larger Version of this Image (42K GIF file)] Analysis of Mutations in the Putative Interfacial Recognition Surfaces of bvPLA2 The x-ray crystal structures of group I-III sPLA2s containing a bound phospholipid analog reveal a common constellation of catalytic residues lying about two-thirds down the length of the active site slot where the substrate binds (6). 

Phrase: "[View Larger Version of this Image"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0333052:Version [Functional Concept]
   753   C2607870:Version [Spatial Concept]

Phrase: "(42K GIF file"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0016094:File [Occupational Activity]
   827   C0180853:File [Medical Device]
   827   C1522646:File [Functional Concept]

Phrase: ")"

Phrase: "] Analysis of Mutations"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   841   C0796357:mutation analysis [Laboratory Procedure]
   790   C0002778:Analysis [Laboratory Procedure]
   790   C0936012:Analysis [Research Activity]
   790   C1524024:analysis [Functional Concept]

Phrase: "in the Putative Interfacial Recognition"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0524637:Recognition [Mental Process]

Phrase: "Surfaces of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205148:Surface [Spatial Concept]

Phrase: "The x-ray crystal structures of group I-III sPLA2s"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   751   C0018266:Structures, Group [Group Attribute]
   736   C0427896:Crystal [Body Substance]
   736   C0444626:Crystal [Chemical Viewed Structurally]
           Crystal Structure
   736   C0678594:structures [Spatial Concept]
   736   C1533132:Crystal [Body Substance]
   736   C1704641:Crystal [Manufactured Object]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "a bound phospholipid analog"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0243071:Analog [Chemical Viewed Structurally]
   727 E C0679213:analogies [Idea or Concept]

Phrase: "reveal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:reveal [Qualitative Concept]

Phrase: "a common constellation of catalytic residues"

Phrase: "lying about two-thirds"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0038846:Lying [Spatial Concept]
   770   C0205437:Third [Quantitative Concept]
   770   C0205448:Two [Quantitative Concept]
   770   C0600261:Lying [Individual Behavior]

Phrase: "down the length"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C1444754:Length [Quantitative Concept]
  1000   C1706316:LENGTH [Research Activity]
   928 E C0205166:Long [Qualitative Concept]
   928 E C1522425:Longest [Qualitative Concept]
   928 E C1706317:Long [Qualitative Concept]

Phrase: "of the active site slot where"

Phrase: "the substrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1710236:Substrate [Manufactured Object]

Phrase: "binds"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "(6"

Phrase: ")."
Processing 00000000.tx.131: Despite these common features, the global topology of bvPLA2 is very different than those of group I and II sPLA2s. 

Phrase: "Despite these common features,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1521970:Feature [Qualitative Concept]
   827   C1706388:Feature [Conceptual Entity]
   827   C2346469:Feature [Qualitative Concept]
   827   C2348519:Feature [Qualitative Concept]

Phrase: "the global topology of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0002812:Topology [Biomedical Occupation or Discipline]

Phrase: "is"

Phrase: "very different than those of group I"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1705242:Different [Qualitative Concept]

Phrase: "and"

Phrase: "II sPLA2s."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   923   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]
Processing 00000000.tx.132: It is currently thought that the surface of bvPLA2 that contacts the membrane bilayer, the interfacial recognition surface (IRS), surrounds the opening of the active site slot (Figs. 3 and 4). 

Phrase: "It"

Phrase: "is"

Phrase: "currently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0521116:Currently [Temporal Concept]

Phrase: "thought"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039869:Thought [Mental Process]

Phrase: "that"

Phrase: "the surface of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0205148:Surface [Spatial Concept]

Phrase: "that"

Phrase: "contacts"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332158:contact [Functional Concept]
  1000   C0337611:Contact [Population Group]
  1000   C1705415:Contact [Idea or Concept]

Phrase: "the membrane bilayer,"

Phrase: "the interfacial recognition surface (IRS),"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205148:Surface [Spatial Concept]

Phrase: "surrounds"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1282914:Surround [Spatial Concept]

Phrase: "the opening of the active site slot"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0175566:Opening [Spatial Concept]
   748   C1882151:Opening [Spatial Concept]

Phrase: "(Figs. 3"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0349966:Figs [Food]
   827 E C1337208:FIG [Food]

Phrase: "and"

Phrase: "4"

Phrase: ")."
Processing 00000000.tx.133: This putative IRS of bvPLA2 is composed of residues that lie on one face of an -helix (composed of residues 76-91), of residues in the N-terminal portion of the protein, and of a portion of the Ca2+-binding loop (35, 43). 

Phrase: "This putative IRS of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0205148:Surface [Spatial Concept]

Phrase: "is"

Phrase: "composed of residues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   756   C1709915:Residue [Conceptual Entity]
   756   C1882936:RESIDUE [Phenomenon or Process]
   706 E C1609982:Residual [Qualitative Concept]

Phrase: "that"

Phrase: "lie on one face of an -helix"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0015450:Face [Body Location or Region]
   748   C0018882:Helix [Eukaryote]
   748   C0205447:One [Quantitative Concept]
   748   C0229304:Helix [Body Part, Organ, or Organ Component]
   748   C1281591:Face [Body Part, Organ, or Organ Component]
   748   C1704821:Helix [Spatial Concept]
   748   C1705682:Helix [Anatomical Structure]

Phrase: "("

Phrase: "composed of residues 76-91"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C1709915:Residue [Conceptual Entity]
   726   C1882936:RESIDUE [Phenomenon or Process]

Phrase: ")"

Phrase: ","

Phrase: "of residues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   966   C1709915:Residue [Conceptual Entity]
   966   C1882936:RESIDUE [Phenomenon or Process]
   916 E C1609982:Residual [Qualitative Concept]

Phrase: "in the N-terminal portion"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0449719:Portion [Spatial Concept]

Phrase: "of the protein,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and of a portion of the Ca2+-binding loop"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   742   C0243122:binding [Functional Concept]
   742   C0419518:Loop [Medical Device]
   742   C0445022:Loop [Spatial Concept]
   742   C0449719:Portion [Spatial Concept]
   742   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   742   C1145667:Binding [Activity]
   742   C1167622:Binding [Molecular Function]
   742   C1515981:And [Idea or Concept]

Phrase: "(35,"

Phrase: "43"

Phrase: ")."
Processing 00000000.tx.134: K0.5 values for the inhibition of 125I-OS2 binding to N-type receptors by bvPLA2 proteins containing mutations in the IRS are listed in Table II, and inhibition curves for some of the mutants are shown in Fig. 

Phrase: "K0.5 values for the inhibition of 125I-OS2 binding"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   739   C0042295:Values [Qualitative Concept]
   706 E C1522609:Value [Quantitative Concept]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "by bvPLA2 proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "mutations in the IRS"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0026882:Mutations [Genetic Function]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "listed in Table II,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0039224:Table [Manufactured Object]
   770   C1706073:Table [Medical Device]
   770   C1706074:Table [Intellectual Product]
   737   C0745732:List [Conceptual Entity]
   737   C3272378:LIST [Intellectual Product]

Phrase: "and"

Phrase: "inhibition"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0021467:Inhibition [Mental Process]
  1000   C0021469:Inhibition [Molecular Function]
  1000   C1628982:% inhibition [Quantitative Concept]
  1000   C3463820:Inhibition [Activity]
   928 E C0311403:Inhibited [Qualitative Concept]

Phrase: "curves for some of the mutants"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0205134:Curve [Spatial Concept]
   753   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.135: 5. 

Phrase: "5."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]
Processing 00000000.tx.136: For these studies, a number of mutants were made in which the wild-type residue was replaced with cysteine. 

Phrase: "For these studies,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "a number of mutants"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0237753:*Number [Quantitative Concept]
   770   C0449788:Number [Quantitative Concept]

Phrase: "were"

Phrase: "made in which"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1881534:Make [Functional Concept]

Phrase: "the wild-type residue"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   827   C1709915:Residue [Conceptual Entity]
   827   C1882936:RESIDUE [Phenomenon or Process]
   755 E C1609982:Residual [Qualitative Concept]
   734   C1883559:Wild Type [Organism Attribute]

Phrase: "was"

Phrase: "replaced with cysteine."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   790   C0559956:Replaced [Functional Concept]
   790   C1299987:replaced [Functional Concept]
   756 E C1554078:Replace [Idea or Concept]
Processing 00000000.tx.137: During in vitro refolding of mutants, cysteine and cystine are present in the buffer to provide a redox couple that favors formation of the five disulfide bridges that are present in natural bvPLA2. 

Phrase: "During in vitro refolding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   734   C0021135:In Vitro [Intellectual Product]
   734   C1533691:in vitro [Qualitative Concept]
   734   C2827718:In Vitro [Functional Concept]

Phrase: "of mutants,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "cysteine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "cystine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0010682:Cystine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
  1000   C0546634:CYSTINE [Laboratory Procedure]

Phrase: "are"

Phrase: "present in the buffer to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0150312:Present [Quantitative Concept]
   760   C0449450:Present [Idea or Concept]

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "a redox"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030012:Redox [Molecular Function]

Phrase: "couple"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0010222:couple [Family Group]
  1000   C1948027:Couple [Functional Concept]

Phrase: "that favors formation of the five disulfide bridges"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0220781:formation [Biologic Function]
   744   C0439634:formation [Spatial Concept]
   744   C1522492:Formation [Functional Concept]

Phrase: "that"

Phrase: "are"

Phrase: "present in natural bvPLA2."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0150312:Present [Quantitative Concept]
   770   C0449450:Present [Idea or Concept]
Processing 00000000.tx.138: After refolding of all mutant proteins containing the desired additional cysteines, the cysteines end up in a disulfide linkage to a free cysteine from the redox buffer. 

Phrase: "After refolding"

Phrase: "of all mutant proteins"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1564139:Mutant Proteins [Amino Acid, Peptide, or Protein]
   861   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "the desired additional cysteines,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0010654:cysteines [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "the cysteines"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010654:cysteines [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "end up"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0444930:End [Spatial Concept]
   833   C2746065:End [Temporal Concept]

Phrase: "in a disulfide linkage"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511997:Disulfide Linkage [Amino Acid Sequence]
   861   C0023745:linkage [Molecular Function]

Phrase: "to a free cysteine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "from the redox buffer."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
Processing 00000000.tx.139: This is useful for initial studies aimed at mapping the receptor recognition surface of bvPLA2, since the wild-type residue is replaced by a fairly large residue that is also zwitterionic at physiological pH and thus very hydrophilic. 

Phrase: "This"

Phrase: "is"

Phrase: "useful for initial studies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   783   C0869040:Use studies [Research Activity]

Phrase: "aimed at mapping"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C1283195:Mapping [Activity]
   756   C1947946:Aim [Idea or Concept]
   756   C2948600:Aim [Pharmacologic Substance]
   756   C3540471:AIM [Gene or Genome]
   756   C3540472:AIM [Functional Concept]

Phrase: "the receptor recognition surface of bvPLA2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0205148:Surface [Spatial Concept]

Phrase: "since"

Phrase: "the wild-type residue"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   827   C1709915:Residue [Conceptual Entity]
   827   C1882936:RESIDUE [Phenomenon or Process]
   755 E C1609982:Residual [Qualitative Concept]
   734   C1883559:Wild Type [Organism Attribute]

Phrase: "is"

Phrase: "replaced by a fairly large residue"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   790   C1299987:Replaced by [Functional Concept]
           replaced
   753   C0549177:Large [Quantitative Concept]
   753   C0559956:Replaced [Functional Concept]
   753   C1709915:Residue [Conceptual Entity]
   753   C1882936:RESIDUE [Phenomenon or Process]
   719 E C1554078:Replace [Idea or Concept]

Phrase: "that"

Phrase: "is"

Phrase: "also zwitterionic at physiological pH"

Phrase: "and"

Phrase: "thus very hydrophilic."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0475370:Hydrophilic [Qualitative Concept]
Processing 00000000.tx.140: Fig. 

Phrase: "Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.141: 3. 

Phrase: "3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]
Processing 00000000.tx.142: Stereo ribbon drawing of the bvPLA2 structure. 

Phrase: "Stereo ribbon drawing of the bvPLA2 structure."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0013113:drawing [Intellectual Product]
Processing 00000000.tx.143: The view is such that the methyl groups at the ends of the alkyl chains of the active site phospholipid analog inhibitor (unfilled bonds) are pointing toward the reader. 

Phrase: "The view"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "is"

Phrase: "such"

Phrase: "that"

Phrase: "the methyl groups at the ends of the alkyl"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   762   C0596066:alkyl group [Organic Chemical]
   742   C0441833:Group [Idea or Concept]
   742   C0687744:group [Population Group]
   742   C1257890:Group [Population Group]
   742   C1552516:Group [Health Care Related Organization]
   742   C1552839:groups [Idea or Concept]
   742   C1705428:Group [Conceptual Entity]
   742   C1705429:Group [Population Group]
   731   C0596922:Methyl Group [Organic Chemical]

Phrase: "chains of the active site phospholipid analog inhibitor"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   770   C0205681:Active Site [Functional Concept]
   767   C0597221:phospholipid inhibitor [Pharmacologic Substance]
   767   C2945843:Site of [Qualitative Concept]
   744   C0031676:Phospholipid [Biologically Active Substance,Lipid]
   744   C0202177:Phospholipid [Laboratory Procedure]
   744   C0205145:Site [Spatial Concept]
   744   C0205177:Active [Functional Concept]
   744   C0243071:Analog [Chemical Viewed Structurally]
   744   C0337112:Chain [Manufactured Object]
   744   C1515974:Site [Body Location or Region]
   744   C1524075:Chain [Idea or Concept]
   744   C1999216:Inhibitor [Qualitative Concept]
   744   C2825164:Site [Spatial Concept]

Phrase: "(unfilled bonds"

Phrase: ")"

Phrase: "are"

Phrase: "pointing toward the reader."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C1514743:Reader [Professional or Occupational Group]
   770   C1706461:Reader [Manufactured Object]
   737   C1552961:Point [Quantitative Concept]
   737   C2347617:point [Quantitative Concept]
Processing 00000000.tx.144: The front face is probably the IRS. 

Phrase: "The front face"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0015450:Face [Body Location or Region]
   861   C1281591:Face [Body Part, Organ, or Organ Component]

Phrase: "is"

Phrase: "probably"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750492:Probably [Idea or Concept]

Phrase: "the IRS."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205148:Surface [Spatial Concept]
Processing 00000000.tx.145: The position of those mutants that increase K0.5 for binding to N-type receptors by at least 100-fold are shown as large red spheres (12, 57,64,78,82), those that increase K0.5 by less than 10-fold are shown as small blue spheres (13, 15, 25, 51, 53, 66,72,87,92,122,133), and those that increase K0.5 by an intermediate amount are shown as medium yellow spheres (1, 2, 14, 23, 24, 58,85,91,94). 

Phrase: "The position of those mutants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0733755:Position [Spatial Concept]

Phrase: "that"

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "K0.5 for binding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "by"

Phrase: "at least 100-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0332462:Fold [Spatial Concept]
   827   C1880834:FOLD [Phenomenon or Process]

Phrase: "are"

Phrase: "shown as large red spheres"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   760   C0332575:Red [Finding]
   760   C0549177:Large [Quantitative Concept]
   760   C0946401:spheres [Organism Attribute]
   760   C1260956:Red [Qualitative Concept]
   726 E C0332501:Sphere [Spatial Concept]
   726   C1547282:Show [Intellectual Product]

Phrase: "(12,"

Phrase: "57,"

Phrase: "64,"

Phrase: "78,"

Phrase: "82"

Phrase: ")"

Phrase: ","

Phrase: "those"

Phrase: "that increase K0.5 by less"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0442805:Increase [Functional Concept]

Phrase: "than 10-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332462:Fold [Spatial Concept]
   861   C1880834:FOLD [Phenomenon or Process]

Phrase: "are"

Phrase: "shown as small blue spheres"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0700321:Small [Quantitative Concept]
   760   C0946401:spheres [Organism Attribute]
   760   C1260957:Blue [Qualitative Concept]
   726 E C0332501:Sphere [Spatial Concept]
   726   C1547282:Show [Intellectual Product]

Phrase: "(13,"

Phrase: "15,"

Phrase: "25,"

Phrase: "51,"

Phrase: "53,"

Phrase: "66,"

Phrase: "72,"

Phrase: "87,"

Phrase: "92,122,133"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "those"

Phrase: "that increase K0.5 by an intermediate amount"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   744   C0205103:Intermediate [Spatial Concept]
   744   C0442805:Increase [Functional Concept]
   744   C1265611:Amount [Quantitative Concept]
   744   C1550465:intermediate [Idea or Concept]
   744   C2827755:INTERMEDIATE [Laboratory or Test Result]

Phrase: "are"

Phrase: "shown as medium yellow spheres"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   760   C0009458:Medium [Intellectual Product]
   760   C0221205:Yellow [Qualitative Concept]
   760   C0439536:Medium [Quantitative Concept]
   760   C0946401:spheres [Organism Attribute]
   760   C1705217:Medium [Substance]
   760   C3244283:medium [Intellectual Product]
   726 E C0332501:Sphere [Spatial Concept]
   726   C1547282:Show [Intellectual Product]

Phrase: "(1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "14,"

Phrase: "23,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: "24,"

Phrase: "58,"

Phrase: "85,"

Phrase: "91,"

Phrase: "94"

Phrase: ")."
Processing 00000000.tx.146: The image was created with the MolScript program (56). 

Phrase: "The image"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1704254:Image [Intellectual Product]
  1000   C1704922:Image [Entity]
  1000   C3542466:Image [Intellectual Product]

Phrase: "was"

Phrase: "created with the MolScript program"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C1706214:Created [Activity]
   760   C1709697:Program [Conceptual Entity]
   760   C2728259:Program [Pharmacologic Substance]
   760   C3484370:Program [Functional Concept]
   726 E C3244320:create [Functional Concept]

Phrase: "(56"

Phrase: ")."
Processing 00000000.tx.147: [View Larger Version of this Image (32K GIF file)] Fig. 

Phrase: "[View Larger Version of this Image"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0333052:Version [Functional Concept]
   753   C2607870:Version [Spatial Concept]

Phrase: "(32K GIF file"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0016094:File [Occupational Activity]
   827   C0180853:File [Medical Device]
   827   C1522646:File [Functional Concept]

Phrase: ")"

Phrase: "] Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.148: 4. 

Phrase: "4."
Processing 00000000.tx.149: Molecular surface of bvPLA2. 

Phrase: "Molecular surface of bvPLA2."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205148:Surface [Spatial Concept]
   770   C1521991:Molecular [Qualitative Concept]
Processing 00000000.tx.150: The view is the same as in Fig. 

Phrase: "The view"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "is"

Phrase: "the same"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0445247:Same [Qualitative Concept]

Phrase: "as in Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
Processing 00000000.tx.151: 3 and was created with the program GRASP. 

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "and"

Phrase: "was"

Phrase: "created with the program GRASP."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   760   C0220843:grasp [Organism Function]
   760   C1425726:GRASP [Gene or Genome]
   760   C1706214:Created [Activity]
   760   C1709697:Program [Conceptual Entity]
   760   C2728259:Program [Pharmacologic Substance]
   760   C3484370:Program [Functional Concept]
   726 E C3244320:create [Functional Concept]
Processing 00000000.tx.152: The positions of mutants that affect the binding to N-type receptors by a large amount, an intermediate amount, and a small amount are shown in red, yellow, and blue, respectively. 

Phrase: "The positions of mutants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0733755:positions [Spatial Concept]

Phrase: "that"

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "the binding to N-type receptors"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   767   C0597358:Receptor Binding [Molecular Function]
   753   C0243122:binding [Functional Concept]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]

Phrase: "by a large amount,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1265611:Amount [Quantitative Concept]

Phrase: "an intermediate amount,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1265611:Amount [Quantitative Concept]

Phrase: "and"

Phrase: "a small amount"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1265611:Amount [Quantitative Concept]

Phrase: "are"

Phrase: "shown in red,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0332575:Red [Finding]
   790   C1260956:Red [Qualitative Concept]
   756   C1547282:Show [Intellectual Product]

Phrase: "yellow,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0221205:Yellow [Qualitative Concept]

Phrase: "and"

Phrase: "blue,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260957:Blue [Qualitative Concept]

Phrase: "respectively."
Processing 00000000.tx.153: The inhibitor is shown with blue sticks. 

Phrase: "The inhibitor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999216:Inhibitor [Qualitative Concept]

Phrase: "is"

Phrase: "shown with blue sticks."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C1260957:Blue [Qualitative Concept]
   737   C1547282:Show [Intellectual Product]
   737   C1706582:Stick [Biomedical or Dental Material]
   737   C1706583:Stick [Quantitative Concept]
Processing 00000000.tx.154: [View Larger Version of this Image (70K GIF file)] Fig. 

Phrase: "[View Larger Version of this Image"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0333052:Version [Functional Concept]
   753   C2607870:Version [Spatial Concept]

Phrase: "(70K GIF file"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0016094:File [Occupational Activity]
   827   C0180853:File [Medical Device]
   827   C1522646:File [Functional Concept]

Phrase: ")"

Phrase: "] Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.155: 5. 

Phrase: "5."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]
Processing 00000000.tx.156: Inhibition of 125I-OS2 binding to N-type receptors by the various bvPLA2 mutants produced in E.coli. 

Phrase: "Inhibition of 125I-OS2 binding"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   844   C2259198:inhibition of binding [Molecular Function]
   760   C0021467:Inhibition [Mental Process]
   760   C0021469:Inhibition [Molecular Function]
   760   C1628982:% inhibition [Quantitative Concept]
   760   C3463820:Inhibition [Activity]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "by the various bvPLA2 mutants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "produced in E.coli."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C0014834:E coli [Bacterium]
Processing 00000000.tx.157: Experiments and results are the same as described in the legend to Fig. 

Phrase: "Experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0681814:Experiments [Research Activity]
   966 E C1706386:Experiment [Conceptual Entity]
   916 E C1517586:Experimental [Qualitative Concept]

Phrase: "and"

Phrase: "results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "the same"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0445247:Same [Qualitative Concept]

Phrase: "as"

Phrase: "described in the legend"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1552738:described [Idea or Concept]
   770   C2729544:Legend [Pharmacologic Substance]

Phrase: "to Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.158: 1. 

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.159: A-D indicate K0.5 values of bvPLA2 containing mutations in the IRS mutants, the Ca2+-binding loop, the hydrophobic channel/active site, and in other parts of the bvPLA2 structure, respectively. 

Phrase: "A-D"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0718133:a & d [Organic Chemical,Pharmacologic Substance,Vitamin]

Phrase: "indicate"

Phrase: "K0.5 values of bvPLA2 containing mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C0042295:Values [Qualitative Concept]
   714 E C1522609:Value [Quantitative Concept]

Phrase: "in the IRS mutants,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "the Ca2+-binding loop,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0243122:binding [Functional Concept]
   827   C0419518:Loop [Medical Device]
   827   C0445022:Loop [Spatial Concept]
   827   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1145667:Binding [Activity]
   827   C1167622:Binding [Molecular Function]

Phrase: "the hydrophobic channel/active site,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0205681:Active Site [Functional Concept]
   812   C0205145:Site [Spatial Concept]
   812   C0205177:Active [Functional Concept]
   812   C1515974:Site [Body Location or Region]
   812   C2825164:Site [Spatial Concept]

Phrase: "and in other parts of the bvPLA2 structure,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   754   C1292711:Part of [Spatial Concept]
   750   C0442052:Part structure [Spatial Concept]
   744   C0449719:parts [Spatial Concept]
   744   C0678594:Structure [Spatial Concept]
   744   C1515981:And [Idea or Concept]
   744   C1709471:PARTS [Quantitative Concept]

Phrase: "respectively."
Processing 00000000.tx.160: [View Larger Version of this Image (50K GIF file)] Replacement of Ile-1 and Ile-2 by cysteine (I1CC and I2CC, respectively, where CC denotes the protein's cysteine disulfide linked to a free cysteine) results in a 20-25-fold increase in K0.5 value (i.e. 20-25-fold decrease in receptor affinity) as compared with that of wild-type bvPLA2, suggesting that these two positions play a role in recognition of N-type receptors (Table II). 

Phrase: "[View Larger Version of this Image"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0333052:Version [Functional Concept]
   753   C2607870:Version [Spatial Concept]

Phrase: "(50K GIF file"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0016094:File [Occupational Activity]
   827   C0180853:File [Medical Device]
   827   C1522646:File [Functional Concept]

Phrase: ")"

Phrase: "] Replacement of Ile-1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0035139:Replacement [Therapeutic or Preventive Procedure]
   770   C0559956:Replacement [Functional Concept]
   770   C1555302:Replacement [Idea or Concept]

Phrase: "and"

Phrase: "Ile-2 by cysteine"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C0022192:Ile [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   770   C0523728:ILE [Laboratory Procedure]

Phrase: "(I1CC"

Phrase: "and"

Phrase: "I2CC,"

Phrase: "respectively,"

Phrase: "where CC"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538933:CC [Cell Component]

Phrase: "denotes"

Phrase: "the protein's cysteine disulfide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0012771:disulfide [Chemical Viewed Structurally]

Phrase: "linked to a free cysteine"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0332296:free [Functional Concept]
   760   C1880497:Free [Qualitative Concept]
   760   C1996904:Free [Qualitative Concept]
   726   C1517892:Link [Intellectual Product]
   726   C1704666:Link [Intellectual Product]

Phrase: ")"

Phrase: "results in a 20-25-fold increase"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C1690939:20/25 [Finding]
   748   C0332462:Fold [Spatial Concept]
   748   C0442805:Increase [Functional Concept]
   748   C1274040:Result [Functional Concept]
   748   C1546471:Result [Idea or Concept]
   748   C1880834:FOLD [Phenomenon or Process]
   748   C2825142:Result [Finding]

Phrase: "in K0.5 value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1522609:Value [Quantitative Concept]

Phrase: "(i.e. 20-25-fold decrease in receptor affinity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0392756:Decrease [Qualitative Concept]
   742   C0547047:Decrease [Quantitative Concept]

Phrase: ")"

Phrase: "as"

Phrase: "compared with that of wild-type bvPLA2,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C1883559:Wild Type [Organism Attribute]
   748   C0332307:Type [Qualitative Concept]
   748   C0445392:Wild [Intellectual Product]
   748   C1547052:*Type [Quantitative Concept]
   748   C1707455:Compared [Activity]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "these two positions"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0733755:positions [Spatial Concept]
   777 E C0240795:POSITIONAL [Finding]

Phrase: "play"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:play [Finding]

Phrase: "a role in recognition of N-type receptors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]

Phrase: "(Table II"

Phrase: ")."
Processing 00000000.tx.161: Mutations of surface residues located within the 76-91 helix also lead to reduced binding properties. 

Phrase: "Mutations of surface residues"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0026882:Mutations [Genetic Function]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "located within the 76-91 helix also"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0018882:Helix [Eukaryote]
   748   C0229304:Helix [Body Part, Organ, or Organ Component]
   748   C1704821:Helix [Spatial Concept]
   748   C1705682:Helix [Anatomical Structure]

Phrase: "lead to reduced binding properties."
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0243122:binding [Functional Concept]
   760   C0392756:Reduced [Qualitative Concept]
   760   C0871161:properties [Qualitative Concept]
   760   C1145667:Binding [Activity]
   760   C1167622:Binding [Molecular Function]
   760   C1292721:properties [Functional Concept]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]
   726 E C1882134:Property [Conceptual Entity]
   726 E C2347695:Property [Entity]
Processing 00000000.tx.162: Mutations of Lys-85 into cysteine (K85CC) or glutamic acid (K85E) reduce the affinity by a factor of about 40(Table II). 

Phrase: "Mutations of Lys-85"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0026882:Mutations [Genetic Function]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "into cysteine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(K85CC"

Phrase: ")"

Phrase: "or"

Phrase: "glutamic acid"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0061472:Glutamic Acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
  1000   C0523665:Glutamic Acid [Laboratory Procedure]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "(K85E"

Phrase: ")"

Phrase: "reduce"

Phrase: "the affinity by a factor of about 40"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "(Table II"

Phrase: ")."
Processing 00000000.tx.163: Binding properties of double and triple mutants involving K85E have also been analyzed. 

Phrase: "Binding properties of double"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0871161:properties [Qualitative Concept]
   770   C1292721:properties [Functional Concept]
   737 E C1882134:Property [Conceptual Entity]
   737 E C2347695:Property [Entity]

Phrase: "and"

Phrase: "triple mutants"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205174:Triple [Quantitative Concept]
   861   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "involving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1314939:Involving [Functional Concept]

Phrase: "K85E"

Phrase: "have"

Phrase: "also"

Phrase: "been"

Phrase: "analyzed."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]
Processing 00000000.tx.164: When Lys-85 is mutated together with either Lys-133 (K85E/K133E), Arg-23 and Lys-133 (R23E/K85E/K133E), or with Lys-94 and Lys-133 (K85E/K94E/K133E), a dramatic decrease in receptor binding was observed, especially for triple mutants (Table II). 

Phrase: "When"

Phrase: "Lys-85"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0024337:Lys [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "is"

Phrase: "mutated together with either Lys-133"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   753   C0024337:Lys [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   753   C1705285:Mutated [Cell or Molecular Dysfunction]
   753   C1883357:Together [Qualitative Concept]
   719 E C1513776:Mutate [Genetic Function]

Phrase: "(K85E/K133E"

Phrase: ")"

Phrase: ","

Phrase: "Arg-23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450348:23 [Quantitative Concept]

Phrase: "and"

Phrase: "Lys-133"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0024337:Lys [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "(R23E/K85E/K133E"

Phrase: ")"

Phrase: ","

Phrase: "or with Lys-94"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0024337:Lys [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "Lys-133"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0024337:Lys [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "(K85E/K94E/K133E"

Phrase: ")"

Phrase: ","

Phrase: "a dramatic decrease in receptor binding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0392756:Decrease [Qualitative Concept]
   753   C0547047:Decrease [Quantitative Concept]

Phrase: "was"

Phrase: "observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]

Phrase: ","

Phrase: "especially for triple mutants"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205174:Triple [Quantitative Concept]
   770   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "(Table II"

Phrase: ")."
Processing 00000000.tx.165: Mutations of hydrophobic surface residues of the 76-91 helix also lead to a significant decrease in the binding affinity of bvPLA2 to N-type receptors. 

Phrase: "Mutations of hydrophobic surface residues of the 76-91 helix also"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   738   C0026882:Mutations [Genetic Function]
   704 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "lead to a significant decrease"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0237881:significant [Quantitative Concept]
   760   C0392756:Decrease [Qualitative Concept]
   760   C0547047:Decrease [Quantitative Concept]
   760   C0750502:Significant [Idea or Concept]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C1546944:Significant [Qualitative Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "in the binding affinity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "of bvPLA2"

Phrase: "to N-type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.166: Mutation of Ile-91 into phenylalanine (I91F) leads to a mutant with a K0.5 of 98nM. 

Phrase: "Mutation of Ile-91"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0026882:Mutation [Genetic Function]
   770   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "into phenylalanine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0031453:Phenylalanine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "(I91F"

Phrase: ")"

Phrase: "leads to a mutant"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   770   C0181586:leads [Medical Device]
   770   C0596988:Mutant [Cell or Molecular Dysfunction]
   770   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   770   C1522538:Lead [Functional Concept]
   770   C2348269:Lead [Element, Ion, or Isotope]
   770   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "with a K0.5"

Phrase: "of 98nM."
Processing 00000000.tx.167: Furthermore, mutation of Ile-78 and Phe-82 to cysteine (I78CC and F82CC, respectively) dramatically decreases the affinity of bvPLA2 (K0.5 values of 490and 280nM, respectively) (Fig. 5A). 

Phrase: "Furthermore,"

Phrase: "mutation of Ile-78"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0026882:Mutation [Genetic Function]
   770   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "and"

Phrase: "Phe-82 to cysteine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C0031453:Phe [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "(I78CC"

Phrase: "and"

Phrase: "F82CC,"

Phrase: "respectively"

Phrase: ")"

Phrase: "dramatically"

Phrase: "decreases"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0392756:Decrease [Qualitative Concept]
  1000   C0547047:Decrease [Quantitative Concept]

Phrase: "the affinity of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "(K0.5 values of 490and 280nM,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0042295:Values [Qualitative Concept]
   719 E C1522609:Value [Quantitative Concept]

Phrase: "respectively"

Phrase: ")"

Phrase: "(Fig. 5A"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1553637:5a [Medical Device]

Phrase: ")."
Processing 00000000.tx.168: Conversely, mutation of Ile-78 to tyrosine has no dramatic effect on the affinity of bvPLA2 to N-type receptors (Table II), highlighting the importance of the hydrophobic nature of the residue at position 78for receptor binding. 

Phrase: "Conversely,"

Phrase: "mutation of Ile-78"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0026882:Mutation [Genetic Function]
   770   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "to tyrosine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041485:Tyrosine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "has"

Phrase: "no dramatic effect on the affinity of bvPLA2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C1301751:No effect [Qualitative Concept]
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "(Table II"

Phrase: ")"

Phrase: ","

Phrase: "highlighting"

Phrase: "the importance of the hydrophobic nature of the residue"

Phrase: "at position 78for receptor binding."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0597358:Receptor Binding [Molecular Function]
   812   C0243122:binding [Functional Concept]
   812   C1145667:Binding [Activity]
   812   C1167622:Binding [Molecular Function]
Processing 00000000.tx.169: Finally, mutations of Tyr-87 to phenylalanine (Y87F) and of Asp-92 to cysteine (D92CC) have only a minor effect on the binding properties of bvPLA2, probably because the side chains of these residues are pointing toward the center of the protein (Table II and Fig. 3). 

Phrase: "Finally,"

Phrase: "mutations of Tyr-87"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0026882:Mutations [Genetic Function]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "to phenylalanine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0031453:Phenylalanine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "(Y87F"

Phrase: ")"

Phrase: "and of Asp-92"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0206293:Asp [Reptile]
   770   C1515981:And [Idea or Concept]
   770   C3541260:ASP [Gene or Genome]

Phrase: "to cysteine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(D92CC"

Phrase: ")"

Phrase: "have"

Phrase: "only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "a minor effect on the binding properties of bvPLA2,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C1280500:Effect [Qualitative Concept]
   742   C2348382:Effect [Qualitative Concept]

Phrase: "probably"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750492:Probably [Idea or Concept]

Phrase: "because"

Phrase: "the side chains of these residues"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0337112:chains [Manufactured Object]
   753   C0441987:Side [Spatial Concept]
   753   C1524075:Chains [Idea or Concept]

Phrase: "are"

Phrase: "pointing toward the center of the protein"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0205099:Center [Spatial Concept]
   714   C1552961:Point [Quantitative Concept]
   714   C2347617:point [Quantitative Concept]

Phrase: "(Table II"

Phrase: "and"

Phrase: "Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.170: Altogether, these data suggest that the N-terminal region and the 76-91 helix of bvPLA2 are involved in the interaction with N-type receptors. 

Phrase: "Altogether,"

Phrase: "these data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the N-terminal region"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   827   C0017446:Region [Geographic Area]
   827   C0205088:Terminal [Temporal Concept]
   827   C0205147:Region [Spatial Concept]
   827   C1705314:Terminal [Manufactured Object]
   827   C1705315:Terminal [Spatial Concept]
   755 E C0205276:Regional [Spatial Concept]
   755 E C1947913:Regional [Spatial Concept]

Phrase: "and"

Phrase: "the 76-91 helix of bvPLA2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0018882:Helix [Eukaryote]
   753   C0229304:Helix [Body Part, Organ, or Organ Component]
   753   C1704821:Helix [Spatial Concept]
   753   C1705682:Helix [Anatomical Structure]

Phrase: "are"

Phrase: "involved in the interaction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1314939:Involved [Functional Concept]
   770   C1704675:Interaction [Functional Concept]

Phrase: "with N-type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.171: Analysis of Mutations in the Ca2+-binding Loop The Ca2+-binding loops of sPLA2s anchor a single Ca2+ ion in the active site where it functions to bind one of the oxygens of the substrate's phosphate group and may also serve as a Lewis acid to activate the carbonyl of the enzyme susceptible ester (6). 

Phrase: "Analysis of Mutations"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   841   C0796357:mutation analysis [Laboratory Procedure]
   790   C0002778:Analysis [Laboratory Procedure]
   790   C0936012:Analysis [Research Activity]
   790   C1524024:analysis [Functional Concept]

Phrase: "in the Ca2+-binding Loop"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0243122:binding [Functional Concept]
   827   C0419518:Loop [Medical Device]
   827   C0445022:Loop [Spatial Concept]
   827   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1145667:Binding [Activity]
   827   C1167622:Binding [Molecular Function]

Phrase: "The Ca2+-binding loops of sPLA2s"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   750   C1523907:phospholipase binding [Molecular Function]
   744   C0181687:loops [Medical Device]
   744   C0243122:binding [Functional Concept]
   744   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   744   C1145667:Binding [Activity]
   744   C1167622:Binding [Molecular Function]
   711 E C0419518:Loop [Medical Device]
   711 E C0445022:Loop [Spatial Concept]

Phrase: "anchor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1293132:anchor [Therapeutic or Preventive Procedure]

Phrase: "a single Ca2+ ion in the active site where"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0022023:Ion [Element, Ion, or Isotope]
   742   C1700702:ION [Functional Concept]

Phrase: "it"

Phrase: "functions"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0031843:function [Physiologic Function]
  1000   C0542341:Function [Functional Concept]
  1000   C0700205:FUNCTION [Classification]
  1000   C1705273:Function [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "bind"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "one of the oxygens of the substrate's phosphate group"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0205447:One [Quantitative Concept]

Phrase: "and"

Phrase: "may"

Phrase: "also"

Phrase: "serve as a Lewis acid to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0302917:Lewis acid [Inorganic Chemical]
   753   C0001128:Acid [Chemical]
   753   C0202406:Acid [Laboratory Procedure]

Phrase: "activate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515877:Activate [Functional Concept]
  1000   C1879547:Activate [Activity]

Phrase: "the carbonyl of the enzyme susceptible ester"

Phrase: "(6"

Phrase: ")."
Processing 00000000.tx.172: The Ca2+-binding loop of bvPLA2 consists of residues 7-14, while in group I and group II sPLA2s, it comprises residues 26-33 (35). 

Phrase: "The Ca2+-binding loop of bvPLA2"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0243122:binding [Functional Concept]
   753   C0419518:Loop [Medical Device]
   753   C0445022:Loop [Spatial Concept]
   753   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]

Phrase: "consists of residues 7-14,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   797   C0593972:14 7 [Quantitative Concept]
   760   C0332529:CONSIST [Qualitative Concept]
   726   C1709915:Residue [Conceptual Entity]
   726   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "while in group I"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   833   C0441843:Group I [Intellectual Product]
   819 E C1959640:I group [Clinical Attribute]
   770   C0021966:I- [Inorganic Chemical]
   770   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0441833:Group [Idea or Concept]
   770   C0687744:group [Population Group]
   770   C0750519:while [Idea or Concept]
   770   C1257890:Group [Population Group]
   770   C1552516:Group [Health Care Related Organization]
   770   C1705428:Group [Conceptual Entity]
   770   C1705429:Group [Population Group]

Phrase: "and"

Phrase: "group II sPLA2s,"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   991   C1959603:Group II Secretory Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
           Group II Phospholipases A2
   884   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   840   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "it"

Phrase: "comprises"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2700400:Comprise [Activity]

Phrase: "residues 26-33"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   793   C1709915:Residue [Conceptual Entity]
   793   C1882936:RESIDUE [Phenomenon or Process]
   743 E C1609982:Residual [Qualitative Concept]

Phrase: "(35"

Phrase: ")."
Processing 00000000.tx.173: Despite this very different localization in the primary sequence, the conformation of the bvPLA2 Ca2+-binding loop is strikingly similar to that of group I and group II sPLA2s, and it contains the consensus motif X-Cys-Gly-X-Gly found in all catalytically active sPLA2s (35). 

Phrase: "Despite this very different localization"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0475264:Localisation [Functional Concept]
   827   C1744691:localisation [Biologic Function]

Phrase: "in the primary sequence,"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   861   C0004793:Sequence [Nucleotide Sequence]
   861   C0162326:Sequence [Nucleotide Sequence]
   861   C0162327:Sequence [Nucleotide Sequence]
   861   C1519249:Sequence [Functional Concept]
   789 E C1548958:Sequential [Idea or Concept]
   789 E C1705294:Sequential [Qualitative Concept]

Phrase: "the conformation of the bvPLA2 Ca2+-binding loop"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0026377:Conformation [Spatial Concept]

Phrase: "is"

Phrase: "strikingly similar to that of group I"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C2348205:Similar [Qualitative Concept]

Phrase: "and"

Phrase: "group II sPLA2s,"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   991   C1959603:Group II Secretory Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
           Group II Phospholipases A2
   884   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   840   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "and"

Phrase: "it"

Phrase: "contains"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:contain [Functional Concept]
  1000   C2700400:Contain [Activity]

Phrase: "the consensus motif X-Cys-Gly-X-Gly"

Phrase: "found in all catalytically active sPLA2s"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   800   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   770   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0150312:Found [Quantitative Concept]
   744   C0205177:Active [Functional Concept]
   744   C1327616:Secretory [Cell Function]
   737 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   737 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   711 E C0243095:Find [Finding]

Phrase: "(35"

Phrase: ")."
Processing 00000000.tx.174: Mutations of Asn-13 and Ser-15 to cysteine (N13CC and S15CC, respectively) have a weak effect on the receptor binding properties of bvPLA2 (Fig. 5B and Table II). 

Phrase: "Mutations of Asn-13"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0026882:Mutations [Genetic Function]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "and"

Phrase: "Ser-15 to cysteine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(N13CC"

Phrase: "and"

Phrase: "S15CC,"

Phrase: "respectively"

Phrase: ")"

Phrase: "have"

Phrase: "a weak effect on the receptor binding properties of bvPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C1280500:Effect [Qualitative Concept]
   739   C2348382:Effect [Qualitative Concept]

Phrase: "(Fig. 5B"

Phrase: "and"

Phrase: "Table II"

Phrase: ")."
Processing 00000000.tx.175: Mutation of Lys-14 to glutamic acid (K14E) or to cysteine (K14CC) also have a modest effect on receptor binding, although the double mutant K14E/R23E binds 580-fold less tightly to N-type receptor. 

Phrase: "Mutation of Lys-14"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0026882:Mutation [Genetic Function]
   770   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "to glutamic acid"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0061472:Glutamic Acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
  1000   C0523665:Glutamic Acid [Laboratory Procedure]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "(K14E"

Phrase: ")"

Phrase: "or to cysteine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(K14CC"

Phrase: ")"

Phrase: "also"

Phrase: "have"

Phrase: "a modest effect on receptor binding,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "although"

Phrase: "the double mutant K14E/R23E"

Phrase: "binds"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "580-fold less tightly to N-type receptor."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   744   C0332307:Type [Qualitative Concept]
   744   C0332462:Fold [Spatial Concept]
   744   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   744   C1547052:*Type [Quantitative Concept]
   744   C1880834:FOLD [Phenomenon or Process]
Processing 00000000.tx.176: Mutations at position 12have interesting consequences. 

Phrase: "Mutations at position 12have interesting consequences."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0026882:Mutations [Genetic Function]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]
Processing 00000000.tx.177: Replacement of Gly-12 with the hydrophilic residues cysteine (G12CC) or serine (together with a conservative mutation of Lys-14 into arginine, which was inadvertently introduced during PCR) (G12S/K14R) weakens receptor binding only slightly. 

Phrase: "Replacement of Gly-12"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0035139:Replacement [Therapeutic or Preventive Procedure]
   770   C0559956:Replacement [Functional Concept]
   770   C1555302:Replacement [Idea or Concept]

Phrase: "with the hydrophilic residues cysteine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(G12CC"

Phrase: ")"

Phrase: "or"

Phrase: "serine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0036720:Serine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "("

Phrase: "together with a conservative mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "of Lys-14"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0024337:Lys [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "into arginine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003765:Arginine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "which"

Phrase: "was"

Phrase: "inadvertently"

Phrase: "introduced during PCR) (G12S/K14R"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   760   C0677874:pCR [Finding]
   726   C1292748:introduce [Functional Concept]

Phrase: ")"

Phrase: "weakens"

Phrase: "receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "binding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0243122:binding [Functional Concept]
  1000   C1145667:Binding [Activity]
  1000   C1167622:Binding [Molecular Function]

Phrase: "only slightly."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205171:Only [Quantitative Concept]
   861   C0750482:Slightly [Idea or Concept]
   861   C1720467:Only [Intellectual Product]
Processing 00000000.tx.178: However, mutation of Gly-12 to the hydrophobic residue alanine (G12A) results in a protein that does not detectably bind to N-type receptors, suggesting that the N-type receptor donates a residue that forms a specific contact with residue 12(Table II). 

Phrase: "However,"

Phrase: "mutation of Gly-12"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0026882:Mutation [Genetic Function]
   770   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "to the hydrophobic residue alanine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0001898:Alanine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(G12A"

Phrase: ")"

Phrase: "results in a protein"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   819   C0038164:Protein A [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   770   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C1274040:Result [Functional Concept]
   770   C1546471:Result [Idea or Concept]
   770   C2825142:Result [Finding]

Phrase: "that"

Phrase: "does"

Phrase: "not detectably"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "bind to N-type receptors,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1145667:Bind [Activity]
   760   C1167622:bind [Molecular Function]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the N-type receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "donates"

Phrase: "a residue"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1709915:Residue [Conceptual Entity]
  1000   C1882936:RESIDUE [Phenomenon or Process]
   928 E C1609982:Residual [Qualitative Concept]

Phrase: "that"

Phrase: "forms"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0348078:Form [Qualitative Concept]
  1000   C0376315:Form [Manufactured Object]
  1000   C1522492:Form [Functional Concept]

Phrase: "a specific contact with residue 12"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0332158:Contact with [Functional Concept]
           contact
   753   C0337611:Contact [Population Group]
   753   C1705415:Contact [Idea or Concept]

Phrase: "(Table II"

Phrase: ")."
Processing 00000000.tx.179: The weak effects observed with the Ser-15 mutant is in accordance with the fact that its side chain is pointing toward the center of the protein and thus is not likely to contact the N-type receptor. 

Phrase: "The weak effects"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1280500:effects [Qualitative Concept]
   827 E C2348382:Effect [Qualitative Concept]

Phrase: "observed with the Ser-15 mutant"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0596988:Mutant [Cell or Molecular Dysfunction]
   753   C1441672:Observed [Functional Concept]

Phrase: "is in accordance with the fact"

Phrase: "that"

Phrase: "its side chain"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0337112:Chain [Manufactured Object]
   861   C0441987:Side [Spatial Concept]
   861   C1524075:Chain [Idea or Concept]

Phrase: "is"

Phrase: "pointing toward the center of the protein"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0205099:Center [Spatial Concept]
   714   C1552961:Point [Quantitative Concept]
   714   C2347617:point [Quantitative Concept]

Phrase: "and"

Phrase: "thus"

Phrase: "is"

Phrase: "not likely to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0332148:Likely [Qualitative Concept]
   827   C0750492:Likely [Idea or Concept]
   827   C1518422:Not [Functional Concept]

Phrase: "contact"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332158:contact [Functional Concept]
  1000   C0337611:Contact [Population Group]
  1000   C1705415:Contact [Idea or Concept]

Phrase: "the N-type receptor."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.180: Taken together, these results indicate that the Ca2+-binding loop is also involved in the interaction with N-type receptors. 

Phrase: "Taken"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883727:Taken [Conceptual Entity]
   966 E C1515187:Take [Health Care Activity]

Phrase: "together,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883357:Together [Qualitative Concept]

Phrase: "these results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "indicate"

Phrase: "that"

Phrase: "the Ca2+-binding loop"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0243122:binding [Functional Concept]
   827   C0419518:Loop [Medical Device]
   827   C0445022:Loop [Spatial Concept]
   827   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1145667:Binding [Activity]
   827   C1167622:Binding [Molecular Function]

Phrase: "is"

Phrase: "also"

Phrase: "involved in the interaction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1314939:Involved [Functional Concept]
   770   C1704675:Interaction [Functional Concept]

Phrase: "with N-type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.181: Analysis of Mutations in the Active Site Slot Mutations were also made on residues located in the active site slot region of bvPLA2 (Fig. 3). 

Phrase: "Analysis of Mutations"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   841   C0796357:mutation analysis [Laboratory Procedure]
   790   C0002778:Analysis [Laboratory Procedure]
   790   C0936012:Analysis [Research Activity]
   790   C1524024:analysis [Functional Concept]

Phrase: "in the Active Site Slot Mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0026882:Mutations [Genetic Function]
   779 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "were"

Phrase: "also"

Phrase: "made on residues"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   756   C1709915:Residue [Conceptual Entity]
   756   C1881534:Make [Functional Concept]
   756   C1882936:RESIDUE [Phenomenon or Process]
   706 E C1609982:Residual [Qualitative Concept]

Phrase: "located in the active site slot region of bvPLA2"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   764   C0205681:Active Site [Functional Concept]
   762   C2945843:Site of [Qualitative Concept]
   742   C0017446:Region [Geographic Area]
   742   C0205145:Site [Spatial Concept]
   742   C0205147:Region [Spatial Concept]
   742   C0205177:Active [Functional Concept]
   742   C1515974:Site [Body Location or Region]
   742   C2825164:Site [Spatial Concept]

Phrase: "(Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.182: Among these residues, Thr-57 forms a portion of the wall of the active site slot and is known to hydrogen bond directly with the sn-3 phosphate of bound phospholipid substrate (43). 

Phrase: "Among these residues,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   966   C1709915:Residue [Conceptual Entity]
   966   C1882936:RESIDUE [Phenomenon or Process]
   916 E C1609982:Residual [Qualitative Concept]

Phrase: "Thr-57"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0040005:Thr [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "forms"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0348078:Form [Qualitative Concept]
  1000   C0376315:Form [Manufactured Object]
  1000   C1522492:Form [Functional Concept]

Phrase: "a portion of the wall of the active site slot"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0449719:Portion [Spatial Concept]

Phrase: "and"

Phrase: "is"

Phrase: "known to hydrogen bond directly"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0020276:hydrogen bond [Natural Phenomenon or Process]
   760   C0020275:Hydrogen [Element, Ion, or Isotope]
   760   C0205309:Known [Qualitative Concept]
   760   C0523702:HYDROGEN [Laboratory Procedure]
   760   C0885426:hydrogen [Inorganic Chemical]
   760   C1947931:Directly [Qualitative Concept]

Phrase: "with the sn-3 phosphate"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   827   C0031701:phosphate [Organophosphorus Compound]
   827   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "of bound phospholipid substrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1710236:Substrate [Manufactured Object]

Phrase: "(43"

Phrase: ")."
Processing 00000000.tx.183: This residue appears very important for binding of bvPLA2 to N-type receptors, since mutation to phenylalanine (T57F), valine (T57V), leucine (T57L), and aspartic or glutamic acid (T57D and T57E, respectively) strongly decreases or abolishes the binding of bvPLA2 to the receptor (Fig. 5C and Table II). 

Phrase: "This residue"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1709915:Residue [Conceptual Entity]
  1000   C1882936:RESIDUE [Phenomenon or Process]
   928 E C1609982:Residual [Qualitative Concept]

Phrase: "appears"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "very important for binding of bvPLA2"

Phrase: "to N-type receptors,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "since"

Phrase: "mutation to phenylalanine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0026882:Mutation [Genetic Function]
   790   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "(T57F"

Phrase: ")"

Phrase: ","

Phrase: "valine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0042285:Valine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "(T57V"

Phrase: ")"

Phrase: ","

Phrase: "leucine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023401:Leucine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "(T57L"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "aspartic"

Phrase: "or"

Phrase: "glutamic acid"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0061472:Glutamic Acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
  1000   C0523665:Glutamic Acid [Laboratory Procedure]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "(T57D"

Phrase: "and"

Phrase: "T57E,"

Phrase: "respectively"

Phrase: ")"

Phrase: "strongly"

Phrase: "decreases"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0392756:Decrease [Qualitative Concept]
  1000   C0547047:Decrease [Quantitative Concept]

Phrase: "or"

Phrase: "abolishes"

Phrase: "the binding of bvPLA2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]

Phrase: "to the receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "(Fig. 5C"

Phrase: "and"

Phrase: "Table II"

Phrase: ")."
Processing 00000000.tx.184: We have also analyzed the effects of mutation of Asp-64, which is directly involved in the catalytic mechanism (35, 44). 

Phrase: "We"

Phrase: "have"

Phrase: "also"

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: "the effects of mutation of Asp-64,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C1280500:effects [Qualitative Concept]
   714 E C2348382:Effect [Qualitative Concept]

Phrase: "which"

Phrase: "is"

Phrase: "directly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1947931:Directly [Qualitative Concept]

Phrase: "involved in the catalytic mechanism"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0007382:Catalytic [Natural Phenomenon or Process]
   760   C0441712:Mechanism [Functional Concept]
   760   C1314939:Involved [Functional Concept]
   760   C1706376:Mechanism [Manufactured Object]

Phrase: "(35,"

Phrase: "44"

Phrase: ")."
Processing 00000000.tx.185: This residue corresponds to the active site residue Asp-99 of group I and group II sPLA2s, which is conserved in all catalytically active enzymes including both neurotoxic and nontoxic sPLA2s (5). 

Phrase: "This residue"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1709915:Residue [Conceptual Entity]
  1000   C1882936:RESIDUE [Phenomenon or Process]
   928 E C1609982:Residual [Qualitative Concept]

Phrase: "corresponds to the active site residue Asp-99 of group I"
Meta Candidates (Total=20; Excluded=1; Pruned=0; Remaining=19)
   756   C0205681:Active Site [Functional Concept]
   756   C0441843:Group I [Intellectual Product]
   754 E C1959640:I group [Clinical Attribute]
   754   C2945843:Site of [Qualitative Concept]
   738   C0021966:I- [Inorganic Chemical]
   738   C0205145:Site [Spatial Concept]
   738   C0205177:Active [Functional Concept]
   738   C0206293:Asp [Reptile]
   738   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   738   C0441833:Group [Idea or Concept]
   738   C0687744:group [Population Group]
   738   C1257890:Group [Population Group]
   738   C1515974:Site [Body Location or Region]
   738   C1552516:Group [Health Care Related Organization]
   738   C1705428:Group [Conceptual Entity]
   738   C1705429:Group [Population Group]
   738   C1709915:Residue [Conceptual Entity]
   738   C1882936:RESIDUE [Phenomenon or Process]
   738   C2825164:Site [Spatial Concept]
   738   C3541260:ASP [Gene or Genome]

Phrase: "and"

Phrase: "group II sPLA2s,"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   991   C1959603:Group II Secretory Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
           Group II Phospholipases A2
   884   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   840   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "which"

Phrase: "is"

Phrase: "conserved in all catalytically active enzymes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0014442:Enzymes [Enzyme,Organic Chemical]
   753   C0014445:enzymes [Functional Concept]
   753   C0205177:Active [Functional Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "both neurotoxic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0235032:Neurotoxicity [Injury or Poisoning]

Phrase: "and"

Phrase: "nontoxic sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   923   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.186: Mutation of Asp-64 to alanine (D64A) results in a dramatic decrease in receptor affinity (K0.5>1M). 

Phrase: "Mutation of Asp-64"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0026882:Mutation [Genetic Function]
   770   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "to alanine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001898:Alanine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(D64A"

Phrase: ")"

Phrase: "results in a dramatic decrease"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0392756:Decrease [Qualitative Concept]
   760   C0547047:Decrease [Quantitative Concept]
   760   C1274040:Result [Functional Concept]
   760   C1546471:Result [Idea or Concept]
   760   C2825142:Result [Finding]

Phrase: "in receptor affinity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "(K0.5"

Phrase: ">1M"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0470296:1M [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.187: However, more conservative substitutions of Asp-64 by glutamic acid (D64E) or by asparagine (D64N) do not lead to a dramatic decrease in receptor affinity (Fig. 5C). 

Phrase: "However,"

Phrase: "more conservative substitutions of Asp-64"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C1555721:Substitution [Idea or Concept]
   719   C1706204:Substitution [Activity]

Phrase: "by glutamic acid"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0061472:Glutamic Acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
  1000   C0523665:Glutamic Acid [Laboratory Procedure]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "(D64E"

Phrase: ")"

Phrase: "or by asparagine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0003995:Asparagine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(D64N"

Phrase: ")"

Phrase: "do"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "lead to a dramatic decrease"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0392756:Decrease [Qualitative Concept]
   760   C0547047:Decrease [Quantitative Concept]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "in receptor affinity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "(Fig. 5C"

Phrase: ")."
Processing 00000000.tx.188: Finally, a double mutant where Asp-64 is replaced by a glutamic acid (D64E) together with a mutation at position 66 (D64E/K66CC, D64E was introduced inadvertently during the preparation of K66CC by PCR) also retains a high affinity for N-type receptors (Table II). 

Phrase: "Finally,"

Phrase: "a double mutant where Asp-64"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   804   C0205173:Double [Functional Concept]
   804   C0206293:Asp [Reptile]
   804   C0596988:Mutant [Cell or Molecular Dysfunction]
   804   C1705764:Double [Activity]
   804   C1705765:Double [Qualitative Concept]
   804   C3541260:ASP [Gene or Genome]

Phrase: "is"

Phrase: "replaced by a glutamic acid"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   806   C0061472:Glutamic Acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   806   C0523665:Glutamic Acid [Laboratory Procedure]
   806   C1299987:Replaced by [Functional Concept]
           replaced
   760   C0001128:Acid [Chemical]
   760   C0202406:Acid [Laboratory Procedure]
   760   C0559956:Replaced [Functional Concept]
   726 E C1554078:Replace [Idea or Concept]

Phrase: "(D64E"

Phrase: ")"

Phrase: "together with a mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0026882:Mutation [Genetic Function]
  1000   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "at position 66"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0733755:Position [Spatial Concept]
   789 E C0240795:POSITIONAL [Finding]

Phrase: "(D64E/K66CC,"

Phrase: "D64E"

Phrase: "was"

Phrase: "introduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1292748:introduce [Functional Concept]

Phrase: "inadvertently during the preparation of K66CC"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0455052:Preparation [Health Care Activity]
   753   C1521827:Preparation [Functional Concept]

Phrase: "by PCR) also"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   861   C0677874:pCR [Finding]

Phrase: "retains"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333118:Retain [Functional Concept]

Phrase: "a high affinity for N-type receptors"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0205250:High [Qualitative Concept]
   748   C1299351:High [Qualitative Concept]
   748   C1510827:Affinity [Natural Phenomenon or Process]
   748   C2700149:HIGH [Intellectual Product]

Phrase: "(Table II"

Phrase: ")."
Processing 00000000.tx.189: Analysis of Deletions and Other Mutations bvPLA2 is a basic enzyme (pI=8.04) that has a number of lysine and arginine residues on its surface that may interact with N-type receptors. 

Phrase: "Analysis of Deletions"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0002778:Analysis [Laboratory Procedure]
   790   C0936012:Analysis [Research Activity]
   790   C1524024:analysis [Functional Concept]

Phrase: "and"

Phrase: "Other Mutations bvPLA2"

Phrase: "is"

Phrase: "a basic enzyme"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0014442:Enzyme [Enzyme,Organic Chemical]
   777 E C0014445:enzymes [Functional Concept]

Phrase: "(pI=8.04"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0429863:PI [Clinical Attribute]
   827   C3537219:PI [Gene or Genome]
   827   C3539772:PI [Intellectual Product]

Phrase: ")"

Phrase: "that"

Phrase: "has"

Phrase: "a number of lysine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0237753:*Number [Quantitative Concept]
   770   C0449788:Number [Quantitative Concept]

Phrase: "and"

Phrase: "arginine residues on its surface"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C1709915:Residue [Conceptual Entity]
   726   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "that"

Phrase: "may"

Phrase: "interact with N-type receptors."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.190: This protein also contains several solvent-exposed threonine and serine residues that might also have a role in receptor binding. 

Phrase: "This protein also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "contains"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:contain [Functional Concept]
  1000   C2700400:Contain [Activity]

Phrase: "several solvent-exposed threonine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0040005:Threonine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "serine residues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C1709915:Residue [Conceptual Entity]
   827   C1882936:RESIDUE [Phenomenon or Process]
   777 E C1609982:Residual [Qualitative Concept]

Phrase: "that"

Phrase: "might"

Phrase: "also"

Phrase: "have"

Phrase: "a role in receptor binding."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0035820:Role [Social Behavior]
   760   C1705810:Role [Conceptual Entity]
Processing 00000000.tx.191: Mutation of lysines 66and 72,which are located on the side of bvPLA2 opposite of the IRS, to either cysteine (K66CC and K72CC) or glutamic acid (K66E) has no effect on the K0.5 (Table II), suggesting that this region of the molecule is not involved in binding to N-type receptors. 

Phrase: "Mutation of lysines 66and 72,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0026882:Mutation [Genetic Function]
   760   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "which"

Phrase: "are"

Phrase: "located on the side of bvPLA2 opposite of the IRS,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   736   C0205148:Surface [Spatial Concept]
   736   C0441987:Side [Spatial Concept]
   736   C0524637:Recognition [Mental Process]
   736   C1521805:Opposite [Spatial Concept]

Phrase: "to either cysteine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(K66CC"

Phrase: "and"

Phrase: "K72CC"

Phrase: ")"

Phrase: "or"

Phrase: "glutamic acid"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0061472:Glutamic Acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
  1000   C0523665:Glutamic Acid [Laboratory Procedure]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "(K66E"

Phrase: ")"

Phrase: "has"

Phrase: "no effect on the K0.5"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1301751:No effect [Qualitative Concept]
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "(Table II"

Phrase: ")"

Phrase: ","

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "this region of the molecule"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0017446:Region [Geographic Area]
   760   C0205147:Region [Spatial Concept]

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "involved in binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]
   790   C1314939:Involved [Functional Concept]

Phrase: "to N-type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.192: Similarly, mutation of Lys-122 and Lys-133 to glutamine (K122Q) or glutamic acid (K133E) produces only modest effects on receptor binding (Table II). 

Phrase: "Similarly,"

Phrase: "mutation of Lys-122"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0026882:Mutation [Genetic Function]
   770   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "and"

Phrase: "Lys-133 to glutamine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0017797:Glutamine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   770   C0024337:Lys [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "(K122Q"

Phrase: ")"

Phrase: "or"

Phrase: "glutamic acid"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0061472:Glutamic Acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
  1000   C0523665:Glutamic Acid [Laboratory Procedure]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "(K133E"

Phrase: ")"

Phrase: "produces"

Phrase: "only modest effects on receptor binding"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "(Table II"

Phrase: ")."
Processing 00000000.tx.193: Conversely, mutation of Lys-94 to glutamic acid leads to a moderate but significative decrease in the binding affinity of the mutant bvPLA2 relative to the wild-type enzyme (Table II). 

Phrase: "Conversely,"

Phrase: "mutation of Lys-94"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0026882:Mutation [Genetic Function]
   770   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "to glutamic acid"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0061472:Glutamic Acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
  1000   C0523665:Glutamic Acid [Laboratory Procedure]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "leads to a moderate"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   770   C0181586:leads [Medical Device]
   770   C0205081:Moderate [Qualitative Concept]
   770   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   770   C1522538:Lead [Functional Concept]
   770   C1881878:Moderate [Qualitative Concept]
   770   C2348269:Lead [Element, Ion, or Isotope]
   770   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "but"

Phrase: "significative decrease in the binding affinity of the mutant bvPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0392756:Decrease [Qualitative Concept]
   739   C0547047:Decrease [Quantitative Concept]

Phrase: "relative to the wild-type enzyme"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0080103:Relative [Family Group]
   753   C0205345:Relative [Qualitative Concept]
   753   C1547039:*Relative [Quantitative Concept]

Phrase: "(Table II"

Phrase: ")."
Processing 00000000.tx.194: Similarly, mutation of Arg-58 into alanine (R58A) also results in a decrease of the K0.5 value, the corresponding K0.5 value is more than 35times higher than that of the wild-type enzyme. 

Phrase: "Similarly,"

Phrase: "mutation of Arg-58"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0026882:Mutation [Genetic Function]
   770   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "into alanine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001898:Alanine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(R58A"

Phrase: ")"

Phrase: "also"

Phrase: "results in a decrease of the K0.5 value,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   742   C0392756:Decrease [Qualitative Concept]
   742   C0547047:Decrease [Quantitative Concept]
   742   C1274040:Result [Functional Concept]
   742   C1522609:Value [Quantitative Concept]
   742   C1546471:Result [Idea or Concept]
   742   C2825142:Result [Finding]

Phrase: "the corresponding K0.5 value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1522609:Value [Quantitative Concept]

Phrase: "is"

Phrase: "more than 35times"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205172:More [Functional Concept]

Phrase: "higher than that of the wild-type enzyme."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   711   C0205250:High [Qualitative Concept]
   711   C1299351:High [Qualitative Concept]
   711   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.195: In addition, a synergistic effect was observed with the double mutant R23E/R58A in that this protein did not detectably bind to N-type receptors (Table II). 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "a synergistic effect"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1280500:Effect [Qualitative Concept]
   861   C2348382:Effect [Qualitative Concept]
   861   C2986495:Synergistic [Qualitative Concept]

Phrase: "was"

Phrase: "observed with the double mutant R23E/R58A"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0205173:Double [Functional Concept]
   748   C0596988:Mutant [Cell or Molecular Dysfunction]
   748   C1441672:Observed [Functional Concept]
   748   C1705764:Double [Activity]
   748   C1705765:Double [Qualitative Concept]

Phrase: "in"

Phrase: "that"

Phrase: "this protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "did"

Phrase: "not detectably"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "bind to N-type receptors"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1145667:Bind [Activity]
   760   C1167622:bind [Molecular Function]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "(Table II"

Phrase: ")."
Processing 00000000.tx.196: This result is not surprising since Lys-94 and Arg-58 are located in the vicinity of the 76-91 helix, and residues of this helix have already been shown to be involved in receptor binding (see above). 

Phrase: "This result"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1274040:Result [Functional Concept]
  1000   C1546471:Result [Idea or Concept]
  1000   C2825142:Result [Finding]

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "surprising"

Phrase: "since"

Phrase: "Lys-94"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0024337:Lys [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "Arg-58"

Phrase: "are"

Phrase: "located in the vicinity of the 76-91 helix,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C0018882:Helix [Eukaryote]
   742   C0229304:Helix [Body Part, Organ, or Organ Component]
   742   C1704821:Helix [Spatial Concept]
   742   C1705682:Helix [Anatomical Structure]

Phrase: "and"

Phrase: "residues of this helix"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   737   C1709915:Residue [Conceptual Entity]
   737   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "have"

Phrase: "already"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "involved in receptor binding"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C0597358:Receptor Binding [Molecular Function]
   770   C0243122:binding [Functional Concept]
   770   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]
   770   C1314939:Involved [Functional Concept]

Phrase: "("

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "above"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1282910:Above [Spatial Concept]
  1000   C1552828:above [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.197: Threonines 51and 53are located on the surface of bvPLA2, but far away from the IRS (Fig. 3). 

Phrase: "Threonines 51and 53are"

Phrase: "located on the surface of bvPLA2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0205148:Surface [Spatial Concept]

Phrase: "but"

Phrase: "far away from the IRS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0205108:far [Spatial Concept]

Phrase: "(Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.198: As expected, mutation of these residues into cysteine (T51CC and T53CC) fail to produce drastic effects on receptor binding (Table II). 

Phrase: "As"

Phrase: "expected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]

Phrase: ","

Phrase: "mutation of these residues"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0026882:Mutation [Genetic Function]
   770   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "into cysteine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(T51CC"

Phrase: "and"

Phrase: "T53CC"

Phrase: ")"

Phrase: "fail"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:fail [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "produce"

Phrase: "drastic effects on receptor binding"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: "(Table II"

Phrase: ")."
Processing 00000000.tx.199: Basic residues are also found on the surface of the bvPLA2, in a loop located between the Ca2+ binding site and the -helix containing the active site residue His-34 (Fig. 3). 

Phrase: "Basic residues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C1709915:Residue [Conceptual Entity]
   827   C1882936:RESIDUE [Phenomenon or Process]
   777 E C1609982:Residual [Qualitative Concept]

Phrase: "are"

Phrase: "also"

Phrase: "found on the surface of the bvPLA2,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   748   C0150312:Found [Quantitative Concept]
   748   C0205148:Surface [Spatial Concept]
   714 E C0243095:Find [Finding]

Phrase: "in a loop"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0419518:Loop [Medical Device]
  1000   C0445022:Loop [Spatial Concept]

Phrase: "located between the Ca2+ binding site"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   790   C0005456:Binding Site [Receptor]
   790   C0682969:Binding Site [Amino Acid Sequence]
   753   C0205145:Site [Spatial Concept]
   753   C0243122:binding [Functional Concept]
   753   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]
   753   C1515974:Site [Body Location or Region]
   753   C2825164:Site [Spatial Concept]

Phrase: "and"

Phrase: "the -helix"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0018882:Helix [Eukaryote]
  1000   C0229304:Helix [Body Part, Organ, or Organ Component]
  1000   C1704821:Helix [Spatial Concept]
  1000   C1705682:Helix [Anatomical Structure]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "the active site residue"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   827   C1709915:Residue [Conceptual Entity]
   827   C1882936:RESIDUE [Phenomenon or Process]
   755 E C1609982:Residual [Qualitative Concept]
   734   C0205681:Active Site [Functional Concept]

Phrase: "His-34"

Phrase: "(Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.200: Relative to the IRS, this loop lies toward the center of the globular protein, at the left edge of the structure, and thus the amino acid side chains of this loop are relatively far from the Ca2+ loop and from the IRS. 

Phrase: "Relative to the IRS,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0080103:Relative [Family Group]
   753   C0205345:Relative [Qualitative Concept]
   753   C1547039:*Relative [Quantitative Concept]

Phrase: "this loop"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0419518:Loop [Medical Device]
  1000   C0445022:Loop [Spatial Concept]

Phrase: "lies toward the center of the globular protein,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0178663:globular protein [Amino Acid, Peptide, or Protein]
   744   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0205099:Center [Spatial Concept]
   744   C0332501:Globular [Spatial Concept]

Phrase: "at the left edge"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205154:Edge [Spatial Concept]
   861   C2697523:Edge [Conceptual Entity]

Phrase: "of the structure,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678594:Structure [Spatial Concept]

Phrase: "and"

Phrase: "thus"

Phrase: "the amino acid side chains of this loop"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0337112:chains [Manufactured Object]
   744   C0441987:Side [Spatial Concept]
   744   C1524075:Chains [Idea or Concept]

Phrase: "are"

Phrase: "relatively far from the Ca2+ loop"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0205108:far [Spatial Concept]
   753   C0419518:Loop [Medical Device]
   753   C0445022:Loop [Spatial Concept]
   753   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "and from the IRS."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0205148:Surface [Spatial Concept]
   753   C0524637:Recognition [Mental Process]
   753   C1515981:And [Idea or Concept]
Processing 00000000.tx.201: When Lys-25 of this loop was mutated to glutamine, the corresponding mutant (K25Q) retains binding properties (K0.5=2.7nM) very similar to that of wild-type recombinant bvPLA2, indicating that this position is not involved in binding to N-type receptors (Fig. 5D). 

Phrase: "When"

Phrase: "Lys-25 of this loop"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0024337:Lys [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   760   C0419518:Loop [Medical Device]
   760   C0445022:Loop [Spatial Concept]

Phrase: "was"

Phrase: "mutated to glutamine,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0017797:Glutamine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   790   C1705285:Mutated [Cell or Molecular Dysfunction]
   756 E C1513776:Mutate [Genetic Function]

Phrase: "the corresponding mutant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "(K25Q"

Phrase: ")"

Phrase: "retains"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333118:Retain [Functional Concept]

Phrase: "binding properties"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0871161:properties [Qualitative Concept]
   861   C1292721:properties [Functional Concept]
   827 E C1882134:Property [Conceptual Entity]
   827 E C2347695:Property [Entity]

Phrase: "(K0.5"

Phrase: "=2.7nM"

Phrase: ")"

Phrase: "very similar to that of wild-type recombinant bvPLA2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C2348205:Similar [Qualitative Concept]

Phrase: "indicating"

Phrase: "that"

Phrase: "this position"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0733755:Position [Spatial Concept]
   928 E C0240795:POSITIONAL [Finding]

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "involved in binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]
   790   C1314939:Involved [Functional Concept]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "(Fig. 5D"

Phrase: ")."
Processing 00000000.tx.202: Mutations of the neighboring Arg-23 and Phe-24, which are located closer to the IRS than Lys-23 (Fig. 3), into either glutamic acid (R23E and F24E, respectively) or cysteine (R23CC and F24CC) result in a significative decrease in receptor binding (Fig. 5D and Table II), consistent with the results obtained with the double mutant K14E/R23E (see above). 

Phrase: "Mutations of the neighboring Arg-23"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0026882:Mutations [Genetic Function]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "and"

Phrase: "Phe-24,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0031453:Phe [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "which"

Phrase: "are"

Phrase: "located"

Phrase: "closer to the IRS"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0205148:Surface [Spatial Concept]
   753   C0524637:Recognition [Mental Process]
   719   C0587267:Close [Functional Concept]

Phrase: "than Lys-23"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0024337:Lys [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   861   C0450348:23 [Quantitative Concept]

Phrase: "(Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")"

Phrase: ","

Phrase: "into either glutamic acid"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0061472:Glutamic Acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   901   C0523665:Glutamic Acid [Laboratory Procedure]
   827   C0001128:Acid [Chemical]
   827   C0202406:Acid [Laboratory Procedure]

Phrase: "(R23E"

Phrase: "and"

Phrase: "F24E,"

Phrase: "respectively"

Phrase: ")"

Phrase: "or"

Phrase: "cysteine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010654:Cysteine [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(R23CC"

Phrase: "and"

Phrase: "F24CC"

Phrase: ")"

Phrase: "result in a significative decrease"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0392756:Decrease [Qualitative Concept]
   760   C0547047:Decrease [Quantitative Concept]
   760   C1274040:Result [Functional Concept]
   760   C1546471:Result [Idea or Concept]
   760   C2825142:Result [Finding]

Phrase: "in receptor binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0597358:Receptor Binding [Molecular Function]
   861   C0243122:binding [Functional Concept]
   861   C1145667:Binding [Activity]
   861   C1167622:Binding [Molecular Function]

Phrase: "(Fig. 5D"

Phrase: "and"

Phrase: "Table II"

Phrase: ")"

Phrase: ","

Phrase: "consistent with the results"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "obtained with the double mutant K14E/R23E"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   748   C0205173:Double [Functional Concept]
   748   C0596988:Mutant [Cell or Molecular Dysfunction]
   748   C1301820:Obtained [Functional Concept]
   748   C1705764:Double [Activity]
   748   C1705765:Double [Qualitative Concept]
   714 E C1706701:Obtain [Activity]

Phrase: "("

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "above"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1282910:Above [Spatial Concept]
  1000   C1552828:above [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.203: We have also analyzed the role of the -sheet-like structure composed of residues 99-118 of bvPLA2 (Fig. 3) in receptor binding. 

Phrase: "We"

Phrase: "have"

Phrase: "also"

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: "the role of the -sheet-like structure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0035820:Role [Social Behavior]
   748   C1705810:Role [Conceptual Entity]

Phrase: "composed of residues 99-118 of bvPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   714   C1709915:Residue [Conceptual Entity]
   714   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "(Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")"

Phrase: "in receptor binding."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0597358:Receptor Binding [Molecular Function]
   861   C0243122:binding [Functional Concept]
   861   C1145667:Binding [Activity]
   861   C1167622:Binding [Molecular Function]
Processing 00000000.tx.204: Interestingly, a similar structure is also found in group I and group II sPLA2s (2, 5), but no role has been proposed for this domain in supporting the enzymatic activity or toxicity of sPLA2s. 

Phrase: "Interestingly,"

Phrase: "a similar structure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0678594:Structure [Spatial Concept]

Phrase: "is"

Phrase: "also"

Phrase: "found in group I"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   833   C0441843:Group I [Intellectual Product]
   819 E C1959640:I group [Clinical Attribute]
   770   C0021966:I- [Inorganic Chemical]
   770   C0150312:Found [Quantitative Concept]
   770   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0441833:Group [Idea or Concept]
   770   C0687744:group [Population Group]
   770   C1257890:Group [Population Group]
   770   C1552516:Group [Health Care Related Organization]
   770   C1705428:Group [Conceptual Entity]
   770   C1705429:Group [Population Group]
   737 E C0243095:Find [Finding]

Phrase: "and"

Phrase: "group II sPLA2s"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   991   C1959603:Group II Secretory Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
           Group II Phospholipases A2
   884   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   840   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "but"

Phrase: "no role"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0035820:Role [Social Behavior]
  1000   C1705810:Role [Conceptual Entity]

Phrase: "has"

Phrase: "been"

Phrase: "proposed for this domain"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1441414:PROPOSED [Idea or Concept]
   770   C1553874:Proposed [Qualitative Concept]
   770   C1578820:Proposed [Idea or Concept]
   770   C1880389:Domain [Functional Concept]
   770   C1883221:Domain [Conceptual Entity]
   770   C3541951:Domain [Intellectual Product]

Phrase: "in supporting"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0183683:Support [Medical Device]
   966   C1521721:Support [Conceptual Entity]

Phrase: "the enzymatic activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C2267219:Enzymatic Activity [Molecular Function]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "or"

Phrase: "toxicity of sPLA2s."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0040539:toxicity [Qualitative Concept]
   760   C0600688:Toxicity [Injury or Poisoning]
Processing 00000000.tx.205: When this -sheet domain is deleted (99-118), the mutant bvPLA2 binds to N-type receptors with an affinity (K0.5=7.6 nM) that is similar to that of wild-type protein. 

Phrase: "When"

Phrase: "this -sheet domain"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1880389:Domain [Functional Concept]
   861   C1883221:Domain [Conceptual Entity]
   861   C3541951:Domain [Intellectual Product]

Phrase: "is"

Phrase: "deleted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1880274:Deleted [Activity]

Phrase: "(99-118"

Phrase: ")"

Phrase: ","

Phrase: "the mutant bvPLA2"

Phrase: "binds to N-type receptors"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1145667:Bind [Activity]
   760   C1167622:bind [Molecular Function]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "with an affinity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "(K0.5"

Phrase: "=7.6 nM)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0312860:NM [Cell Function]

Phrase: "that"

Phrase: "is"

Phrase: "similar to that of wild-type protein."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C2348205:Similar [Qualitative Concept]
Processing 00000000.tx.206: This result clearly indicates that the -sheet-like structure does not interact with N-type receptors. 

Phrase: "This result clearly"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1274040:Result [Functional Concept]
   861   C1546471:Result [Idea or Concept]
   861   C2825142:Result [Finding]

Phrase: "indicates"

Phrase: "that"

Phrase: "the -sheet-like structure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0678594:Structure [Spatial Concept]

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "interact with N-type receptors."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.207: Is bvPLA2 Enzymatic Activity Required for Binding to N-type Receptors? 

Phrase: "Is"

Phrase: "bvPLA2 Enzymatic Activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "Required for Binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]
   790   C1514873:Required [Functional Concept]

Phrase: "to N-type Receptors?"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.208: At first glance, Table II shows that most of the mutants having weak receptor binding properties also have low enzymatic activity. 

Phrase: "At first glance,"

Phrase: "Table II"

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "that most of the mutants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "having"

Phrase: "weak receptor binding properties also"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   804   C0871161:properties [Qualitative Concept]
   804   C1292721:properties [Functional Concept]
   771 E C1882134:Property [Conceptual Entity]
   771 E C2347695:Property [Entity]

Phrase: "have"

Phrase: "low enzymatic activity."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]
Processing 00000000.tx.209: However, a detailed comparison of the data indicates that receptor binding and enzymatic activity are two independent molecular events. 

Phrase: "However,"

Phrase: "a detailed comparison of the data"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1707455:Comparison [Activity]

Phrase: "indicates"

Phrase: "that receptor binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0597358:Receptor Binding [Molecular Function]
   861   C0243122:binding [Functional Concept]
   861   C1145667:Binding [Activity]
   861   C1167622:Binding [Molecular Function]

Phrase: "and"

Phrase: "enzymatic activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C2267219:Enzymatic Activity [Molecular Function]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "are"

Phrase: "two independent molecular events."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0441471:Events [Event]
   812   C3541888:Events [Classification]
Processing 00000000.tx.210: Indeed, a clear dissociation between binding and catalytic activity can be found with various mutants of the Ca2+-binding loop and the IRS. 

Phrase: "Indeed,"

Phrase: "a clear dissociation between binding"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0086168:Dissociation [Mental or Behavioral Dysfunction]

Phrase: "and"

Phrase: "catalytic activity"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0243102:catalytic activity [Molecular Function]
  1000   C1264638:Catalytic activity [Functional Concept]
  1000   C1547012:*Catalytic Activity [Quantitative Concept]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "can"

Phrase: "be"

Phrase: "found with various mutants of the Ca2+-binding loop"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   742   C0150312:Found [Quantitative Concept]
   742   C0243122:binding [Functional Concept]
   742   C0419518:Loop [Medical Device]
   742   C0440102:Various [Indicator, Reagent, or Diagnostic Aid]
   742   C0445022:Loop [Spatial Concept]
   742   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   742   C0596988:mutants [Cell or Molecular Dysfunction]
   742   C1145667:Binding [Activity]
   742   C1167622:Binding [Molecular Function]
   708 E C0243095:Find [Finding]

Phrase: "and"

Phrase: "the IRS."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205148:Surface [Spatial Concept]
Processing 00000000.tx.211: For example, G12A has no measurable affinity for N-type receptors, whereas it retained 37% enzymatic activity as compared with wild-type enzyme. 

Phrase: "For example,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707959:Example [Conceptual Entity]

Phrase: "G12A"

Phrase: "has"

Phrase: "no measurable affinity for N-type receptors,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "whereas"

Phrase: "it"

Phrase: "retained"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333118:Retained [Functional Concept]

Phrase: "37% enzymatic activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "as"

Phrase: "compared with wild-type enzyme."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C1883559:Wild Type [Organism Attribute]
   760   C0014442:Enzyme [Enzyme,Organic Chemical]
   760   C0332307:Type [Qualitative Concept]
   760   C0445392:Wild [Intellectual Product]
   760   C1547052:*Type [Quantitative Concept]
   760   C1707455:Compared [Activity]
Processing 00000000.tx.212: K85E/K133E binds to N-type receptors 180-fold weaker than wild-type enzyme, but this mutant retains 69% enzymatic activity. 

Phrase: "K85E/K133E"

Phrase: "binds to N-type receptors 180-fold"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0332307:Type [Qualitative Concept]
   748   C0332462:Fold [Spatial Concept]
   748   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   748   C1145667:Bind [Activity]
   748   C1167622:bind [Molecular Function]
   748   C1547052:*Type [Quantitative Concept]
   748   C1880834:FOLD [Phenomenon or Process]

Phrase: "weaker than wild-type enzyme,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C0004093:Weak [Sign or Symptom]
   726   C1762617:Weak [Qualitative Concept]

Phrase: "but"

Phrase: "this mutant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "retains"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333118:Retain [Functional Concept]

Phrase: "69% enzymatic activity."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]
Processing 00000000.tx.213: K14CC and K85CC have reduced binding properties with K0.5 values of 42and 69nM, respectively, while they still have high enzymatic activity (29and 42% relative to wild-type, respectively). 

Phrase: "K14CC"

Phrase: "and"

Phrase: "K85CC"

Phrase: "have"

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: "binding properties with K0.5 values of 42and 69nM,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   742   C0871161:properties [Qualitative Concept]
   742   C1292721:properties [Functional Concept]
   708 E C1882134:Property [Conceptual Entity]
   708 E C2347695:Property [Entity]

Phrase: "respectively,"

Phrase: "while"

Phrase: "they still"

Phrase: "have"

Phrase: "high enzymatic activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "(29and 42% relative to wild-type, respectively"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0080103:Relative [Family Group]
   748   C0205345:Relative [Qualitative Concept]
   748   C1547039:*Relative [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.214: The F82CC mutant also shows a lack of correlation in receptor binding and enzymatic activity, but to a lesser extent (280nM and 7% enzymatic activity). 

Phrase: "The F82CC mutant also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "a lack of correlation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0332268:lack [Qualitative Concept]

Phrase: "in receptor binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0597358:Receptor Binding [Molecular Function]
   861   C0243122:binding [Functional Concept]
   861   C1145667:Binding [Activity]
   861   C1167622:Binding [Molecular Function]

Phrase: "and"

Phrase: "enzymatic activity,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C2267219:Enzymatic Activity [Molecular Function]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "but to a lesser extent"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0233535:but [Mental or Behavioral Dysfunction]
   760   C0439792:Extent [Spatial Concept]
   760   C0547044:Lesser [Qualitative Concept]

Phrase: "(280nM"

Phrase: "and"

Phrase: "7% enzymatic activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.215: These results indicate that binding to N-type receptors and catalytic activity are independent events, although several residues of the Ca2+-binding loop and of the IRS are required for both activities. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "indicate"

Phrase: "that binding to N-type receptors"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   767   C0597358:Receptor Binding [Molecular Function]
   753   C0243122:binding [Functional Concept]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]

Phrase: "and"

Phrase: "catalytic activity"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0243102:catalytic activity [Molecular Function]
  1000   C1264638:Catalytic activity [Functional Concept]
  1000   C1547012:*Catalytic Activity [Quantitative Concept]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "are"

Phrase: "independent events,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441471:Events [Event]
   861   C3541888:Events [Classification]

Phrase: "although"

Phrase: "several residues of the Ca2+-binding loop"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   714   C1709915:Residue [Conceptual Entity]
   714   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "and of the IRS"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0205148:Surface [Spatial Concept]
   753   C0524637:Recognition [Mental Process]
   753   C1515981:And [Idea or Concept]

Phrase: "are"

Phrase: "required for both activities."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0441655:Activities [Activity]
   770   C1514873:Required [Functional Concept]
   737 E C0205177:Activity [Functional Concept]
   737 E C0439167:% activity [Quantitative Concept]
   737 E C1561536:*Activity [Idea or Concept]
Processing 00000000.tx.216: Relationships between Neurotoxicity, Binding to N-type Receptors, and Enzymatic Activity The neurotoxicity of venom sPLA2s, including bvPLA2, has been previously suggested to be associated with their binding to N-type receptors (19, 33). 

Phrase: "Relationships between Neurotoxicity,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   790   C0439849:Relationships [Qualitative Concept]
   756 E C1705630:Relationship [Idea or Concept]
   756 E C1706279:Relationship [Idea or Concept]
   756 E C3540605:Relationship [Intellectual Product]

Phrase: "Binding to N-type Receptors,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   781   C0597358:Receptor Binding [Molecular Function]
   760   C0243122:binding [Functional Concept]
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1145667:Binding [Activity]
   760   C1167622:Binding [Molecular Function]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "Enzymatic Activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C2267219:Enzymatic Activity [Molecular Function]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "The neurotoxicity of venom sPLA2s,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0235032:Neurotoxicity [Injury or Poisoning]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "bvPLA2,"

Phrase: "has"

Phrase: "been"

Phrase: "previously"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "associated with their binding"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "(19,"

Phrase: "33"

Phrase: ")."
Processing 00000000.tx.217: This is based on the observation that the neurotoxicity of a collection of sPLA2s correlates reasonably well with their affinity for N-type receptors. 

Phrase: "This"

Phrase: "is"

Phrase: "based on the observation"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   770   C0302523:Observation [Research Activity]
   770   C0700325:observation [Health Care Activity]
   770   C1527178:Based [Functional Concept]
   770   C1705938:Based [Idea or Concept]
   770   C1964257:Observation [Diagnostic Procedure]
   737 E C0002055:base [Inorganic Chemical]
   737 E C0178499:Base [Chemical Viewed Functionally]
   737 E C1880279:Base [Biomedical or Dental Material]

Phrase: "that"

Phrase: "the neurotoxicity of a collection of sPLA2s"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0235032:Neurotoxicity [Injury or Poisoning]

Phrase: "correlates"

Phrase: "reasonably well with their affinity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0205170:Well [Qualitative Concept]
   760   C1510827:Affinity [Natural Phenomenon or Process]
   760   C3146287:Well [Manufactured Object]

Phrase: "for N-type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.218: The conclusions from these previous studies would be strengthened by carrying out neurotoxicity studies with point mutant bvPLA2s that retain high enzymatic activity but fail to bind to N-type receptors and those proteins with the vice versa properties. 

Phrase: "The conclusions from these previous studies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1707478:Conclusions [Idea or Concept]

Phrase: "would"

Phrase: "be"

Phrase: "strengthened by carrying out neurotoxicity"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0206243:Carrying [Activity]
   760   C0235032:Neurotoxicity [Injury or Poisoning]
   760   C0439787:Out [Spatial Concept]
   760   C0849355:Out [Qualitative Concept]
   726 E C0699809:carry [Finding]

Phrase: "studies with point mutant bvPLA2s"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0557651:Study [Manufactured Object]
   760   C0596988:Mutant [Cell or Molecular Dysfunction]
   760   C0947630:studies [Laboratory Procedure]
   760   C1552961:Point [Quantitative Concept]
   760   C2347617:point [Quantitative Concept]
   760   C2603343:Study [Research Activity]

Phrase: "that"

Phrase: "retain"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333118:Retain [Functional Concept]

Phrase: "high enzymatic activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "but"

Phrase: "fail"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:fail [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "bind to N-type receptors"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1145667:Bind [Activity]
   760   C1167622:bind [Molecular Function]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "those proteins with the vice versa properties."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.219: Studies along these lines are summarized in Table III. 

Phrase: "Studies along these lines"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   770   C0947630:studies [Laboratory Procedure]
   737 E C0557651:Study [Manufactured Object]
   737 E C2603343:Study [Research Activity]

Phrase: "are"

Phrase: "summarized in Table III."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0039224:Table [Manufactured Object]
   770   C0439070:III [Intellectual Product]
   770   C1705160:III [Qualitative Concept]
   770   C1706073:Table [Medical Device]
   770   C1706074:Table [Intellectual Product]
Processing 00000000.tx.220: For these studies, we have chosen bvPLA2 mutants that show a clear dissociation between enzymatic activity and receptor affinity. 

Phrase: "For these studies,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "we"

Phrase: "have"

Phrase: "chosen bvPLA2 mutants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "a clear dissociation between enzymatic activity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0086168:Dissociation [Mental or Behavioral Dysfunction]

Phrase: "and"

Phrase: "receptor affinity."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1510827:Affinity [Natural Phenomenon or Process]
Processing 00000000.tx.221: The data in Table III indicate that recombinant wild-type bvPLA2 expressed in bacteria as a fusion protein is lethal to mice at very low doses of 25-125 nmol/kg when injected by the intracerebroventricular route. 

Phrase: "The data in Table III"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C1706074:Data Table [Intellectual Product]
   760   C1511726:Data [Idea or Concept]
   760   C3245479:data [Medical Device]

Phrase: "indicate"

Phrase: "that recombinant wild-type bvPLA2"

Phrase: "expressed in bacteria"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0004611:Bacteria [Bacterium]
   790   C1510439:bacteria [Functional Concept]
   790   C2347473:% Bacteria [Quantitative Concept]
   718 E C0521009:Bacterial [Qualitative Concept]

Phrase: "as a fusion protein"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0162768:Fusion protein [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0332466:Fusion [Functional Concept]
   861   C1293131:Fusion [Therapeutic or Preventive Procedure]

Phrase: "is"

Phrase: "lethal to mice"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C3151529:Lethal [Finding]

Phrase: "at very low doses"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   884   C0445550:Low dose [Quantitative Concept]
   884   C1708745:Low-Dose [Research Activity]
   827   C0178602:Doses [Quantitative Concept]
   793 E C0869039:Dose [Quantitative Concept]
   793 E C1114758:Dose # [Clinical Attribute]
   793 E C1428722:DOS [Gene or Genome]
   734   C0442811:Very low [Finding]

Phrase: "of 25-125 nmol/kg"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439283:nmol/kg [Quantitative Concept]
   812   C0022718:KG [Geographic Area]
   812   C0439209:kg [Quantitative Concept]

Phrase: "when"

Phrase: "injected by the intracerebroventricular route."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0595818:Intracerebroventricular route [Spatial Concept]
   760   C0013153:ROUTE [Functional Concept]
   760   C0449444:Route [Spatial Concept]
   760   C1879941:ROUTE [Intellectual Product]
   726   C1720154:Inject [Functional Concept]
Processing 00000000.tx.222: The behavioral symptoms occurring after injection were periods of catalepsy while the mice showed breathing problems, and these events were separated by periods of violent convulsions lasting from 10to 60s. 

Phrase: "The behavioral symptoms"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0004941:Behavioral Symptoms [Sign or Symptom]
  1000   C2707011:Behavioral symptoms [Clinical Attribute]
   861   C0004927:Behavioral [Individual Behavior]
   861   C0683368:symptoms [Functional Concept]
   861   C1457887:Symptoms [Sign or Symptom]
   861   C2986890:Behavioral [Idea or Concept]

Phrase: "occurring after injection"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0021485:injection [Therapeutic or Preventive Procedure]
   790   C1272883:Injection [Biomedical or Dental Material]
   790   C1533685:Injection [Therapeutic or Preventive Procedure]
   790   C1828121:Injection [Functional Concept]
   756   C1709305:Occur [Activity]
   756   C2745955:OCCUR [Temporal Concept]

Phrase: "were"

Phrase: "periods of catalepsy"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   756   C0439531:/period [Temporal Concept]
   756   C1948053:Period [Temporal Concept]
   706 E C0332182:Periodic [Temporal Concept]
   706 E C1706381:PERIODIC [Intellectual Product]

Phrase: "while"

Phrase: "the mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "breathing problems,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1260922:Breathing Problems [Sign or Symptom]
   861   C1546466:Problems [Idea or Concept]
   827 E C0033213:Problem [Finding]

Phrase: "and"

Phrase: "these events"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0441471:Events [Event]
  1000   C3541888:Events [Classification]

Phrase: "were"

Phrase: "separated by periods of violent convulsions"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   753   C0036572:Convulsions [Sign or Symptom]
   753   C0086972:Separated [Finding]
   753   C0242151:VIOLENT [Mental or Behavioral Dysfunction]
   753   C0443299:separated [Spatial Concept]
   753   C0687118:Separated [Functional Concept]
   719   C0439531:/period [Temporal Concept]
   719   C1948053:Period [Temporal Concept]

Phrase: "lasting from 10to 60s."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C1517741:Last [Qualitative Concept]
Processing 00000000.tx.223: These symptoms are very similar to those observed after injection of natural bvPLA2 into rat brain (33). 

Phrase: "These symptoms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0683368:symptoms [Functional Concept]
  1000   C1457887:Symptoms [Sign or Symptom]

Phrase: "are"

Phrase: "very similar to those observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C2348205:Similar [Qualitative Concept]

Phrase: "after"

Phrase: "injection of natural bvPLA2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0021485:injection [Therapeutic or Preventive Procedure]
   770   C1272883:Injection [Biomedical or Dental Material]
   770   C1533685:Injection [Therapeutic or Preventive Procedure]
   770   C1828121:Injection [Functional Concept]

Phrase: "into rat brain"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1882598:Rat Brain [Body Part, Organ, or Organ Component]
   861   C0006104:Brain [Body Part, Organ, or Organ Component]
   861   C1269537:Brain [Body Part, Organ, or Organ Component]

Phrase: "(33"

Phrase: ")."
Processing 00000000.tx.224: These symptoms were also observed with all of the mutants showing neurotoxicity. 

Phrase: "These symptoms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0683368:symptoms [Functional Concept]
  1000   C1457887:Symptoms [Sign or Symptom]

Phrase: "were"

Phrase: "also"

Phrase: "observed with all of the mutants"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0596988:mutants [Cell or Molecular Dysfunction]
   753   C1441672:Observed [Functional Concept]

Phrase: "showing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "neurotoxicity."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0235032:Neurotoxicity [Injury or Poisoning]
Processing 00000000.tx.225: K14CC and K85CC are mutants that retain a high degree of bvPLA2 enzymatic activity (within 4-fold of wild-type enzyme), whereas their K0.5 values for binding to N-type receptors are increased by a factor of 20-30 relative to that of the wild-type protein. 

Phrase: "K14CC"

Phrase: "and"

Phrase: "K85CC"

Phrase: "are"

Phrase: "mutants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "retain"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333118:Retain [Functional Concept]

Phrase: "a high degree of bvPLA2 enzymatic activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0441889:Degree [Qualitative Concept]
   748   C0449286:Degree [Quantitative Concept]
   748   C0542560:Degree [Intellectual Product]
   748   C1561545:degree [Quantitative Concept]
   748   C2348088:Degree [Quantitative Concept]

Phrase: "("

Phrase: "within 4-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332462:Fold [Spatial Concept]
   861   C1880834:FOLD [Phenomenon or Process]

Phrase: "of wild-type enzyme"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0014442:Enzyme [Enzyme,Organic Chemical]
   743 E C0014445:enzymes [Functional Concept]
   734   C1883559:Wild Type [Organism Attribute]

Phrase: ")"

Phrase: ","

Phrase: "whereas"

Phrase: "their K0.5 values for binding"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0042295:Values [Qualitative Concept]
   719 E C1522609:Value [Quantitative Concept]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "are"

Phrase: "increased by a factor of 20-30 relative"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   767   C0960756:factor A [Organic Chemical]
   744   C0080103:Relative [Family Group]
   744   C0205217:Increased [Quantitative Concept]
   744   C0205345:Relative [Qualitative Concept]
   744   C0442805:Increased [Functional Concept]
   744   C1521761:Factor [Functional Concept]
   744   C1547039:*Relative [Quantitative Concept]
   744   C2827422:Factor [Conceptual Entity]

Phrase: "to that"

Phrase: "of the wild-type protein."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   734   C1883559:Wild Type [Organism Attribute]
Processing 00000000.tx.226: The data in Table III show that these mutants are still lethal, although the effective doses needed to kill mice are much higher. 

Phrase: "The data in Table III"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C1706074:Data Table [Intellectual Product]
   760   C1511726:Data [Idea or Concept]
   760   C3245479:data [Medical Device]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "that"

Phrase: "these mutants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "still lethal,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3151529:Lethal [Finding]

Phrase: "although"

Phrase: "the effective doses"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0178602:Doses [Quantitative Concept]
   861   C1280519:effective [Qualitative Concept]
   861   C1704419:Effective [Qualitative Concept]
   827 E C0869039:Dose [Quantitative Concept]
   827 E C1114758:Dose # [Clinical Attribute]
   827 E C1428722:DOS [Gene or Genome]

Phrase: "needed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Needed [Qualitative Concept]
  1000   C0686904:needed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "kill"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0162388:kill [Social Behavior]
  1000   C0681205:Kill [Idea or Concept]
  1000   C1550555:kill [Functional Concept]

Phrase: "mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]

Phrase: "are"

Phrase: "much higher."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   827   C0205250:High [Qualitative Concept]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]
   777 E C0489786:Height [Organism Attribute]
Processing 00000000.tx.227: Indeed, 125 nmol/kg of K14CC killed only three out of six mice, while identical or lower quantities of wild-type bvPLA2 killed all or almost all of the injected mice (Table III). 

Phrase: "Indeed,"

Phrase: "125 nmol/kg of K14CC"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0439283:nmol/kg [Quantitative Concept]
   760   C0022718:KG [Geographic Area]
   760   C0439209:kg [Quantitative Concept]

Phrase: "killed"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0162388:killed [Social Behavior]
   966 E C0681205:Kill [Idea or Concept]
   966 E C1550555:kill [Functional Concept]

Phrase: "only three out of six mice,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   753   C0025914:Mice [Mammal]
   753   C0025929:mice [Mammal]
   753   C0026809:Mice [Mammal]
   753   C0205171:Only [Quantitative Concept]
   753   C0205449:Three [Quantitative Concept]
   753   C0205452:Six [Quantitative Concept]
   753   C0439787:Out [Spatial Concept]
   753   C0849355:Out [Qualitative Concept]
   753   C1720467:Only [Intellectual Product]

Phrase: "while"

Phrase: "identical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205280:Identical [Qualitative Concept]

Phrase: "or"

Phrase: "lower quantities of wild-type bvPLA2"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   753   C1265611:QUANTITIES [Quantitative Concept]
   719 E C1554108:Quantity [Intellectual Product]
   719 E C1561573:Quantity [Intellectual Product]

Phrase: "killed"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0162388:killed [Social Behavior]
   966 E C0681205:Kill [Idea or Concept]
   966 E C1550555:kill [Functional Concept]

Phrase: "all"

Phrase: "or"

Phrase: "almost"

Phrase: "all of the injected mice"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0025914:Mice [Mammal]
   760   C0025929:mice [Mammal]
   760   C0026809:Mice [Mammal]
   760   C0444868:All [Quantitative Concept]
   760   C3539085:All [Idea or Concept]

Phrase: "(Table III"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439070:III [Intellectual Product]
   861   C1705160:III [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.228: Similarly, 250nmol/kg of K85CC is needed to kill four out of nine injected mice, while injections of a 5-fold lower amount of wild-type enzyme killed five out of six mice. 

Phrase: "Similarly,"

Phrase: "250nmol/kg of K85CC"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0022718:KG [Geographic Area]
   770   C0439209:kg [Quantitative Concept]

Phrase: "is"

Phrase: "needed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Needed [Qualitative Concept]
  1000   C0686904:needed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "kill"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0162388:kill [Social Behavior]
  1000   C0681205:Kill [Idea or Concept]
  1000   C1550555:kill [Functional Concept]

Phrase: "four out of nine injected mice,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   753   C0025914:Mice [Mammal]
   753   C0025929:mice [Mammal]
   753   C0026809:Mice [Mammal]
   753   C0205450:Four [Quantitative Concept]
   753   C0205455:Nine [Quantitative Concept]
   753   C0439787:Out [Spatial Concept]
   753   C0849355:Out [Qualitative Concept]

Phrase: "while"

Phrase: "injections of a 5-fold lower amount of wild-type enzyme"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   738   C0021485:injections [Therapeutic or Preventive Procedure]
   738   C1533685:INJECTIONS [Therapeutic or Preventive Procedure]
   738   C1828121:Injections [Functional Concept]
   704 E C1272883:Injection [Biomedical or Dental Material]

Phrase: "killed"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0162388:killed [Social Behavior]
   966 E C0681205:Kill [Idea or Concept]
   966 E C1550555:kill [Functional Concept]

Phrase: "five out of six mice."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0025914:Mice [Mammal]
   760   C0025929:mice [Mammal]
   760   C0026809:Mice [Mammal]
   760   C0205451:Five [Quantitative Concept]
   760   C0205452:Six [Quantitative Concept]
   760   C0439787:Out [Spatial Concept]
   760   C0849355:Out [Qualitative Concept]
Processing 00000000.tx.229: The neurotoxic properties of mutants with very weak or no measurable affinity for N-type receptors were also analyzed. 

Phrase: "The neurotoxic properties of mutants"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   760   C0871161:properties [Qualitative Concept]
   760   C1292721:properties [Functional Concept]
   726 E C1882134:Property [Conceptual Entity]
   726 E C2347695:Property [Entity]

Phrase: "with very weak"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0004093:Weak [Sign or Symptom]
   861   C1762617:Weak [Qualitative Concept]

Phrase: "or"

Phrase: "no measurable affinity for N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "were"

Phrase: "also"

Phrase: "analyzed."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]
Processing 00000000.tx.230: Importantly, some of these mutants still display a high enzymatic activity relative to wild-type bvPLA2 (Table III). 

Phrase: "Importantly,"

Phrase: "some of these mutants still"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0205392:Some [Quantitative Concept]
   760   C0596988:mutants [Cell or Molecular Dysfunction]
   760   C3540770:Some [Intellectual Product]

Phrase: "display"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705417:Display [Manufactured Object]

Phrase: "a high enzymatic activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "relative to wild-type bvPLA2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0080103:Relative [Family Group]
   760   C0205345:Relative [Qualitative Concept]
   760   C1547039:*Relative [Quantitative Concept]

Phrase: "(Table III"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439070:III [Intellectual Product]
   861   C1705160:III [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.231: None of these mutants were lethal in mice, even at the highest doses that are possible to inject (125nmol/kg for K85E/K133E and 250nmol/kg for G12A and F82CC). 

Phrase: "None of these mutants"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0456148:None [Quantitative Concept]
   770   C0549184:None [Quantitative Concept]
   770   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: "were"

Phrase: "lethal in mice,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C3151529:Lethal [Finding]

Phrase: "even at the highest doses"
Meta Candidates (Total=9; Excluded=6; Pruned=0; Remaining=3)
   773   C0444956:High dose [Quantitative Concept]
   760   C0178602:Doses [Quantitative Concept]
   760   C1522410:Highest [Qualitative Concept]
   726 E C0205250:High [Qualitative Concept]
   726 E C0869039:Dose [Quantitative Concept]
   726 E C1114758:Dose # [Clinical Attribute]
   726 E C1299351:High [Qualitative Concept]
   726 E C1428722:DOS [Gene or Genome]
   726 E C2700149:HIGH [Intellectual Product]

Phrase: "that"

Phrase: "are"

Phrase: "possible to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332149:Possible [Qualitative Concept]
   861   C1705910:Possible [Qualitative Concept]
   861   C2362652:Possible [Qualitative Concept]

Phrase: "inject"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1720154:Inject [Functional Concept]

Phrase: "(125nmol/kg for K85E/K133E"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0022718:KG [Geographic Area]
   760   C0439209:kg [Quantitative Concept]

Phrase: "and"

Phrase: "250nmol/kg for G12A"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0022718:KG [Geographic Area]
   770   C0439209:kg [Quantitative Concept]

Phrase: "and"

Phrase: "F82CC"

Phrase: ")."
Processing 00000000.tx.232: Finally, as a control, we checked for the lethal properties of a double mutant (D64E/K66CC) that has both high enzymatic activity and high affinity for N-type receptors (Table III). 

Phrase: "Finally,"

Phrase: "as"

Phrase: "a control,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "we"

Phrase: "checked for the lethal properties of a double mutant"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   745   C0591407:double check [Pharmacologic Substance,Steroid]
   742   C0205173:Double [Functional Concept]
   742   C0596988:Mutant [Cell or Molecular Dysfunction]
   742   C0871161:properties [Qualitative Concept]
   742   C1283174:Checked [Activity]
   742   C1292721:properties [Functional Concept]
   742   C1705764:Double [Activity]
   742   C1705765:Double [Qualitative Concept]
   742   C3151529:Lethal [Finding]
   708 E C1882134:Property [Conceptual Entity]
   708 E C2347695:Property [Entity]

Phrase: "(D64E/K66CC"

Phrase: ")"

Phrase: "that"

Phrase: "has"

Phrase: "both high enzymatic activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "and"

Phrase: "high affinity for N-type receptors"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0205250:High [Qualitative Concept]
   753   C1299351:High [Qualitative Concept]
   753   C1510827:Affinity [Natural Phenomenon or Process]
   753   C2700149:HIGH [Intellectual Product]

Phrase: "(Table III"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439070:III [Intellectual Product]
   861   C1705160:III [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.233: This mutant displays a toxicity very similar to that of the wild-type recombinant bvPLA2, suggesting that this region of the molecule is not required to invoke lethality of bvPLA2 in mice. 

Phrase: "This mutant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "displays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0870432:displays [Functional Concept]
  1000   C1705417:Display [Manufactured Object]

Phrase: "a toxicity"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0040539:toxicity [Qualitative Concept]
  1000   C0600688:Toxicity [Injury or Poisoning]
   928 E C1407029:Toxic [Qualitative Concept]
   907 E C0032346:Poison [Hazardous or Poisonous Substance]
   907 E C1548769:Poison [Intellectual Product]
   907 E C1550590:poison [Idea or Concept]

Phrase: "very similar to that of the wild-type recombinant bvPLA2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C2348205:Similar [Qualitative Concept]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "this region of the molecule"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0017446:Region [Geographic Area]
   760   C0205147:Region [Spatial Concept]

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "invoke"

Phrase: "lethality of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   718   C3151529:Lethal [Finding]

Phrase: "in mice."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]
Processing 00000000.tx.234: Altogether, these results demonstrate that the neurotoxicity of bvPLA2 is related to its ability to bind to N-type receptors and not to its ability to hydrolyze phospholipids. 

Phrase: "Altogether,"

Phrase: "these results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "demonstrate"

Phrase: "that"

Phrase: "the neurotoxicity of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0235032:Neurotoxicity [Injury or Poisoning]

Phrase: "is"

Phrase: "related to its ability to"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   760   C0085732:Ability [Organism Attribute]
   760   C0439849:Related [Qualitative Concept]
   760   C0445223:Related [Finding]
   726 E C0163712:Relate [Organic Chemical]

Phrase: "bind to N-type receptors"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1145667:Bind [Activity]
   760   C1167622:bind [Molecular Function]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "not to its ability to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0085732:Ability [Organism Attribute]
   760   C1518422:Not [Functional Concept]

Phrase: "hydrolyze"

Phrase: "phospholipids."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0031676:Phospholipids [Biologically Active Substance,Lipid]
   966 E C0202177:Phospholipid [Laboratory Procedure]
Processing 00000000.tx.235: Table III. 

Phrase: "Table III."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439070:III [Intellectual Product]
   861   C1705160:III [Qualitative Concept]
Processing 00000000.tx.236: K0.5 value, enzymatic activity, and lethal toxicity to mice of recombinant wild-type and mutant bee venom sPLA2s K0.5 values, enzymatic activity, and lethality of the wild-type and mutant recombinant bee venom sPLA2s have been determined as described under "Experimental Procedures." 

Phrase: "K0.5 value,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1522609:Value [Quantitative Concept]

Phrase: "enzymatic activity,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C2267219:Enzymatic Activity [Molecular Function]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "and"

Phrase: "lethal toxicity to mice of recombinant wild-type"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0040539:toxicity [Qualitative Concept]
   744   C0600688:Toxicity [Injury or Poisoning]

Phrase: "and"

Phrase: "mutant bee venom sPLA2s K0.5 values,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   791   C0042295:Values [Qualitative Concept]
   758 E C1522609:Value [Quantitative Concept]

Phrase: "enzymatic activity,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C2267219:Enzymatic Activity [Molecular Function]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "and"

Phrase: "lethality of the wild-type"

Phrase: "and"

Phrase: "mutant recombinant bee venom sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   845   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   818   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   795   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]
   785 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   785 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "have"

Phrase: "been"

Phrase: "determined"

Phrase: "as"

Phrase: "described under ""Experimental Procedures."""
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   770   C0025664:procedures [Intellectual Product]
   770   C0184661:Procedures [Diagnostic Procedure,Therapeutic or Preventive Procedure]
   770   C1517586:Experimental [Qualitative Concept]
   770   C1552738:described [Idea or Concept]
   770   C2700391:procedures [Activity]
   737 E C1948041:Procedure [Therapeutic or Preventive Procedure]
   737 E C3274430:PROCEDURE [Health Care Activity]
   737 E C3538935:Procedure [Idea or Concept]
   737 E C3539779:Procedure [Intellectual Product]
Processing 00000000.tx.237: sPLA2 Binding activity, K0.5 value Enzymatic activity Amount injected Lethality (dead/injected) nM % of rbvPLA2 nmol/kg rBV 2.0 100 25 1 /3 50 5 /6 125 6 /6 K14C 42 29 125 3 /6 K85C 69 42 250 4 /9 K85E/K133E 360 69 125 0 /4 G12A >1000 37 250 0 /5 F82C 280 7 250 0 /8 K66C/D64E 2.7 85 35 3 /3 DISCUSSION The aim of this paper was 2-fold: to determine the region(s) of bvPLA2 involved in binding to N-type receptors and to determine if binding of bvPLA2 to N-type receptors and/or the enzymatic activity of this protein are required for the neurotoxic effects of bvPLA2. 

Phrase: "sPLA2 Binding activity,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2266866:Binding Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "K0.5 value Enzymatic activity Amount injected Lethality"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   721   C3151529:Lethal [Finding]

Phrase: "(dead/injected"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   789   C0021485:injection [Therapeutic or Preventive Procedure]
   789   C1272883:Injection [Biomedical or Dental Material]
   789   C1533685:INJECTIONS [Therapeutic or Preventive Procedure]
   789   C1828121:Injection [Functional Concept]

Phrase: ")"

Phrase: "nM %"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0312860:NM [Cell Function]

Phrase: "of rbvPLA2 nmol/kg rBV 2.0 100 25 1 /3 50 5 /6 125 6 /6 K14C 42 29 125 3 /6 K85C 69 42 250 4 /9 K85E/K133E 360 69 125 0 /4 G12A"

Phrase: ">1000 37 250 0 /5 F82C 280 7 250 0 /8 K66C/D64E 2.7 85 35 3 /3 DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   783   C0557061:Discussion [Therapeutic or Preventive Procedure]
   783   C2584313:Discussion [Social Behavior]

Phrase: "The aim of this paper"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C1947946:Aim [Idea or Concept]
   760   C2948600:Aim [Pharmacologic Substance]
   760   C3540471:AIM [Gene or Genome]
   760   C3540472:AIM [Functional Concept]

Phrase: "was"

Phrase: "2-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332462:Fold [Spatial Concept]
   861   C1880834:FOLD [Phenomenon or Process]

Phrase: ":"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "determine"

Phrase: "the region"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0017446:Region [Geographic Area]
  1000   C0205147:Region [Spatial Concept]
   928 E C0205276:Regional [Spatial Concept]
   928 E C1947913:Regional [Spatial Concept]

Phrase: "("

Phrase: "s) of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2603362:S' [Clinical Attribute]

Phrase: "involved in binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]
   790   C1314939:Involved [Functional Concept]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "and"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "determine"

Phrase: "if"

Phrase: "binding of bvPLA2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "and/or"

Phrase: "the enzymatic activity of this protein"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C2267219:Enzymatic Activity [Molecular Function]
   783   C1537044:protein activity [Molecular Function]
   753   C0205177:Activity [Functional Concept]
   753   C0439167:% activity [Quantitative Concept]
   753   C0441655:Activity [Activity]
   753   C1561536:*Activity [Idea or Concept]

Phrase: "are"

Phrase: "required for the neurotoxic effects of bvPLA2."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   762   C0235032:Neurotoxic effect [Injury or Poisoning]
   748   C1280500:effects [Qualitative Concept]
   748   C1514873:Required [Functional Concept]
   714 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.238: As a first approach to identify the region(s) of sPLA2 involved in binding to N-type receptors, we performed sequence comparisons between sPLA2s that bind or do not bind to these receptors. 

Phrase: "As a first"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205435:First [Quantitative Concept]
  1000   C1279901:First [Qualitative Concept]

Phrase: "approach"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449445:Approach [Spatial Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "identify"

Phrase: "the region"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0017446:Region [Geographic Area]
  1000   C0205147:Region [Spatial Concept]
   928 E C0205276:Regional [Spatial Concept]
   928 E C1947913:Regional [Spatial Concept]

Phrase: "("

Phrase: "s) of sPLA2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1418616:SPLA2 [Gene or Genome]
   790   C1706169:sPLA2 [Gene or Genome]
   790   C2603362:S' [Clinical Attribute]

Phrase: "involved in binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]
   790   C1314939:Involved [Functional Concept]

Phrase: "to N-type receptors,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "we"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "sequence comparisons between sPLA2s"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C1707455:Comparison [Activity]

Phrase: "that"

Phrase: "bind"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "or"

Phrase: "do"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "bind to these receptors."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   770   C1145667:Bind [Activity]
   770   C1167622:bind [Molecular Function]
Processing 00000000.tx.239: Two different sets of sequence comparisons were made. 

Phrase: "Two different sets of sequence comparisons"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0036849:Set [Mental Process]
   753   C1442518:Set [Functional Concept]
   753   C1705195:Set [Conceptual Entity]

Phrase: "were"

Phrase: "made."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1881534:Make [Functional Concept]
Processing 00000000.tx.240: In the first set, we aligned a large number of group I and group II sPLA2s, including OS1 and OS2, which have a relatively high level of sequence identity but have distinct receptor binding properties (28). 

Phrase: "In the first set,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0036849:Set [Mental Process]
   861   C1442518:Set [Functional Concept]
   861   C1705195:Set [Conceptual Entity]

Phrase: "we"

Phrase: "aligned"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1706765:Aligned [Quantitative Concept]
   966 E C2369992:Align [Pharmacologic Substance]

Phrase: "a large number of group I"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C2985777:Group Number [Quantitative Concept]
   753   C0237753:*Number [Quantitative Concept]
   753   C0449788:Number [Quantitative Concept]

Phrase: "and"

Phrase: "group II sPLA2s,"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   991   C1959603:Group II Secretory Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
           Group II Phospholipases A2
   884   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   840   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "OS1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0029408:OS1 [Disease or Syndrome]

Phrase: "and"

Phrase: "OS2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0409957:OS2 [Disease or Syndrome]

Phrase: "which"

Phrase: "have"

Phrase: "a relatively high level of sequence identity"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0205250:High [Qualitative Concept]
   748   C0441889:Level [Qualitative Concept]
   748   C0456079:Level [Classification]
   748   C1299351:High [Qualitative Concept]
   748   C1547707:Level [Geographic Area]
   748   C2700149:HIGH [Intellectual Product]
   748   C2946261:Level [Pharmacologic Substance]

Phrase: "but"

Phrase: "have"

Phrase: "distinct receptor binding properties"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   812   C0871161:properties [Qualitative Concept]
   812   C1292721:properties [Functional Concept]
   779 E C1882134:Property [Conceptual Entity]
   779 E C2347695:Property [Entity]

Phrase: "(28"

Phrase: ")."
Processing 00000000.tx.241: A second set of sequence alignments was made with group III sPLA2s, since bvPLA2 is a typical member of this group and since it also binds with very high affinity and specificity to N-type receptors. 

Phrase: "A second"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0205436:Second [Quantitative Concept]
  1000   C0457385:Second [Temporal Concept]
  1000   C0565930:/second [Quantitative Concept]
  1000   C1561503:second [Idea or Concept]
  1000   C1705190:Second [Qualitative Concept]
   928 E C0027627:secondary [Neoplastic Process]
   928 E C0175668:Secondary [Temporal Concept]

Phrase: "set of sequence alignments"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   833   C0080143:Sequence Alignments [Molecular Biology Research Technique]
   770   C0004793:Sequence [Nucleotide Sequence]
   770   C0036849:Set [Mental Process]
   770   C0162326:Sequence [Nucleotide Sequence]
   770   C0162327:Sequence [Nucleotide Sequence]
   770   C1442518:Set [Functional Concept]
   770   C1519249:Sequence [Functional Concept]
   770   C1705195:Set [Conceptual Entity]
   737   C1706765:Alignment [Quantitative Concept]

Phrase: "was"

Phrase: "made with group III sPLA2s,"
Meta Candidates (Total=19; Excluded=3; Pruned=0; Remaining=16)
   889   C1955949:Group III Secretory Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
           Group III Phospholipases A2
           Phospholipase A2-III
   824 E C1425188:PHOSPHOLIPASE A2, GROUP III [Gene or Genome]
   814   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   778   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   748   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]
   748   C0439070:III [Intellectual Product]
   748   C0441833:Group [Idea or Concept]
   748   C0687744:group [Population Group]
   748   C1257890:Group [Population Group]
   748   C1327616:Secretory [Cell Function]
   748   C1552516:Group [Health Care Related Organization]
   748   C1705160:III [Qualitative Concept]
   748   C1705428:Group [Conceptual Entity]
   748   C1705429:Group [Population Group]
   745 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   745 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   714   C1881534:Make [Functional Concept]

Phrase: "since"

Phrase: "bvPLA2"

Phrase: "is"

Phrase: "a typical member of this group"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0680022:member [Population Group]
   753   C2698041:Member [Professional or Occupational Group]

Phrase: "and"

Phrase: "since"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1711239:Since [Temporal Concept]

Phrase: "it also"

Phrase: "binds with very high affinity"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   806   C0442804:Very high [Finding]
   760   C0205250:High [Qualitative Concept]
   760   C0442824:Very [Qualitative Concept]
   760   C1145667:Bind [Activity]
   760   C1167622:bind [Molecular Function]
   760   C1299351:High [Qualitative Concept]
   760   C1510827:Affinity [Natural Phenomenon or Process]
   760   C2700149:HIGH [Intellectual Product]

Phrase: "and"

Phrase: "specificity to N-type receptors."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0037791:Specificity [Quantitative Concept]
   760   C1511884:Specificity [Quantitative Concept]
Processing 00000000.tx.242: Other members of group III sPLA2s have been purified from the venom of the Gila monster lizard H.suspectum (45, 46) and of the Mexican beaded lizard Heloderma horridum horridum (47) as well as from the mediterranean medusa Rhopilema nomadica (48). 

Phrase: "Other members of group III sPLA2s"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C0680022:members [Population Group]
   711 E C2698041:Member [Professional or Occupational Group]

Phrase: "have"

Phrase: "been"

Phrase: "purified from the venom of the Gila monster lizard H.suspectum"
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   772   C0580776:Gila monster venom [Biologically Active Substance,Hazardous or Poisonous Substance]
   756   C0327268:Gila monster [Reptile]
   756   C0885407:gila monster [Hazardous or Poisonous Substance]
   754   C0580763:Lizard venom [Biologically Active Substance,Hazardous or Poisonous Substance]
   738   C0023916:Lizard [Reptile]
   738   C0026505:Monster [Congenital Abnormality]
   738   C0033727:H+ [Element, Ion, or Isotope]
   738   C0042479:Venom [Hazardous or Poisonous Substance]
   738   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   738   C0441932:H+ [Classification]
   738   C0564385:/h [Quantitative Concept]
   738   C1026514:Gila [Fish]
   738   C1998793:Purified [Functional Concept]
   718 E C0327267:Venomous lizard [Reptile]

Phrase: "(45,"

Phrase: "46"

Phrase: ")"

Phrase: "and of the Mexican beaded lizard Heloderma horridum horridum"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0327269:Mexican beaded lizard [Reptile]
           Heloderma horridum
   742   C0023916:Lizard [Reptile]
   742   C0240339:Mexican [Population Group]
   742   C0991566:beaded [Biomedical or Dental Material]
   742   C0999104:Heloderma [Reptile]
   742   C1515981:And [Idea or Concept]

Phrase: "(47"

Phrase: ")"

Phrase: "as well as from the mediterranean medusa Rhopilema nomadica"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   764   C1010392:Rhopilema nomadica [Eukaryote]
   742   C0205170:Well [Qualitative Concept]
   742   C0240321:Mediterranean [Population Group]
   742   C0885254:medusa [Pharmacologic Substance]
   742   C1010391:Rhopilema [Eukaryote]
   742   C3146287:Well [Manufactured Object]

Phrase: "(48"

Phrase: ")."
Processing 00000000.tx.243: Of interest for our study are the two sPLA2s, namely Pa2 and Pa5, which are major components of Gila monster (H.suspectum) venom and which have been entirely sequenced (46). 

Phrase: "Of interest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0543488:Interest [Mental Process]

Phrase: "for our study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "are"

Phrase: "the two sPLA2s,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   923   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "namely Pa2"

Phrase: "and"

Phrase: "Pa5,"

Phrase: "which"

Phrase: "are"

Phrase: "major components of Gila monster"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0449432:Components [Manufactured Object]
   726 E C1705248:Component [Conceptual Entity]

Phrase: "(H.suspectum"

Phrase: ")"

Phrase: "venom"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0042479:Venom [Hazardous or Poisonous Substance]

Phrase: "and"

Phrase: "which"

Phrase: "have"

Phrase: "been"

Phrase: "entirely"

Phrase: "sequenced"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   966   C0004793:Sequence [Nucleotide Sequence]
   966   C0162326:Sequence [Nucleotide Sequence]
   966   C0162327:Sequence [Nucleotide Sequence]
   966   C1519249:Sequence [Functional Concept]

Phrase: "(46"

Phrase: ")."
Processing 00000000.tx.244: These two sPLA2s display an overall identity of 38% with the bvPLA2, the level of identity increasing to 58% when the Ca2+-binding loop and the active site region were compared. 

Phrase: "These two sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   923   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "display"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705417:Display [Manufactured Object]

Phrase: "an overall identity of 38%"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0424215:Identity [Mental Process]
   760   C2003939:Identity [Finding]

Phrase: "with the bvPLA2,"

Phrase: "the level of identity increasing"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1547707:Level [Geographic Area]
   760   C2946261:Level [Pharmacologic Substance]

Phrase: "to 58%"

Phrase: "when"

Phrase: "the Ca2+-binding loop"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0243122:binding [Functional Concept]
   827   C0419518:Loop [Medical Device]
   827   C0445022:Loop [Spatial Concept]
   827   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1145667:Binding [Activity]
   827   C1167622:Binding [Molecular Function]

Phrase: "and"

Phrase: "the active site region"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   827   C0017446:Region [Geographic Area]
   827   C0205147:Region [Spatial Concept]
   755 E C0205276:Regional [Spatial Concept]
   755 E C1947913:Regional [Spatial Concept]
   734   C0205681:Active Site [Functional Concept]

Phrase: "were"

Phrase: "compared."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]
Processing 00000000.tx.245: Competition experiments between labeled OS2 and Pa2 and Pa5 for binding to N-type receptors have indicated that these H.suspectum sPLA2s do not bind to N-type receptors (not shown), suggesting that the molecular determinants for binding to these receptors are located within residues that are distinct in the structure of sPLA2s from Heloderma and bee venoms. 

Phrase: "Competition experiments between labeled OS2"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0681814:Experiments [Research Activity]
   726 E C1706386:Experiment [Conceptual Entity]

Phrase: "and"

Phrase: "Pa2"

Phrase: "and"

Phrase: "Pa5 for binding"

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "have"

Phrase: "indicated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1444656:Indicated [Finding]

Phrase: "that"

Phrase: "these H.suspectum sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   884   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   840   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "do"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "bind to N-type receptors"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1145667:Bind [Activity]
   760   C1167622:bind [Molecular Function]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "("

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")"

Phrase: ","

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the molecular determinants for binding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   797   C0003316:Binding Determinants [Immunologic Factor]
   726   C1521761:Determinant [Functional Concept]

Phrase: "to these receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "are"

Phrase: "located within residues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   756   C1709915:Residue [Conceptual Entity]
   756   C1882936:RESIDUE [Phenomenon or Process]
   706 E C1609982:Residual [Qualitative Concept]

Phrase: "that"

Phrase: "are"

Phrase: "distinct in the structure of sPLA2s"

Phrase: "from Heloderma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0999104:Heloderma [Reptile]

Phrase: "and"

Phrase: "bee venoms."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0004920:Bee Venoms [Biologically Active Substance,Hazardous or Poisonous Substance]
   861   C0004923:Bee [Eukaryote]
   861   C0042479:Venoms [Hazardous or Poisonous Substance]
   861   C1692334:venoms [Intellectual Product]
Processing 00000000.tx.246: Despite a detailed analysis of all these sequence alignments, it was essentially impossible to predict with any accuracy the region(s) of sPLA2s that is most probably involved in the interaction with N-type receptors. 

Phrase: "Despite a detailed analysis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0002778:Analysis [Laboratory Procedure]
   861   C0936012:Analysis [Research Activity]
   861   C1524024:analysis [Functional Concept]

Phrase: "of all"

Phrase: "these sequence alignments,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0080143:Sequence Alignments [Molecular Biology Research Technique]
   827   C1706765:Alignment [Quantitative Concept]

Phrase: "it"

Phrase: "was"

Phrase: "essentially impossible to"

Phrase: "predict with any accuracy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0443131:Accuracy [Qualitative Concept]

Phrase: "the region"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0017446:Region [Geographic Area]
  1000   C0205147:Region [Spatial Concept]
   928 E C0205276:Regional [Spatial Concept]
   928 E C1947913:Regional [Spatial Concept]

Phrase: "("

Phrase: "s) of sPLA2s"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   862   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   806   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   773 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   773 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]
   760   C1327616:Secretory [Cell Function]
   760   C2603362:S' [Clinical Attribute]

Phrase: "that"

Phrase: "is"

Phrase: "most probably"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205393:Most [Quantitative Concept]
   861   C0750492:Probably [Idea or Concept]

Phrase: "involved in the interaction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1314939:Involved [Functional Concept]
   770   C1704675:Interaction [Functional Concept]

Phrase: "with N-type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.247: This led us to the present studies using site-specific mutants of bvPLA2; 

Phrase: "This led"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C1708698:LED [Manufactured Object]
   966 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   966 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   966 E C1522538:Lead [Functional Concept]
   966 E C2348269:Lead [Element, Ion, or Isotope]
   966 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "us to the present studies"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   760   C0150312:Present [Quantitative Concept]
   760   C0449450:Present [Idea or Concept]
   760   C0947630:studies [Laboratory Procedure]
   726 E C0557651:Study [Manufactured Object]
   726 E C2603343:Study [Research Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "site-specific mutants of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0596988:mutants [Cell or Molecular Dysfunction]

Phrase: ";"
Processing 00000000.tx.248: because this protein is conveniently expressed in functional form in bacteria (36), its high resolution x-ray structure is known (35), and it binds with high affinity to N-type receptors (19). 

Phrase: "because"

Phrase: "this protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "is"

Phrase: "conveniently"

Phrase: "expressed in functional form"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0205245:Functional [Functional Concept]
   770   C0348078:Form [Qualitative Concept]
   770   C0376315:Form [Manufactured Object]
   770   C0542341:Functional [Functional Concept]
   770   C1522492:Form [Functional Concept]
   770   C2700217:Functional [Conceptual Entity]

Phrase: "in bacteria"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0004611:Bacteria [Bacterium]
  1000   C1510439:bacteria [Functional Concept]
  1000   C2347473:% Bacteria [Quantitative Concept]
   928 E C0521009:Bacterial [Qualitative Concept]

Phrase: "(36"

Phrase: ")"

Phrase: ","

Phrase: "its high resolution x-ray structure"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   840   C0034571:X-ray [Functional Concept]
   840   C0043299:X-ray, NOS [Diagnostic Procedure]
   840   C0043309:X-ray [Natural Phenomenon or Process]
   840   C1306645:X-ray [Diagnostic Procedure]
   840   C1719039:High resolution [Laboratory Procedure]
   840   C1962945:X-ray [Diagnostic Procedure]
   804   C0086894:ray [Fish]
   804   C0205250:High [Qualitative Concept]
   804   C0678594:Structure [Spatial Concept]
   804   C0851346:ray [Natural Phenomenon or Process]
   804   C1299351:High [Qualitative Concept]
   804   C1514893:Resolution [Idea or Concept]
   804   C1706463:Resolution [Quantitative Concept]
   804   C2314876:ray [Fish]
   804   C2699488:Resolution [Conceptual Entity]
   804   C2700149:HIGH [Intellectual Product]

Phrase: "is"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "(35"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "it"

Phrase: "binds with high affinity"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0205250:High [Qualitative Concept]
   770   C1145667:Bind [Activity]
   770   C1167622:bind [Molecular Function]
   770   C1299351:High [Qualitative Concept]
   770   C1510827:Affinity [Natural Phenomenon or Process]
   770   C2700149:HIGH [Intellectual Product]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "(19"

Phrase: ")."
Processing 00000000.tx.249: It may be noted that when the sequence of Pa5 is overlaid onto the structure of bvPLA2, it is apparent that the putative IRS of the Gila monster enzyme lacks most of the basic residues found on the IRS of bvPLA2. 

Phrase: "It"

Phrase: "may"

Phrase: "be"

Phrase: "noted"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1316572:Note [Clinical Attribute]
   966   C1317574:Note [Intellectual Product]
   966   C1369612:Note [Clinical Attribute]

Phrase: "that"

Phrase: "when"

Phrase: "the sequence of Pa5"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0004793:Sequence [Nucleotide Sequence]
   770   C0162326:Sequence [Nucleotide Sequence]
   770   C0162327:Sequence [Nucleotide Sequence]
   770   C1519249:Sequence [Functional Concept]

Phrase: "is"

Phrase: "overlaid onto the structure of bvPLA2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0678594:Structure [Spatial Concept]
   719   C0444456:Overlay [Spatial Concept]
   719   C1706359:Overlay [Medical Device]

Phrase: "it"

Phrase: "is"

Phrase: "apparent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750489:apparent [Idea or Concept]

Phrase: "that"

Phrase: "the putative IRS of the Gila monster enzyme"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0205148:Surface [Spatial Concept]

Phrase: "lacks"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332268:lack [Qualitative Concept]

Phrase: "most of the basic residues"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0205393:Most [Quantitative Concept]
   760   C1527178:Basic [Functional Concept]
   726   C1709915:Residue [Conceptual Entity]
   726   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "found on the IRS of bvPLA2."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   744   C0150312:Found [Quantitative Concept]
   744   C0205148:Surface [Spatial Concept]
   744   C0524637:Recognition [Mental Process]
   711 E C0243095:Find [Finding]
Processing 00000000.tx.250: This may be the reason that Pa5 fails to bind to N-type receptors, since results of the present study indicate that basic residues on the IRS of bvPLA2 are important for receptor binding. 

Phrase: "This"

Phrase: "may"

Phrase: "be"

Phrase: "the reason"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392360:Reason [Idea or Concept]

Phrase: "that Pa5"

Phrase: "fails"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:fail [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "bind to N-type receptors,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1145667:Bind [Activity]
   760   C1167622:bind [Molecular Function]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "since"

Phrase: "results of the present study"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   797   C0683954:result study [Finding]
   760   C0150312:Present [Quantitative Concept]
   760   C0449450:Present [Idea or Concept]
   760   C0557651:Study [Manufactured Object]
   760   C1274040:Result [Functional Concept]
   760   C1546471:Result [Idea or Concept]
   760   C2603343:Study [Research Activity]
   760   C2825142:Result [Finding]

Phrase: "indicate"

Phrase: "that basic residues on the IRS of bvPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   706   C1709915:Residue [Conceptual Entity]
   706   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "are"

Phrase: "important for receptor binding."
Processing 00000000.tx.251: A particular feature of the bvPLA2 is the presence of a high-mannose carbohydrate motif N-linked to Asn-13 (42). 

Phrase: "A particular feature of the bvPLA2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C1521970:Feature [Qualitative Concept]
   753   C1706388:Feature [Conceptual Entity]
   753   C2346469:Feature [Qualitative Concept]
   753   C2348519:Feature [Qualitative Concept]

Phrase: "is"

Phrase: "the presence of a high-mannose carbohydrate motif"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0392148:Presence [Therapeutic or Preventive Procedure]

Phrase: "N-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "linked to Asn-13"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0003995:Asn [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   737   C1517892:Link [Intellectual Product]
   737   C1704666:Link [Intellectual Product]

Phrase: "(42"

Phrase: ")."
Processing 00000000.tx.252: A possible role of this motif in binding to N-type receptors was suggested by comparison of the binding data obtained with recombinant and natural glycosylated bvPLA2. 

Phrase: "A possible role of this motif"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "in binding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0243122:binding [Functional Concept]
  1000   C1145667:Binding [Activity]
  1000   C1167622:Binding [Molecular Function]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "was"

Phrase: "suggested by comparison of the binding data"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0243122:binding [Functional Concept]
   748   C1145667:Binding [Activity]
   748   C1167622:Binding [Molecular Function]
   748   C1511726:Data [Idea or Concept]
   748   C1707455:Comparison [Activity]
   748   C3245479:data [Medical Device]
   714   C1705535:Suggest [Idea or Concept]

Phrase: "obtained with recombinant"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C1301820:Obtained [Functional Concept]
   790   C1514798:recombinant [Organism]
   756 E C1706701:Obtain [Activity]
   718 E C1517378:Gain [Quantitative Concept]

Phrase: "and"

Phrase: "natural glycosylated bvPLA2."
Processing 00000000.tx.253: The five times lower affinity observed with fully deglycosylated bvPLA2 indicates that the carbohydrate moiety contributes to N-type receptor interaction, but only to a minor extent. 

Phrase: "The five times"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0040223:times [Temporal Concept]
   861   C1632851:Times [Quantitative Concept]
   827 E C3541383:Time [Temporal Concept]
   789 E C0442043:Temporal [Spatial Concept]
   789 E C2362314:Temporal [Temporal Concept]

Phrase: "lower"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441994:Lower [Spatial Concept]
  1000   C1548802:Lower [Body Location or Region]
  1000   C2003888:Lower [Activity]

Phrase: "affinity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "observed with fully deglycosylated bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1441672:Observed [Functional Concept]

Phrase: "indicates"

Phrase: "that"

Phrase: "the carbohydrate moiety"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0007004:Carbohydrate [Carbohydrate]

Phrase: "contributes to N-type receptor interaction,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0332307:Type [Qualitative Concept]
   753   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   753   C1547052:*Type [Quantitative Concept]
   753   C1704675:Interaction [Functional Concept]
   753   C1880177:Contribute [Activity]

Phrase: "but"

Phrase: "only to a minor extent."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0026193:Minor [Population Group]
   760   C0205165:Minor [Qualitative Concept]
   760   C0205171:Only [Quantitative Concept]
   760   C0439792:Extent [Spatial Concept]
   760   C1720467:Only [Intellectual Product]
Processing 00000000.tx.254: Therefore, elements of recognition of N-type receptors are clearly within the bvPLA2 protein sequence. 

Phrase: "Therefore,"

Phrase: "elements of recognition of N-type receptors"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C0013879:Elements [Element, Ion, or Isotope]
   714 E C1705248:Element [Conceptual Entity]

Phrase: "are"

Phrase: "clearly within the bvPLA2 protein sequence."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0002518:Protein Sequence [Amino Acid Sequence]
   753   C0004793:Sequence [Nucleotide Sequence]
   753   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C0162326:Sequence [Nucleotide Sequence]
   753   C0162327:Sequence [Nucleotide Sequence]
   753   C1519249:Sequence [Functional Concept]
Processing 00000000.tx.255: As shown in Figs. 

Phrase: "As"

Phrase: "shown in Figs."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0349966:Figs [Food]
   756 E C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.256: 3 and 4, mutations that dramatically reduce the affinity of bvPLA2 to N-type receptors are segregated on the same face of the protein, namely on the 76-91 helix (especially positions 78and 82), the Ca2+-binding loop, and regions of the N terminus of the protein. 

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "and"

Phrase: "4,"

Phrase: "mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that dramatically"

Phrase: "reduce"

Phrase: "the affinity of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "are"

Phrase: "segregated on the same face of the protein,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   767   C1568213:Protein FACE [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0015450:Face [Body Location or Region]
   744   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0445247:Same [Qualitative Concept]
   744   C1281591:Face [Body Part, Organ, or Organ Component]

Phrase: "namely on the 76-91 helix"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0018882:Helix [Eukaryote]
   753   C0229304:Helix [Body Part, Organ, or Organ Component]
   753   C1704821:Helix [Spatial Concept]
   753   C1705682:Helix [Anatomical Structure]

Phrase: "(especially"

Phrase: "positions"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0733755:Position [Spatial Concept]

Phrase: "78and 82"

Phrase: ")"

Phrase: ","

Phrase: "the Ca2+-binding loop,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0243122:binding [Functional Concept]
   827   C0419518:Loop [Medical Device]
   827   C0445022:Loop [Spatial Concept]
   827   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1145667:Binding [Activity]
   827   C1167622:Binding [Molecular Function]

Phrase: "and"

Phrase: "regions of the N terminus of the protein."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   750   C1514562:Protein Region [Amino Acid Sequence]
   711   C0017446:Region [Geographic Area]
   711   C0205147:Region [Spatial Concept]
Processing 00000000.tx.257: These are the same regions that make up the putative IRS that is thought to anchor the enzyme to the membrane interface (35). 

Phrase: "These"

Phrase: "are"

Phrase: "the same regions"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0017446:Region [Geographic Area]
   827   C0205147:Region [Spatial Concept]
   777 E C0205276:Regional [Spatial Concept]
   777 E C1947913:Regional [Spatial Concept]

Phrase: "that make up"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1881534:Make [Functional Concept]

Phrase: "the putative IRS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0205148:Surface [Spatial Concept]

Phrase: "that"

Phrase: "is"

Phrase: "thought"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039869:Thought [Mental Process]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "anchor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1293132:anchor [Therapeutic or Preventive Procedure]

Phrase: "the enzyme to the membrane interface"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0014442:Enzyme [Enzyme,Organic Chemical]

Phrase: "(35"

Phrase: ")."
Processing 00000000.tx.258: It is very likely that specific residues of the IRS directly contact the N-type receptor rather than the membrane to which the receptor is embedded. 

Phrase: "It"

Phrase: "is"

Phrase: "very likely"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332148:Likely [Qualitative Concept]
   861   C0442824:Very [Qualitative Concept]
   861   C0750492:Likely [Idea or Concept]

Phrase: "that specific residues of the IRS directly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   708   C1709915:Residue [Conceptual Entity]
   708   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "contact"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332158:contact [Functional Concept]
  1000   C0337611:Contact [Population Group]
  1000   C1705415:Contact [Idea or Concept]

Phrase: "the N-type receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "rather than"

Phrase: "the membrane to which"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0025255:Membrane [Tissue]
   770   C0596901:Membrane [Cell Component]
   770   C1706182:Membrane [Manufactured Object]

Phrase: "the receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "is"

Phrase: "embedded."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707903:Embedded [Laboratory Procedure]
Processing 00000000.tx.259: This is based on the observation that several point mutations such as G12A which retain good enzymatic activity in a membrane based assay, and thus bind well to membranes, fail to bind to N-type receptors. 

Phrase: "This"

Phrase: "is"

Phrase: "based on the observation"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   770   C0302523:Observation [Research Activity]
   770   C0700325:observation [Health Care Activity]
   770   C1527178:Based [Functional Concept]
   770   C1705938:Based [Idea or Concept]
   770   C1964257:Observation [Diagnostic Procedure]
   737 E C0002055:base [Inorganic Chemical]
   737 E C0178499:Base [Chemical Viewed Functionally]
   737 E C1880279:Base [Biomedical or Dental Material]

Phrase: "that several point mutations such as G12A"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   778   C0162735:Point Mutations [Cell or Molecular Dysfunction]
   748   C0026882:Mutations [Genetic Function]
   748   C1552961:Point [Quantitative Concept]
   748   C2347617:point [Quantitative Concept]
   714 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "which"

Phrase: "retain"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333118:Retain [Functional Concept]

Phrase: "good enzymatic activity in a membrane"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C2267219:Enzymatic Activity [Molecular Function]
   783   C0596897:membrane activity [Cell Function]
   753   C0205177:Activity [Functional Concept]
   753   C0439167:% activity [Quantitative Concept]
   753   C0441655:Activity [Activity]
   753   C1561536:*Activity [Idea or Concept]

Phrase: "based"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C1527178:Based [Functional Concept]
  1000   C1705938:Based [Idea or Concept]
   966 E C0002055:base [Inorganic Chemical]
   966 E C0178499:Base [Chemical Viewed Functionally]
   966 E C1880279:Base [Biomedical or Dental Material]

Phrase: "assay,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005507:Assay [Laboratory Procedure]
  1000   C0243073:assay [Qualitative Concept]
  1000   C1510438:Assay [Laboratory Procedure]

Phrase: "and"

Phrase: "thus"

Phrase: "bind"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "well to membranes,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   790   C0025255:Membranes [Tissue]
   790   C0205170:Well [Qualitative Concept]
   790   C3146287:Well [Manufactured Object]
   756 E C0596901:Membrane [Cell Component]
   756 E C1706182:Membrane [Manufactured Object]
   706 E C0205287:Membranous [Qualitative Concept]

Phrase: "fail"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:fail [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "bind to N-type receptors."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1145667:Bind [Activity]
   760   C1167622:bind [Molecular Function]
   760   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.260: The dramatic effect observed on binding to N-type receptors after the single mutation of Gly-12 to Ala-12 suggests that position 12is crucially involved in the interaction with N-type receptors. 

Phrase: "The dramatic effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280500:Effect [Qualitative Concept]
   861   C2348382:Effect [Qualitative Concept]

Phrase: "observed on binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]
   790   C1441672:Observed [Functional Concept]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "after the single mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "of Gly-12"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017890:Gly [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "to Ala-12"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   789   C0702172:Alar [Hazardous or Poisonous Substance,Organic Chemical]
   768 E C0043189:Wing [Body Part, Organ, or Organ Component]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that position 12is crucially"

Phrase: "involved in the interaction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1314939:Involved [Functional Concept]
   770   C1704675:Interaction [Functional Concept]

Phrase: "with N-type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.261: Interestingly, Gly-30 of porcine pancreatic sPLA2, which is analogous to Gly-12 of bvPLA2, is involved in the binding to M-type receptors (28). 

Phrase: "Interestingly,"

Phrase: "Gly-30 of porcine pancreatic sPLA2,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0017890:Gly [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   753   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   753   C0039005:porcine [Mammal]
   753   C1135183:Porcine, NOS [Mammal]
   753   C1418616:SPLA2 [Gene or Genome]
   753   C1706169:sPLA2 [Gene or Genome]

Phrase: "which"

Phrase: "is"

Phrase: "analogous to Gly-12 of bvPLA2,"

Phrase: "is"

Phrase: "involved in the binding"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]
   770   C1314939:Involved [Functional Concept]

Phrase: "to"

Phrase: "M-"

Phrase: "type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "(28"

Phrase: ")."
Processing 00000000.tx.262: The observation that residues of the Ca2+-binding loop that point away from the protein are important for receptor binding has to be considered along with the previous observation that the binding of OS2 to N-type receptors requires micromolar amounts of Ca2+ (19). 

Phrase: "The observation"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0302523:Observation [Research Activity]
  1000   C0700325:observation [Health Care Activity]
  1000   C1964257:Observation [Diagnostic Procedure]
   928 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: "that residues of the Ca2+-binding loop"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   714   C1709915:Residue [Conceptual Entity]
   714   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "that point away from the protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1552961:Point [Quantitative Concept]
   753   C2347617:point [Quantitative Concept]

Phrase: "are"

Phrase: "important for receptor binding"

Phrase: "has"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "considered along with the previous observation"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0205156:Previous [Temporal Concept]
   753   C0302523:Observation [Research Activity]
   753   C0700325:observation [Health Care Activity]
   753   C0750591:considered [Idea or Concept]
   753   C1552607:previous [Temporal Concept]
   753   C1964257:Observation [Diagnostic Procedure]

Phrase: "that"

Phrase: "the binding of OS2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "requires"

Phrase: "micromolar amounts of Ca2+"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1265611:amounts [Quantitative Concept]

Phrase: "(19"

Phrase: ")."
Processing 00000000.tx.263: It is not yet clear whether this Ca2+ dependence is due to the binding of Ca2+ to the receptor, to sPLA2, or to both. 

Phrase: "It"

Phrase: "is"

Phrase: "not yet"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "clear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2963144:Clear [Qualitative Concept]

Phrase: "whether"

Phrase: "this Ca2+ dependence"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   861   C0011546:Dependence [Mental Process]
   861   C0439857:Dependence [Mental or Behavioral Dysfunction]
   861   C2698668:DEPENDENCE [Regulation or Law]
   789 E C0851827:Dependent [Qualitative Concept]
   789 E C1701901:Dependent [Qualitative Concept]
   789 E C3244310:dependent [Functional Concept]
   761 E C1546937:Dependency [Idea or Concept]

Phrase: "is due to the binding of Ca2+"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C0678226:Due to [Functional Concept]
           due
   748   C0243122:binding [Functional Concept]
   748   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   748   C1145667:Binding [Activity]
   748   C1167622:Binding [Molecular Function]
   748   C3146286:Due [Idea or Concept]

Phrase: "to the receptor,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "to sPLA2,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1418616:SPLA2 [Gene or Genome]
  1000   C1706169:sPLA2 [Gene or Genome]

Phrase: "or to both."
Processing 00000000.tx.264: All of the Ca2+-binding loop mutants examined in the present study retain high enzymatic activity, which implies that they all bind Ca2+. 

Phrase: "All of the Ca2+-binding loop mutants"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   748   C0243122:binding [Functional Concept]
   748   C0419518:Loop [Medical Device]
   748   C0444868:All [Quantitative Concept]
   748   C0445022:Loop [Spatial Concept]
   748   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   748   C0596988:mutants [Cell or Molecular Dysfunction]
   748   C1145667:Binding [Activity]
   748   C1167622:Binding [Molecular Function]
   748   C3539085:All [Idea or Concept]

Phrase: "examined in the present study"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0150312:Present [Quantitative Concept]
   760   C0332128:Examined [Finding]
   760   C0449450:Present [Idea or Concept]
   760   C0557651:Study [Manufactured Object]
   760   C2603343:Study [Research Activity]

Phrase: "retain"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333118:Retain [Functional Concept]

Phrase: "high enzymatic activity,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "which"

Phrase: "implies"

Phrase: "that"

Phrase: "they all"

Phrase: "bind"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "Ca2+."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
Processing 00000000.tx.265: Thus, the failure of mutants such as G12A to bind to N-type receptors is not due to a lack of binding of Ca2+ to the bvPLA2 mutant. 

Phrase: "Thus,"

Phrase: "the failure of mutants"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0231174:Failure [Functional Concept]
   770   C0680095:failure [Individual Behavior]

Phrase: "such as G12A to"

Phrase: "bind to N-type receptors"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1145667:Bind [Activity]
   760   C1167622:bind [Molecular Function]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "is"

Phrase: "not due to a lack of binding of Ca2+"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   764   C0678226:Due to [Functional Concept]
           due
   742   C0243122:binding [Functional Concept]
   742   C0332268:lack [Qualitative Concept]
   742   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   742   C1145667:Binding [Activity]
   742   C1167622:Binding [Molecular Function]
   742   C1518422:Not [Functional Concept]
   742   C3146286:Due [Idea or Concept]

Phrase: "to the bvPLA2 mutant."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596988:Mutant [Cell or Molecular Dysfunction]
Processing 00000000.tx.266: In general, mutations in other regions of bvPLA2 besides the IRS do not drastically affect the binding to N-type receptors. 

Phrase: "In general, mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0026882:Mutations [Genetic Function]
   827 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "in other regions"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   966   C0017446:Region [Geographic Area]
   966   C0205147:Region [Spatial Concept]
   916 E C0205276:Regional [Spatial Concept]
   916 E C1947913:Regional [Spatial Concept]

Phrase: "of bvPLA2"

Phrase: "besides the IRS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205148:Surface [Spatial Concept]

Phrase: "do"

Phrase: "not drastically"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "the binding to N-type receptors."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   767   C0597358:Receptor Binding [Molecular Function]
   753   C0243122:binding [Functional Concept]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]
Processing 00000000.tx.267: The exceptions are mutations at positions 57and 64,located in the active site slot near the center of the globular protein and amino acids substitution at these positions dramatically reduce receptor binding. 

Phrase: "The exceptions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1554961:exception [Idea or Concept]
   966   C1705847:Exception [Conceptual Entity]

Phrase: "are"

Phrase: "mutations at positions 57and 64,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0026882:Mutations [Genetic Function]
   726 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "located in the active site slot"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0205681:Active Site [Functional Concept]
   753   C0205145:Site [Spatial Concept]
   753   C0205177:Active [Functional Concept]
   753   C1515974:Site [Body Location or Region]
   753   C2825164:Site [Spatial Concept]

Phrase: "near the center"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205099:Center [Spatial Concept]

Phrase: "of the globular protein"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0178663:globular protein [Amino Acid, Peptide, or Protein]
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0332501:Globular [Spatial Concept]
   789 E C1337528:Globule [Biomedical or Dental Material]
   789 E C2984568:GLOBULE [Quantitative Concept]

Phrase: "and"

Phrase: "amino acids substitution at these positions dramatically"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C0525038:Amino Acid Substitution [Genetic Function,Molecular Biology Research Technique]
   748   C1555721:Substitution [Idea or Concept]
   748   C1706204:Substitution [Activity]

Phrase: "reduce"

Phrase: "receptor binding."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0597358:Receptor Binding [Molecular Function]
   861   C0243122:binding [Functional Concept]
   861   C1145667:Binding [Activity]
   861   C1167622:Binding [Molecular Function]
Processing 00000000.tx.268: One interpretation of these surprising results is that a portion of the N-type receptor penetrates the active site slot and directly contacts Thr-57 and Asp-64. 

Phrase: "One interpretation of these surprising results"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0459471:Interpretation [Intellectual Product]
   753   C3173575:Interpretation [Clinical Attribute]

Phrase: "is"

Phrase: "that"

Phrase: "a portion of the N-type receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0449719:Portion [Spatial Concept]

Phrase: "penetrates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205321:penetrate [Functional Concept]

Phrase: "the active site slot"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C0205681:Active Site [Functional Concept]

Phrase: "and"

Phrase: "directly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1947931:Directly [Qualitative Concept]

Phrase: "contacts"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332158:contact [Functional Concept]
  1000   C0337611:Contact [Population Group]
  1000   C1705415:Contact [Idea or Concept]

Phrase: "Thr-57"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0040005:Thr [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "Asp-64."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0206293:Asp [Reptile]
   861   C3541260:ASP [Gene or Genome]
Processing 00000000.tx.269: However, it is also possible, and perhaps more likely, that positions 57and 64mutants have structural alterations that propagate out to the surface of the protein. 

Phrase: "However,"

Phrase: "it"

Phrase: "is"

Phrase: "also possible,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332149:Possible [Qualitative Concept]
   861   C1705910:Possible [Qualitative Concept]
   861   C2362652:Possible [Qualitative Concept]

Phrase: "and"

Phrase: "perhaps more likely,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0332148:Likely [Qualitative Concept]
   827   C0750492:Likely [Idea or Concept]

Phrase: "that"

Phrase: "positions"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0733755:Position [Spatial Concept]

Phrase: "57and 64mutants"

Phrase: "have"

Phrase: "structural alterations"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1515926:Alteration [Idea or Concept]

Phrase: "that"

Phrase: "propagate"

Phrase: "out to the surface of the protein."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   774   C0025252:protein surface [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0205148:Surface [Spatial Concept]
   748   C0439787:Out [Spatial Concept]
   748   C0849355:Out [Qualitative Concept]
Processing 00000000.tx.270: Key observations are obtained with the mutants D64N and D64A. 

Phrase: "Key observations"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   861   C0302523:observations [Research Activity]
   861   C0700325:observations [Health Care Activity]
   861   C3244290:observations [Functional Concept]
   827 E C1964257:Observation [Diagnostic Procedure]
   777 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: "are"

Phrase: "obtained with the mutants D64N"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0596988:mutants [Cell or Molecular Dysfunction]
   760   C1301820:Obtained [Functional Concept]
   726 E C1706701:Obtain [Activity]

Phrase: "and"

Phrase: "D64A."
Processing 00000000.tx.271: Asp-64 of wild-type bvPLA2 is hydrogen-bonded to the NH of His-34 that faces away from the active site slot. 

Phrase: "Asp-64 of wild-type bvPLA2"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C1883559:Wild Type [Organism Attribute]
   753   C0206293:Asp [Reptile]
   753   C0332307:Type [Qualitative Concept]
   753   C0445392:Wild [Intellectual Product]
   753   C1547052:*Type [Quantitative Concept]
   753   C3541260:ASP [Gene or Genome]

Phrase: "is"

Phrase: "hydrogen-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0020275:Hydrogen [Element, Ion, or Isotope]
  1000   C0523702:HYDROGEN [Laboratory Procedure]
  1000   C0885426:hydrogen [Inorganic Chemical]

Phrase: "bonded to the NH of His-34"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0019602:His [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   748   C0268059:NH [Disease or Syndrome]
   748   C1412323:HIS [Gene or Genome]

Phrase: "that faces away from the active site slot."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C0015450:Faces [Body Location or Region]
   711 E C1281591:Face [Body Part, Organ, or Organ Component]
Processing 00000000.tx.272: When this residue is replaced with the iso-structural Asn, the D64N mutant retains good receptor binding affinity. 

Phrase: "When"

Phrase: "this residue"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1709915:Residue [Conceptual Entity]
  1000   C1882936:RESIDUE [Phenomenon or Process]
   928 E C1609982:Residual [Qualitative Concept]

Phrase: "is"

Phrase: "replaced with the iso-structural Asn,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   753   C0003995:Asn [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C0559956:Replaced [Functional Concept]
   753   C0678594:Structural [Spatial Concept]
   753   C1299987:replaced [Functional Concept]
   753   C1668248:Iso [Fish]
   719 E C1554078:Replace [Idea or Concept]

Phrase: "the D64N mutant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "retains"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0333118:Retain [Functional Concept]

Phrase: "good receptor binding affinity."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1510827:Affinity [Natural Phenomenon or Process]
Processing 00000000.tx.273: The same result is obtained with D64E/K66CC. 

Phrase: "The same result"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1274040:Result [Functional Concept]
   861   C1546471:Result [Idea or Concept]
   861   C2825142:Result [Finding]

Phrase: "is"

Phrase: "obtained with D64E/K66CC."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C1301820:Obtained [Functional Concept]
   737 E C1706701:Obtain [Activity]
Processing 00000000.tx.274: However, the D64A mutant fails to bind to N-type receptors almost certainly, because loss of the Asp-64-His-34 hydrogen bond results in nonlocalized structural changes that affect receptor binding. 

Phrase: "However,"

Phrase: "the D64A mutant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "fails"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:fail [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "bind to N-type receptors almost certainly,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0332307:Type [Qualitative Concept]
   748   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   748   C1145667:Bind [Activity]
   748   C1167622:bind [Molecular Function]
   748   C1547052:*Type [Quantitative Concept]

Phrase: "because"

Phrase: "loss of the Asp-64-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1517945:Loss [Quantitative Concept]

Phrase: "His-34 hydrogen bond results in nonlocalized structural changes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   708   C1274040:Result [Functional Concept]
   708   C1546471:Result [Idea or Concept]
   708   C2825142:Result [Finding]

Phrase: "that"

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "receptor binding."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0597358:Receptor Binding [Molecular Function]
   861   C0243122:binding [Functional Concept]
   861   C1145667:Binding [Activity]
   861   C1167622:Binding [Molecular Function]
Processing 00000000.tx.275: Results obtained with the deletion mutant 99-118 are interesting in light of the fact that removal of such a large structural domain of bvPLA2 has essentially no effect on the enzymatic activity or the receptor binding affinity of the mutant. 

Phrase: "Results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "obtained with the deletion mutant 99-118"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   748   C0596988:Mutant [Cell or Molecular Dysfunction]
   748   C1301820:Obtained [Functional Concept]
   748   C1442161:Deletion [Cell or Molecular Dysfunction]
   748   C1511760:Deletion [Genetic Function]
   748   C1880274:Deletion [Activity]
   714 E C1706701:Obtain [Activity]

Phrase: "are"

Phrase: "interesting in light of the fact"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0023693:Light [Natural Phenomenon or Process]
   753   C0543488:interesting [Mental Process]
   753   C1306462:Light [Functional Concept]
   753   C1881376:Light [Qualitative Concept]

Phrase: "that removal of such"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0015252:Removal [Therapeutic or Preventive Procedure]
   770   C0728940:Removal [Therapeutic or Preventive Procedure]

Phrase: "a large structural domain of bvPLA2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1880389:Domain [Functional Concept]
   753   C1883221:Domain [Conceptual Entity]
   753   C3541951:Domain [Intellectual Product]

Phrase: "has"

Phrase: "essentially"

Phrase: "no effect on the enzymatic activity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1301751:No effect [Qualitative Concept]
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "or"

Phrase: "the receptor binding affinity of the mutant."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1510827:Affinity [Natural Phenomenon or Process]
Processing 00000000.tx.276: Furthermore, this -sheet structure, which lies adjacent to the IRS, is found in group I, II, and III sPLA2s, suggesting that it has been conserved since the divergence between vertebrates and insects (5). 

Phrase: "Furthermore,"

Phrase: "this -sheet structure,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0678594:Structure [Spatial Concept]

Phrase: "which"

Phrase: "lies"

Phrase: "adjacent to the IRS,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205117:Adjacent to [Spatial Concept]
           Adjacent

Phrase: "is"

Phrase: "found in group I,"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   833   C0441843:Group I [Intellectual Product]
   819 E C1959640:I group [Clinical Attribute]
   770   C0021966:I- [Inorganic Chemical]
   770   C0150312:Found [Quantitative Concept]
   770   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0441833:Group [Idea or Concept]
   770   C0687744:group [Population Group]
   770   C1257890:Group [Population Group]
   770   C1552516:Group [Health Care Related Organization]
   770   C1705428:Group [Conceptual Entity]
   770   C1705429:Group [Population Group]
   737 E C0243095:Find [Finding]

Phrase: "II,"

Phrase: "and"

Phrase: "III sPLA2s,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   923   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "it"

Phrase: "has"

Phrase: "been"

Phrase: "conserved"

Phrase: "since"

Phrase: "the divergence between vertebrates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0443204:Divergence [Spatial Concept]

Phrase: "and"

Phrase: "insects"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0021585:Insects [Eukaryote]
   966 E C0770740:INSECT [Pharmacologic Substance]
   966 E C1546678:Insect [Intellectual Product]

Phrase: "(5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.277: The biological role, if any, of this domain remains to be established. 

Phrase: "The biological role,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0035820:Role [Social Behavior]
   861   C1705810:Role [Conceptual Entity]

Phrase: "if"

Phrase: "any,"

Phrase: "of this domain"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1880389:Domain [Functional Concept]
  1000   C1883221:Domain [Conceptual Entity]
  1000   C3541951:Domain [Intellectual Product]

Phrase: "remains"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "established."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0443211:Established [Qualitative Concept]
  1000   C1272684:Established [Qualitative Concept]
Processing 00000000.tx.278: Since bvPLA2 is neurotoxic, has high enzymatic activity, and also binds with high affinity to N-type receptors that have been suggested previously to be involved in neurotoxicity of venom sPLA2s (19), it was important to probe the relationships between the receptor binding properties of bvPLA2 mutants and their neurotoxicity (as measured by the evaluation of their lethality in mice). 

Phrase: "Since"

Phrase: "bvPLA2"

Phrase: "is"

Phrase: "neurotoxic,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0235032:Neurotoxicity [Injury or Poisoning]

Phrase: "has"

Phrase: "high enzymatic activity,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2267219:Enzymatic Activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "and"

Phrase: "also"

Phrase: "binds with high affinity"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0205250:High [Qualitative Concept]
   770   C1145667:Bind [Activity]
   770   C1167622:bind [Molecular Function]
   770   C1299351:High [Qualitative Concept]
   770   C1510827:Affinity [Natural Phenomenon or Process]
   770   C2700149:HIGH [Intellectual Product]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "that"

Phrase: "have"

Phrase: "been"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "previously to"

Phrase: "be"

Phrase: "involved in neurotoxicity of venom sPLA2s"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   800   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   770   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0042479:Venom [Hazardous or Poisonous Substance]
   744   C0235032:Neurotoxicity [Injury or Poisoning]
   744   C1314939:Involved [Functional Concept]
   744   C1327616:Secretory [Cell Function]
   737 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   737 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(19"

Phrase: ")"

Phrase: ","

Phrase: "it"

Phrase: "was"

Phrase: "important to"

Phrase: "probe"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0182400:Probe [Medical Device]
  1000   C1704681:Probe [Gene or Genome]
  1000   C2347609:Probe [Chemical Viewed Functionally]
  1000   C3536729:Probe [Manufactured Object]

Phrase: "the relationships between the receptor binding properties of bvPLA2 mutants"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   755   C2698891:Property of Relationship [Conceptual Entity]
   739   C0439849:Relationships [Qualitative Concept]
   706 E C1705630:Relationship [Idea or Concept]
   706 E C1706279:Relationship [Idea or Concept]
   706 E C3540605:Relationship [Intellectual Product]

Phrase: "and"

Phrase: "their neurotoxicity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0235032:Neurotoxicity [Injury or Poisoning]

Phrase: "("

Phrase: "as"

Phrase: "measured by the evaluation of their lethality"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   748   C0220825:Evaluation [Functional Concept]
   748   C0444706:Measured [Qualitative Concept]
   748   C1261322:Evaluation [Health Care Activity]
   748   C3541902:MEASURED [Diagnostic Procedure]
   714 E C0079809:Measure [Quantitative Concept]
   714 E C0242485:Measure [Functional Concept]

Phrase: "in mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]

Phrase: ")."
Processing 00000000.tx.279: Table III indicates that the residues of bvPLA2 that are involved in its lethal properties are located on the surface of the enzyme, namely in the 76-91 helix and in the Ca2+-binding loop. 

Phrase: "Table III"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439070:III [Intellectual Product]
   861   C1705160:III [Qualitative Concept]

Phrase: "indicates"

Phrase: "that"

Phrase: "the residues of bvPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   737   C1709915:Residue [Conceptual Entity]
   737   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "that"

Phrase: "are"

Phrase: "involved in its lethal properties"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   760   C0871161:properties [Qualitative Concept]
   760   C1292721:properties [Functional Concept]
   760   C1314939:Involved [Functional Concept]
   760   C3151529:Lethal [Finding]
   726 E C1882134:Property [Conceptual Entity]
   726 E C2347695:Property [Entity]

Phrase: "are"

Phrase: "located on the surface of the enzyme,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0014442:Enzyme [Enzyme,Organic Chemical]
   748   C0205148:Surface [Spatial Concept]

Phrase: "namely in the 76-91 helix"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0018882:Helix [Eukaryote]
   753   C0229304:Helix [Body Part, Organ, or Organ Component]
   753   C1704821:Helix [Spatial Concept]
   753   C1705682:Helix [Anatomical Structure]

Phrase: "and in the Ca2+-binding loop."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   753   C0243122:binding [Functional Concept]
   753   C0419518:Loop [Medical Device]
   753   C0445022:Loop [Spatial Concept]
   753   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]
   753   C1515981:And [Idea or Concept]
Processing 00000000.tx.280: Mutations that reduce binding to N-type receptors also reduce the lethal properties, even when the mutation does not significantly decrease the lipolytic enzymatic activity of the mutant. 

Phrase: "Mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "reduce"

Phrase: "binding to N-type receptors also"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   767   C0597358:Receptor Binding [Molecular Function]
   753   C0243122:binding [Functional Concept]
   753   C0332307:Type [Qualitative Concept]
   753   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]
   753   C1547052:*Type [Quantitative Concept]

Phrase: "reduce"

Phrase: "the lethal properties,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0871161:properties [Qualitative Concept]
   861   C1292721:properties [Functional Concept]
   827 E C1882134:Property [Conceptual Entity]
   827 E C2347695:Property [Entity]

Phrase: "even"

Phrase: "when"

Phrase: "the mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0026882:Mutation [Genetic Function]
  1000   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "does"

Phrase: "not significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "decrease"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0392756:Decrease [Qualitative Concept]
  1000   C0547047:Decrease [Quantitative Concept]

Phrase: "the lipolytic enzymatic activity of the mutant."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C2267219:Enzymatic Activity [Molecular Function]
   748   C0205177:Activity [Functional Concept]
   748   C0439167:% activity [Quantitative Concept]
   748   C0441655:Activity [Activity]
   748   C1561536:*Activity [Idea or Concept]
Processing 00000000.tx.281: This result indicates that the neurotoxicity of bvPLA2 is closely related to its affinity for N-type receptors rather than to its enzymatic activity. 

Phrase: "This result"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1274040:Result [Functional Concept]
  1000   C1546471:Result [Idea or Concept]
  1000   C2825142:Result [Finding]

Phrase: "indicates"

Phrase: "that"

Phrase: "the neurotoxicity of bvPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0235032:Neurotoxicity [Injury or Poisoning]

Phrase: "is"

Phrase: "closely"

Phrase: "related to its affinity"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0439849:Related [Qualitative Concept]
   770   C0445223:Related [Finding]
   770   C1510827:Affinity [Natural Phenomenon or Process]
   737 E C0163712:Relate [Organic Chemical]

Phrase: "for N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "rather than to its enzymatic activity."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C2267219:Enzymatic Activity [Molecular Function]
   753   C0205177:Activity [Functional Concept]
   753   C0439167:% activity [Quantitative Concept]
   753   C0441655:Activity [Activity]
   753   C1561536:*Activity [Idea or Concept]
Processing 00000000.tx.282: Previous structure-function studies using toxic group I and group II sPLA2s have suggested the involvement of two distinct regions of sPLA2 sequences in conferring neurotoxicity to these enzymes. 

Phrase: "Previous structure-function studies"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   812   C0031843:function [Physiologic Function]
   812   C0542341:Function [Functional Concept]
   812   C0678594:Structure [Spatial Concept]
   812   C0700205:FUNCTION [Classification]
   812   C0947630:studies [Laboratory Procedure]
   812   C1705273:Function [Intellectual Product]
   779 E C0557651:Study [Manufactured Object]
   779 E C2603343:Study [Research Activity]
   741 E C0205245:Functional [Functional Concept]
   741 E C2700217:Functional [Conceptual Entity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "toxic group I"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0441843:Group I [Intellectual Product]
   827   C0021966:I- [Inorganic Chemical]
   827   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "and"

Phrase: "group II sPLA2s"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   991   C1959603:Group II Secretory Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
           Group II Phospholipases A2
   884   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   840   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   806 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "have"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "the involvement of two distinct regions of sPLA2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1314939:Involvement [Functional Concept]

Phrase: "sequences in conferring neurotoxicity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0004793:Sequence [Nucleotide Sequence]
   770   C0162326:Sequence [Nucleotide Sequence]
   770   C0162327:Sequence [Nucleotide Sequence]
   770   C0235032:Neurotoxicity [Injury or Poisoning]
   770   C1519249:Sequence [Functional Concept]

Phrase: "to these enzymes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0014442:Enzymes [Enzyme,Organic Chemical]
  1000   C0014445:enzymes [Functional Concept]
Processing 00000000.tx.283: Comparisons of primary structures of a large number of sPLA2s have suggested that the N-terminal region of sPLA2 is involved in neurotoxicity (49). 

Phrase: "Comparisons of primary structures of a large number of sPLA2s"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   703   C1707455:Comparison [Activity]

Phrase: "have"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the N-terminal region of sPLA2"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0017446:Region [Geographic Area]
   753   C0205088:Terminal [Temporal Concept]
   753   C0205147:Region [Spatial Concept]
   753   C1705314:Terminal [Manufactured Object]
   753   C1705315:Terminal [Spatial Concept]

Phrase: "is"

Phrase: "involved in neurotoxicity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0235032:Neurotoxicity [Injury or Poisoning]
   790   C1314939:Involved [Functional Concept]

Phrase: "(49"

Phrase: ")."
Processing 00000000.tx.284: This notion is consistent with the result of the present study. 

Phrase: "This notion"

Phrase: "is"

Phrase: "consistent with the result of the present study."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0332290:Consistent with [Idea or Concept]
           Consistent
Processing 00000000.tx.285: In accordance with this hypothesis, chemical modifications of residues located in the N-terminal region of notexin led to a decrease in its lethal properties (50, 51). 

Phrase: "In accordance with this hypothesis,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1512571:Hypothesis [Idea or Concept]

Phrase: "chemical modifications of residues"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   737   C0392747:Modification [Functional Concept]
   737   C1554963:modification [Qualitative Concept]

Phrase: "located in the N-terminal region of notexin"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   744   C0017446:Region [Geographic Area]
   744   C0069043:notexin [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
   744   C0205088:Terminal [Temporal Concept]
   744   C0205147:Region [Spatial Concept]
   744   C1705314:Terminal [Manufactured Object]
   744   C1705315:Terminal [Spatial Concept]

Phrase: "led to a decrease"
Meta Candidates (Total=8; Excluded=5; Pruned=0; Remaining=3)
   770   C0392756:Decrease [Qualitative Concept]
   770   C0547047:Decrease [Quantitative Concept]
   770   C1708698:LED [Manufactured Object]
   737 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   737 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   737 E C1522538:Lead [Functional Concept]
   737 E C2348269:Lead [Element, Ion, or Isotope]
   737 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "in its lethal properties"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0871161:properties [Qualitative Concept]
   861   C1292721:properties [Functional Concept]
   827 E C1882134:Property [Conceptual Entity]
   827 E C2347695:Property [Entity]

Phrase: "(50,"

Phrase: "51"

Phrase: ")."
Processing 00000000.tx.286: However, other studies also based on sequence comparisons have suggested that the hydrophobic region located at the C-terminal end (residues 80-110) of neurotoxic sPLA2s is involved in neurotoxicity (52). 

Phrase: "However,"

Phrase: "other studies also"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "based on sequence comparisons"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   802   C0004793:Base Sequence [Nucleotide Sequence]
           Sequence
   770   C0162326:Sequence [Nucleotide Sequence]
   770   C0162327:Sequence [Nucleotide Sequence]
   770   C1519249:Sequence [Functional Concept]
   770   C1527178:Based [Functional Concept]
   770   C1705938:Based [Idea or Concept]
   737 E C0002055:base [Inorganic Chemical]
   737 E C0178499:Base [Chemical Viewed Functionally]
   737   C1707455:Comparison [Activity]
   737 E C1880279:Base [Biomedical or Dental Material]

Phrase: "have"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the hydrophobic region"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0017446:Region [Geographic Area]
   861   C0205147:Region [Spatial Concept]
   789 E C0205276:Regional [Spatial Concept]
   789 E C1947913:Regional [Spatial Concept]

Phrase: "located at the C-terminal end (residues 80-110"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   764   C1707271:C-Terminal [Amino Acid Sequence]
   742   C0205088:Terminal [Temporal Concept]
   742   C0444930:End [Spatial Concept]
   742   C1705314:Terminal [Manufactured Object]
   742   C1705315:Terminal [Spatial Concept]
   742   C2746065:End [Temporal Concept]
   708   C1709915:Residue [Conceptual Entity]
   708   C1882936:RESIDUE [Phenomenon or Process]

Phrase: ")"

Phrase: "of neurotoxic sPLA2s"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   923   C2756983:Phospholipases A2, Secretory [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031667:Phospholipases A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "is"

Phrase: "involved in neurotoxicity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0235032:Neurotoxicity [Injury or Poisoning]
   790   C1314939:Involved [Functional Concept]

Phrase: "(52"

Phrase: ")."
Processing 00000000.tx.287: This second hypothesis is supported by results of chemical modifications of notexin on tryptophan residues (53) and by immunological approaches using antipeptide antibodies directed against the C-terminal part of ammodytoxin A and crotoxin (54, 55). 

Phrase: "This second hypothesis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1512571:Hypothesis [Idea or Concept]

Phrase: "is"

Phrase: "supported by results of chemical modifications of notexin"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   744   C0069043:notexin [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
   744   C0220806:Chemical [Chemical]
   744   C1521721:Supported [Conceptual Entity]
   744   C3272558:Chemical [Intellectual Product]
   711 E C0183683:Support [Medical Device]
   711   C0392747:Modification [Functional Concept]
   711   C1274040:Result [Functional Concept]
   711   C1546471:Result [Idea or Concept]
   711   C1554963:modification [Qualitative Concept]
   711   C2825142:Result [Finding]

Phrase: "on tryptophan residues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C1709915:Residue [Conceptual Entity]
   827   C1882936:RESIDUE [Phenomenon or Process]
   777 E C1609982:Residual [Qualitative Concept]

Phrase: "(53"

Phrase: ")"

Phrase: "and by immunological approaches"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0205470:Immunological [Functional Concept]
   770   C0449445:Approaches [Spatial Concept]
   770   C1292724:Approaches [Functional Concept]
   770   C1515981:And [Idea or Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "antipeptide antibodies"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "directed against the C-terminal part of ammodytoxin A"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   764   C0103055:ammodytoxin A [Biologically Active Substance,Hazardous or Poisonous Substance]
   764   C1292711:Part of [Spatial Concept]
   764   C1707271:C-Terminal [Amino Acid Sequence]
   762   C0051701:ammodytoxin C [Biologically Active Substance,Hazardous or Poisonous Substance]
   742   C0205088:Terminal [Temporal Concept]
   742   C0449719:Part [Spatial Concept]
   742   C1705314:Terminal [Manufactured Object]
   742   C1705315:Terminal [Spatial Concept]
   742   C1709471:Part [Quantitative Concept]
   708   C0439851:Direct [Qualitative Concept]
   708   C1947931:Direct [Qualitative Concept]

Phrase: "and"

Phrase: "crotoxin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010377:Crotoxin [Amino Acid, Peptide, or Protein,Enzyme,Hazardous or Poisonous Substance]

Phrase: "(54,"

Phrase: "55"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450382:55 [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.288: In conclusion, this work has shown that residues of the IRS of bvPLA2 (Ca2+-binding loop and 76-91 helix) are implicated both in binding to N-type receptors and in neurotoxicity, strongly suggesting that toxicity is related to binding to N-type receptors. 

Phrase: "In conclusion,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusion [Idea or Concept]

Phrase: "this work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "has"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that residues of the IRS of bvPLA2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   708   C1709915:Residue [Conceptual Entity]
   708   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "(Ca2+-binding loop"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0243122:binding [Functional Concept]
   827   C0419518:Loop [Medical Device]
   827   C0445022:Loop [Spatial Concept]
   827   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1145667:Binding [Activity]
   827   C1167622:Binding [Molecular Function]

Phrase: "and"

Phrase: "76-91 helix"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0018882:Helix [Eukaryote]
   827   C0229304:Helix [Body Part, Organ, or Organ Component]
   827   C1704821:Helix [Spatial Concept]
   827   C1705682:Helix [Anatomical Structure]

Phrase: ")"

Phrase: "are"

Phrase: "implicated"

Phrase: "both in binding"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0238767:Both [Spatial Concept]
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]
   790   C1706086:Both [Qualitative Concept]

Phrase: "to N-type receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "and in neurotoxicity,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0235032:Neurotoxicity [Injury or Poisoning]
   790   C1515981:And [Idea or Concept]

Phrase: "strongly"

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that toxicity"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0040539:toxicity [Qualitative Concept]
  1000   C0600688:Toxicity [Injury or Poisoning]
   928 E C1407029:Toxic [Qualitative Concept]
   907 E C0032346:Poison [Hazardous or Poisonous Substance]
   907 E C1548769:Poison [Intellectual Product]
   907 E C1550590:poison [Idea or Concept]

Phrase: "is"

Phrase: "related to binding"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   790   C0243122:binding [Functional Concept]
   790   C0439849:Related [Qualitative Concept]
   790   C0445223:Related [Finding]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]
   756 E C0163712:Relate [Organic Chemical]

Phrase: "to N-type receptors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.289: Whether other venom sPLA2s belonging to group I/II also use similar residues to bind to N-type receptors and to exert neurotoxicity remains to be elucidated. 

Phrase: "Whether"

Phrase: "other venom sPLA2s belonging to group I/II also"

Phrase: "use"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042153:use [Functional Concept]
  1000   C0457083:Use [Functional Concept]
  1000   C1947944:Use [Intellectual Product]

Phrase: "similar residues to"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   793   C1709915:Residue [Conceptual Entity]
   793   C1882936:RESIDUE [Phenomenon or Process]
   743 E C1609982:Residual [Qualitative Concept]

Phrase: "bind to N-type receptors"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0332307:Type [Qualitative Concept]
   760   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   760   C1145667:Bind [Activity]
   760   C1167622:bind [Molecular Function]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "exert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015264:exert [Organism Function]

Phrase: "neurotoxicity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0235032:Neurotoxicity [Injury or Poisoning]

Phrase: "remains"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "elucidated."
Processing 00000000.tx.290: FOOTNOTES * This work was supported in part by the Centre National de la Recherche Scientifique (CNRS), Ministre de la Dfense Nationale Grant DRET 93/122, National Institutes of Health Grant HL36235, and by an "Unrestricted Award" from the Bristol Myers Squibb Co.

Phrase: "FOOTNOTES"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2825232:Footnote [Intellectual Product]

Phrase: "*"

Phrase: "This work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "was"

Phrase: "supported in part"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0449719:Part [Spatial Concept]
   790   C1521721:Supported [Conceptual Entity]
   790   C1709471:Part [Quantitative Concept]
   756 E C0183683:Support [Medical Device]

Phrase: "by the Centre National de la Recherche Scientifique (CNRS),"

Phrase: "Ministre de la Dfense Nationale Grant DRET 93/122,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   791   C0011198:DE [Geographic Area]
   791   C0017480:DE [Geographic Area]
   791   C0018173:Grant [Quantitative Concept]
   791   C0023031:La [Element, Ion, or Isotope]
   791   C1548284:Grant [Idea or Concept]
   791   C3541240:DE [Idea or Concept]

Phrase: "National Institutes of Health Grant HL36235,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C0027468:National Institutes of Health [Health Care Related Organization]

Phrase: "and by an ""Unrestricted Award"""
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0004446:Award [Manufactured Object]
   760   C1515981:And [Idea or Concept]

Phrase: "from the Bristol Myers Squibb Co."
Processing 00000000.tx.291: The costs of publication of this article were defrayed in part by the payment of page charges. 

Phrase: "The costs of publication of this article"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0010186:Costs [Quantitative Concept]
   748   C0220812:Costs [Quantitative Concept]

Phrase: "were"

Phrase: "defrayed in part"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0449719:Part [Spatial Concept]
   790   C1709471:Part [Quantitative Concept]

Phrase: "by the payment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0220808:payment [Quantitative Concept]
  1000   C0680264:payment [Quantitative Concept]

Phrase: "of page charges."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0007961:Charges [Quantitative Concept]
   827 E C1706211:Charge [Organism Attribute]
Processing 00000000.tx.292: The article must therefore be hereby marked "advertisement" in accordance with 18U.S.C. 

Phrase: "The article"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706852:Article [Intellectual Product]

Phrase: "must"

Phrase: "therefore"

Phrase: "be"

Phrase: "hereby"

Phrase: "marked"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0522501:Marked [Qualitative Concept]
  1000   C1706089:Marked [Qualitative Concept]

Phrase: """advertisement"""
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0949214:advertisement [Intellectual Product]

Phrase: "in accordance with 18U.S.C."
Processing 00000000.tx.293: Section 1734 solely to indicate this fact.  

Phrase: "Section 1734 solely to"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   812   C0205155:Section [Spatial Concept]
   812   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   812   C1522472:Section [Substance]
   812   C1552923:Section [Quantitative Concept]
   812   C1705191:Section [Physical Object]

Phrase: "indicate"

Phrase: "this fact."
Processing 00000000.tx.294: Recipient of a grant DRET from the Dlgation Gnrale pour l'Armement, Ministre de la Dfense Nationale.  

Phrase: "Recipient of a grant DRET"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1709854:Recipient [Human]

Phrase: "from the Dlgation Gnrale"

Phrase: "pour"

Phrase: "l'Armement,"

Phrase: "Ministre de la Dfense Nationale."
Processing 00000000.tx.295: The first three authors contributed equally to this work. 

Phrase: "The first three authors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0221193:Authors [Professional or Occupational Group]

Phrase: "contributed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1880177:Contribute [Activity]

Phrase: "equally to this work."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0043227:Work [Occupational Activity]
Processing 00000000.tx.296: ** To whom correspondence should be addressed: Inst. de Pharmacologie Molculaire et Cellulaire, CNRS, 660Route des Lucioles, Sophia Antipolis, 06560Valbonne, France. 

Phrase: "*"

Phrase: "*"

Phrase: "To whom correspondence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282413:Correspondence [Intellectual Product]

Phrase: "should"

Phrase: "be"

Phrase: "addressed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0376649:Address [Intellectual Product]
   966   C1442065:Address [Spatial Concept]

Phrase: ":"

Phrase: "Inst. de Pharmacologie Molculaire et Cellulaire,"

Phrase: "CNRS,"

Phrase: "660Route des Lucioles,"

Phrase: "Sophia Antipolis,"

Phrase: "06560Valbonne,"

Phrase: "France."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016674:France [Geographic Area]
Processing 00000000.tx.297: Tel.:33-4-93-95-77-00 (or 02or 03); 

Phrase: "Tel.:33-4-93-95-77-00"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   795   C0254343:TEL [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0796520:TEL [Gene or Genome]
   795   C3272379:TEL [Intellectual Product]

Phrase: "("

Phrase: "or"

Phrase: "02or 03"

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.298: Fax: 33-4-93-95-77-04; 

Phrase: "Fax"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0085205:Fax [Manufactured Object]
  1000   C1549619:FAX [Conceptual Entity]
  1000   C1880669:Fax [Manufactured Object]

Phrase: ":"

Phrase: "33-4-93-95-77-04"

Phrase: ";"
Processing 00000000.tx.299: E-mail: ipmc{at}unice.fr (for Prof. Lazdunski) or Dept. of Chemistry and Biochemistry, University of Washington, Seattle, WA 98195-1700.Tel.:206-543-7142; 

Phrase: "E-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "ipmc{at}unice.fr (for Prof. Lazdunski"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C2348513:Fr. [Conceptual Entity]
   748   C3538902:FR [Gene or Genome]

Phrase: ")"

Phrase: "or"

Phrase: "Dept."

Phrase: "of Chemistry"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0007996:Chemistry [Occupation or Discipline]
  1000   C0079107:chemistry [Classification]
  1000   C0201682:Chemistry [Laboratory Procedure]

Phrase: "and"

Phrase: "Biochemistry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005477:Biochemistry [Occupation or Discipline]

Phrase: "University of Washington,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0041740:University [Manufactured Object,Organization]
   827   C0043038:Washington [Geographic Area]

Phrase: "Seattle,"

Phrase: "WA 98195-1700.Tel.:206-543-7142"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   795   C0043038:WA [Geographic Area]
   795   C0254343:TEL [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   795   C0796520:TEL [Gene or Genome]
   795   C3272379:TEL [Intellectual Product]

Phrase: ";"
Processing 00000000.tx.300: Fax: 206-685-8665; 

Phrase: "Fax"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0085205:Fax [Manufactured Object]
  1000   C1549619:FAX [Conceptual Entity]
  1000   C1880669:Fax [Manufactured Object]

Phrase: ":"

Phrase: "206-685-8665"

Phrase: ";"
Processing 00000000.tx.301: E-mail: gelb{at}chem.washington.edu (for Prof. Gelb). 

Phrase: "E-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "gelb{at}chem.washington.edu"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0059804:EDU [Organic Chemical,Pharmacologic Substance]

Phrase: "("

Phrase: "for Prof. Gelb"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0165519:GELB [Amino Acid, Peptide, or Protein,Enzyme]
   861   C1334523:GELB [Gene or Genome]
   861   C1708832:GELB [Gene or Genome]

Phrase: ")."
Processing 00000000.tx.302: 1 The abbreviations used are: sPLA2(s), secretory phospholipase(s) A2; 

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "The abbreviations"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0000723:Abbreviations [Intellectual Product]

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "are"

Phrase: ":"

Phrase: "sPLA2(s"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1418616:SPLA2 [Gene or Genome]
   861   C1706169:sPLA2 [Gene or Genome]

Phrase: ")"

Phrase: ","

Phrase: "secretory phospholipase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0031671:Phospholipase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "("

Phrase: "s)"

Phrase: "A2"

Phrase: ";"
Processing 00000000.tx.303: bvPLA2, bee venom phospholipase A2; 

Phrase: "bvPLA2,"

Phrase: "bee venom phospholipase A2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031667:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   861   C1744635:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3539768:Phospholipase A2 [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031671:Phospholipase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: ";"
Processing 00000000.tx.304: PCR, polymerase chain reaction; 

Phrase: "PCR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
  1000   C0677874:pCR [Finding]

Phrase: "polymerase chain reaction"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0337112:Chain [Manufactured Object]
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]
   827   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C1524075:Chain [Idea or Concept]

Phrase: ";"
Processing 00000000.tx.305: IRS, interfacial recognition surface; 

Phrase: "IRS,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205148:Surface [Spatial Concept]

Phrase: "interfacial recognition surface"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205148:Surface [Spatial Concept]

Phrase: ";"
Processing 00000000.tx.306: Tricine, N-[2hydroxy-1, 1-bis(hydroxymethyl)ethyl]glycine. 

Phrase: "Tricine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0077068:tricine [Organic Chemical]

Phrase: "N-[2hydroxy-1,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441922:N+ [Intellectual Product]
   827   C1553036:[n] [Quantitative Concept]

Phrase: "1-bis("
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0556985:BIS [Temporal Concept]
   861   C2247301:BIS [Molecular Function]
   861   C3540495:BIS [Intellectual Product]

Phrase: "hydroxymethyl"

Phrase: ")"

Phrase: "ethyl"

Phrase: "]glycine."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017890:Glycine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
  1000   C0522461:Glycine [Plant]
Processing 00000000.tx.307: Acknowledgments We are very grateful to Drs. 

Phrase: "Acknowledgments"

Phrase: "We"

Phrase: "are"

Phrase: "very grateful to Drs."
Processing 00000000.tx.308: Thomas Dudler and Robert Annand for constructing some of the mutants used in this study and to Prof. 

Phrase: "Thomas Dudler"

Phrase: "and"

Phrase: "Robert Annand for constructing"

Phrase: "some of the mutants"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205392:Some [Quantitative Concept]
   770   C0596988:mutants [Cell or Molecular Dysfunction]
   770   C3540770:Some [Intellectual Product]

Phrase: "used in this study"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   802   C0869040:study use [Research Activity]
   770   C0557651:Study [Manufactured Object]
   770   C1273517:used [Finding]
   770   C2603343:Study [Research Activity]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]

Phrase: "and to Prof."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0599518:Prof. [Professional or Occupational Group]
   790   C1515981:And [Idea or Concept]
Processing 00000000.tx.309: Andr Vandermeers and Prof. 

Phrase: "Andr Vandermeers"

Phrase: "and"

Phrase: "Prof."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0599518:Prof. [Professional or Occupational Group]
Processing 00000000.tx.310: Jean Christophe, Universit Libre de Bruxelles, for the generous gift of Pa2 and Pa5 from the venom of Heloderma suspectum. 

Phrase: "Jean Christophe,"

Phrase: "Universit Libre de Bruxelles,"

Phrase: "for the generous gift"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   789   C0423899:Gifted [Finding]

Phrase: "of Pa2"

Phrase: "and"

Phrase: "Pa5 from the venom of Heloderma suspectum."
Processing 00000000.tx.311: We thank Dr Minh Vuong for help with the representation of bvPLA2 structure and Nathalie Gomez and Dahvya Doume for their most skillful assistance. 

Phrase: "We"

Phrase: "thank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986676:THANK [Gene or Genome]

Phrase: "Dr Minh Vuong for"

Phrase: "help with the representation of bvPLA2 structure"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0018896:Help [Social Behavior]
   748   C0678594:Structure [Spatial Concept]
   748   C1514861:Representation [Conceptual Entity]
   748   C1552861:help [Idea or Concept]
   748   C1882932:Representation [Activity]

Phrase: "and"

Phrase: "Nathalie Gomez"

Phrase: "and"

Phrase: "Dahvya Doume for their most skillful assistance."
Processing 00000000.tx.312: We thank Prof. 

Phrase: "We"

Phrase: "thank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986676:THANK [Gene or Genome]

Phrase: "Prof."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0599518:Prof. [Professional or Occupational Group]
Processing 00000000.tx.313: C.

Phrase: "C."
Processing 00000000.tx.314: Verlinde for assistance with the MolScript and GRASP programs. 

Phrase: "Verlinde for assistance"

Phrase: "with the MolScript"

Phrase: "and"

Phrase: "GRASP programs."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0376691:Programs [Intellectual Product]
   861   C3484370:Programs [Functional Concept]
   827 E C1709697:Program [Conceptual Entity]
   827 E C2728259:Program [Pharmacologic Substance]
Processing 00000000.tx.315: REFERENCES Verheij, H. 

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Verheij,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.316: M., Slotboom, A. 

Phrase: "M."

Phrase: ","

Phrase: "Slotboom,"

Phrase: "A."
Processing 00000000.tx.317: J., and De Haas, G. 

Phrase: "J.,"

Phrase: "and"

Phrase: "De Haas,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1828470:HAA [Cell Component]

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.318: (1981) Rev. 

Phrase: "(1981"

Phrase: ")"

Phrase: "Rev."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347961:Rev. [Professional or Occupational Group]
Processing 00000000.tx.319: Physiol. 

Phrase: "Physiol."
Processing 00000000.tx.320: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.321: Pharmacol. 

Phrase: "Pharmacol."
Processing 00000000.tx.322: 91, 91-203 [Medline] [OrderarticleviaInfotrieve] Dennis, E. 

Phrase: "91,"

Phrase: "91-203"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Dennis,"

Phrase: "E."
Processing 00000000.tx.323: A. 

Phrase: "A."
Processing 00000000.tx.324: (1994) J. 

Phrase: "(1994"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.325: Biol. 

Phrase: "Biol."
Processing 00000000.tx.326: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.327: 269, 13057-13060 [Free FullText] Gelb, M. 

Phrase: "269,"

Phrase: "13057-13060"

Phrase: "[Free FullText"

Phrase: "] Gelb,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0165519:GELB [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1334523:GELB [Gene or Genome]
  1000   C1708832:GELB [Gene or Genome]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.328: H., Jain, M. 

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Jain,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0337694:Jain [Idea or Concept]
  1000   C1998092:Jain [Population Group]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.329: K., Hanel, A. 

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Hanel,"

Phrase: "A."
Processing 00000000.tx.330: M., and Berg, O. 

Phrase: "M."

Phrase: ","

Phrase: "and"

Phrase: "Berg,"

Phrase: "O."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]
Processing 00000000.tx.331: G. 

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.332: (1995) Annu. 

Phrase: "(1995"

Phrase: ")"

Phrase: "Annu."
Processing 00000000.tx.333: Rev. 

Phrase: "Rev."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347961:Rev. [Professional or Occupational Group]
Processing 00000000.tx.334: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.335: 64, 653-688 [CrossRef][Medline] [OrderarticleviaInfotrieve] Heinrikson, R. 

Phrase: "64,"

Phrase: "653-688"

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Heinrikson,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.336: L., Krueger, E. 

Phrase: "L., Krueger,"

Phrase: "E."
Processing 00000000.tx.337: T., and Keim, P. 

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "and"

Phrase: "Keim,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.338: S. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.339: (1977) J. 

Phrase: "(1977"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.340: Biol. 

Phrase: "Biol."
Processing 00000000.tx.341: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.342: 252, 4913-4921 [Abstract] Davidson, F. 

Phrase: "252,"

Phrase: "4913-4921"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Davidson,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.343: F., and Dennis, E. 

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "and"

Phrase: "Dennis,"

Phrase: "E."
Processing 00000000.tx.344: A. 

Phrase: "A."
Processing 00000000.tx.345: (1990) J. 

Phrase: "(1990"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.346: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.347: Evol. 

Phrase: "Evol."
Processing 00000000.tx.348: 31, 228-238 [Medline] [OrderarticleviaInfotrieve] Scott, D. 

Phrase: "31,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: "228-238"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Scott,"

Phrase: "D."
Processing 00000000.tx.349: L., and Sigler, P. 

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "and"

Phrase: "Sigler,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.350: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.351: (1994) Adv. 

Phrase: "(1994"

Phrase: ")"

Phrase: "Adv."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001483:ADV [Virus]
Processing 00000000.tx.352: Protein Chem. 

Phrase: "Protein Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.353: 45, 53-88 [Medline] [OrderarticleviaInfotrieve] Pruzanski, W., and Vadas, P. 

Phrase: "45,"

Phrase: "53-88"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Pruzanski,"

Phrase: "W.,"

Phrase: "and"

Phrase: "Vadas,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.354: (1991) Immunol. 

Phrase: "(1991"

Phrase: ")"

Phrase: "Immunol."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.355: Today 12, 143-146 [Medline] [OrderarticleviaInfotrieve] Kramer, R. 

Phrase: "Today 12,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0310367:Today [Antibiotic,Organic Chemical]
   861   C0750526:Today [Temporal Concept]

Phrase: "143-146"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Kramer,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0331847:Kramer [Health Care Related Organization]

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.356: M. 

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.357: (1993) in Cell Signalling: Biology and Medicine of Signal Transduction (Brown, B. L., and Dobson, P. R.M., eds), pp. 

Phrase: "(1993"

Phrase: ")"

Phrase: "in Cell Signalling"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C3537152:signalling [Biologic Function]
   793 E C1710082:Signal [Phenomenon or Process]

Phrase: ":"

Phrase: "Biology"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0005532:Biology [Biomedical Occupation or Discipline]
   928 E C0205460:Biologic [Qualitative Concept]
   928 E C2979985:BIOLOGIC [Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "Medicine of Signal Transduction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0013227:Medicine, NOS [Pharmacologic Substance]
   770   C0025118:Medicine [Biomedical Occupation or Discipline]

Phrase: "(Brown,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "B. L.,"

Phrase: "and"

Phrase: "Dobson,"

Phrase: "P. R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "M."

Phrase: ","

Phrase: "eds"

Phrase: ")"

Phrase: ","

Phrase: "pp."
Processing 00000000.tx.358: 81-89, Raven Press, New York Kudo, I., Murakami, M., Hara, S., and Inoue, K. 

Phrase: "81-89,"

Phrase: "Raven Press,"

Phrase: "New York Kudo,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C0027976:New York [Geographic Area]

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Murakami,"

Phrase: "M."

Phrase: ","

Phrase: "Hara,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2758676:Hara [Fish]

Phrase: "S."

Phrase: ","

Phrase: "and"

Phrase: "Inoue,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.359: (1993) Biochim. 

Phrase: "(1993"

Phrase: ")"

Phrase: "Biochim."
Processing 00000000.tx.360: Biophys. 

Phrase: "Biophys."
Processing 00000000.tx.361: Acta 1170, 217-231 [Medline] [OrderarticleviaInfotrieve] Vadas, P., Browning, J., Edelson, J., and Pruzanski, W. 

Phrase: "Acta 1170,"

Phrase: "217-231"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Vadas,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Browning,"

Phrase: "J.,"

Phrase: "Edelson,"

Phrase: "J.,"

Phrase: "and"

Phrase: "Pruzanski,"

Phrase: "W."
Processing 00000000.tx.362: (1993) J. 

Phrase: "(1993"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.363: Lipid Mediators 8, 1-30 [Medline] [OrderarticleviaInfotrieve] Mukherjee, A. 

Phrase: "Lipid Mediators 8,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   884   C0599745:lipid mediator [Biologically Active Substance]
   827   C0023779:Lipid [Lipid]
   827   C0127400:mediators [Organic Chemical,Pharmacologic Substance]
   793 E C1363844:Mediator [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "1-30"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2827734:1+ [Quantitative Concept]
   861   C2981698:1+ [Classification]

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Mukherjee,"

Phrase: "A."
Processing 00000000.tx.364: B., Miele, L., and Pattabiraman, N. 

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Miele,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "and"

Phrase: "Pattabiraman,"

Phrase: "N."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]
Processing 00000000.tx.365: (1994) Biochem. 

Phrase: "(1994"

Phrase: ")"

Phrase: "Biochem."
Processing 00000000.tx.366: Pharmacol. 

Phrase: "Pharmacol."
Processing 00000000.tx.367: 48, 1-10 [CrossRef][Medline] [OrderarticleviaInfotrieve] Arita, H., Hanasaki, K., Nakano, T., Oka, S., Teraoka, H., and Matsumoto, K. 

Phrase: "48,"

Phrase: "1-10"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2827734:1+ [Quantitative Concept]
   861   C2981698:1+ [Classification]

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Arita,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2811087:Arita [Eukaryote]

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Hanasaki,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Nakano,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Oka,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0069389:OKA [Hazardous or Poisonous Substance,Organic Chemical]

Phrase: "S."

Phrase: ","

Phrase: "Teraoka,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Matsumoto,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.368: (1991) J. 

Phrase: "(1991"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.369: Biol. 

Phrase: "Biol."
Processing 00000000.tx.370: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.371: 266, 19139-19141 [Abstract/Free FullText] Nakajima, M., Hanasaki, K., Ueda, M., and Arita, H. 

Phrase: "266,"

Phrase: "19139-19141"

Phrase: "[Abstract/Free FullText"

Phrase: "] Nakajima,"

Phrase: "M."

Phrase: ","

Phrase: "Hanasaki,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Ueda,"

Phrase: "M."

Phrase: ","

Phrase: "and"

Phrase: "Arita,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2811087:Arita [Eukaryote]

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.372: (1992) FEBS Lett. 

Phrase: "(1992"

Phrase: ")"

Phrase: "FEBS Lett."
Processing 00000000.tx.373: 309, 261-264 [CrossRef][Medline] [OrderarticleviaInfotrieve] Sommers, C. 

Phrase: "309,"

Phrase: "261-264"

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Sommers,"

Phrase: "C."
Processing 00000000.tx.374: D., Bobbitt, J. 

Phrase: "D."

Phrase: ","

Phrase: "Bobbitt,"

Phrase: "J."
Processing 00000000.tx.375: L., Bemis, K. 

Phrase: "L., Bemis,"

Phrase: "K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.376: G., and Snyder, D. 

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "and"

Phrase: "Snyder,"

Phrase: "D."
Processing 00000000.tx.377: W. 

Phrase: "W."
Processing 00000000.tx.378: (1992) Eur. 

Phrase: "(1992"

Phrase: ")"

Phrase: "Eur."
Processing 00000000.tx.379: J.

Phrase: "J."
Processing 00000000.tx.380: Pharmacol. 

Phrase: "Pharmacol."
Processing 00000000.tx.381: 216, 87-96 [Medline] [OrderarticleviaInfotrieve] Vadas, P., Pruzanski, W., Kim, J., and Fornasier, V. 

Phrase: "216,"

Phrase: "87-96"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Vadas,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Pruzanski,"

Phrase: "W.,"

Phrase: "Kim,"

Phrase: "J.,"

Phrase: "and"

Phrase: "Fornasier,"

Phrase: "V."
Processing 00000000.tx.382: (1989) Am. 

Phrase: "(1989"

Phrase: ")"

Phrase: "Am."
Processing 00000000.tx.383: J.Pathol. 

Phrase: "J.Pathol."
Processing 00000000.tx.384: 134, 807-811 [Abstract] Kini, R. 

Phrase: "134,"

Phrase: "807-811"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Kini,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.385: M., and Evans, H. 

Phrase: "M."

Phrase: ","

Phrase: "and"

Phrase: "Evans,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.386: J. 

Phrase: "J."
Processing 00000000.tx.387: (1989) Toxicon 27, 613-635 [Medline] [OrderarticleviaInfotrieve] Hawgood, B., and Bon, C. 

Phrase: "(1989"

Phrase: ")"

Phrase: "Toxicon 27,"

Phrase: "613-635"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Hawgood,"

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "and"

Phrase: "Bon,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1552041:Bon [Idea or Concept]
  1000   C2986536:BON [Disease or Syndrome]

Phrase: "C."
Processing 00000000.tx.388: (1991) in Handbook of Natural Toxins (Tu, A. T., ed), pp. 

Phrase: "(1991"

Phrase: ")"

Phrase: "in Handbook"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596654:handbook [Intellectual Product]

Phrase: "of Natural Toxins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0040549:Toxins [Biologically Active Substance,Hazardous or Poisonous Substance]

Phrase: "(Tu,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1532464:TU [Quantitative Concept]
  1000   C2700314:TU [Fish]

Phrase: "A. T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "ed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538926:ED [Idea or Concept]

Phrase: ")"

Phrase: ","

Phrase: "pp."
Processing 00000000.tx.389: 3-52, Marcel Dekker, Inc., New York Strong, P. 

Phrase: "3-52,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439086:<3 [Quantitative Concept]
   861   C2827736:3+ [Quantitative Concept]
   861   C2981702:3+ [Classification]

Phrase: "Marcel Dekker,"

Phrase: "Inc.,"

Phrase: "New York Strong, P."
Processing 00000000.tx.390: N. 

Phrase: "N."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]
Processing 00000000.tx.391: (1987) in Cellular and Molecular Basis of Cholinergic Function (Dowdall, M. J., and Hawthorne, J. N., eds), pp. 

Phrase: "(1987"

Phrase: ")"

Phrase: "in Cellular"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0007634:Cellular [Cell]
  1000   C0178539:Cellular [Functional Concept]
   928 E C1516377:Cellularity [Qualitative Concept]

Phrase: "and"

Phrase: "Molecular Basis of Cholinergic Function"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C1853126:MOLECULAR BASIS [Idea or Concept]
   760   C1527178:Basis [Functional Concept]
   760   C1874451:Basis [Pharmacologic Substance]

Phrase: "(Dowdall,"

Phrase: "M. J.,"

Phrase: "and"

Phrase: "Hawthorne,"

Phrase: "J. N., eds"

Phrase: ")"

Phrase: ","

Phrase: "pp."
Processing 00000000.tx.392: 534-549, Ellis Horwoods, Chichester, UK Lambeau, G., Barhanin, J., Schweitz, H., Qar, J., and Lazdunski, M. 

Phrase: "534-549,"

Phrase: "Ellis Horwoods,"

Phrase: "Chichester,"

Phrase: "UK Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Barhanin,"

Phrase: "J.,"

Phrase: "Schweitz,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Qar,"

Phrase: "J.,"

Phrase: "and"

Phrase: "Lazdunski,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.393: (1989) J. 

Phrase: "(1989"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.394: Biol. 

Phrase: "Biol."
Processing 00000000.tx.395: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.396: 264, 11503-11510 [Abstract/Free FullText] Lambeau, G., Schmid-Alliana, A., Lazdunski, M., and Barhanin, J. 

Phrase: "264,"

Phrase: "11503-11510"

Phrase: "[Abstract/Free FullText"

Phrase: "] Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Schmid-Alliana,"

Phrase: "A.,"

Phrase: "Lazdunski,"

Phrase: "M."

Phrase: ","

Phrase: "and"

Phrase: "Barhanin,"

Phrase: "J."
Processing 00000000.tx.397: (1990) J. 

Phrase: "(1990"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.398: Biol. 

Phrase: "Biol."
Processing 00000000.tx.399: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.400: 265, 9526-9532 [Abstract/Free FullText] Lambeau, G., Ancian, P., Barhanin, J., and Lazdunski, M. 

Phrase: "265,"

Phrase: "9526-9532"

Phrase: "[Abstract/Free FullText"

Phrase: "] Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Ancian,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Barhanin,"

Phrase: "J.,"

Phrase: "and"

Phrase: "Lazdunski,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.401: (1994) J. 

Phrase: "(1994"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.402: Biol. 

Phrase: "Biol."
Processing 00000000.tx.403: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.404: 269, 1575-1578 [Abstract/Free FullText] Ishizaki, J., Hanasaki, K., Higashino, K., Kishino, J., Kikuchi, N., Ohara, O., and Arita, H. 

Phrase: "269,"

Phrase: "1575-1578"

Phrase: "[Abstract/Free FullText"

Phrase: "] Ishizaki,"

Phrase: "J.,"

Phrase: "Hanasaki,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Higashino,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Kishino,"

Phrase: "J.,"

Phrase: "Kikuchi,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Ohara,"

Phrase: "O.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]

Phrase: "and"

Phrase: "Arita,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2811087:Arita [Eukaryote]

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.405: (1994) J. 

Phrase: "(1994"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.406: Biol. 

Phrase: "Biol."
Processing 00000000.tx.407: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.408: 269, 5897-5904 [Abstract/Free FullText] Higashino, K., Ishizaki, J., Kishino, J., Ohara, O., and Arita, H. 

Phrase: "269,"

Phrase: "5897-5904"

Phrase: "[Abstract/Free FullText"

Phrase: "] Higashino,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Ishizaki,"

Phrase: "J.,"

Phrase: "Kishino,"

Phrase: "J.,"

Phrase: "Ohara,"

Phrase: "O.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]

Phrase: "and"

Phrase: "Arita,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2811087:Arita [Eukaryote]

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.409: (1994) Eur. 

Phrase: "(1994"

Phrase: ")"

Phrase: "Eur."
Processing 00000000.tx.410: J.

Phrase: "J."
Processing 00000000.tx.411: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.412: 225, 375-382 [Abstract] Ancian, P., Lambeau, G., Matti, M.-G., and Lazdunski, M. 

Phrase: "225,"

Phrase: "375-382"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Ancian,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Matti,"

Phrase: "M.-"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "and"

Phrase: "Lazdunski,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.413: (1995) J. 

Phrase: "(1995"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.414: Biol. 

Phrase: "Biol."
Processing 00000000.tx.415: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.416: 270, 8963-8970 [Abstract/Free FullText] Ishizaki, J., Kishino, J., Teraoka, H., Ohara, O., and Arita, H. 

Phrase: "270,"

Phrase: "8963-8970"

Phrase: "[Abstract/Free FullText"

Phrase: "] Ishizaki,"

Phrase: "J.,"

Phrase: "Kishino,"

Phrase: "J.,"

Phrase: "Teraoka,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Ohara,"

Phrase: "O.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]

Phrase: "and"

Phrase: "Arita,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2811087:Arita [Eukaryote]

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.417: (1993) FEBS Lett. 

Phrase: "(1993"

Phrase: ")"

Phrase: "FEBS Lett."
Processing 00000000.tx.418: 324, 349-52 [CrossRef][Medline] [OrderarticleviaInfotrieve] Ancian, P., Lambeau, G., and Lazdunski, M. 

Phrase: "324,"

Phrase: "349-52"

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Ancian,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "and"

Phrase: "Lazdunski,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.419: (1995) Biochemistry 34, 13146-13151 [Medline] [OrderarticleviaInfotrieve] Zvaritch, E., Lambeau, G., and Lazdunski, P. 

Phrase: "(1995"

Phrase: ")"

Phrase: "Biochemistry 34,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005477:Biochemistry [Occupation or Discipline]

Phrase: "13146-13151"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Zvaritch,"

Phrase: "E.,"

Phrase: "Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "and"

Phrase: "Lazdunski,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.420: (1996) J. 

Phrase: "(1996"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.421: Biol. 

Phrase: "Biol."
Processing 00000000.tx.422: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.423: 271, 250-257 [Abstract/Free FullText] Lambeau, G., Ancian, P., Nicolas, J.-P., Beiboer, S. 

Phrase: "271,"

Phrase: "250-257"

Phrase: "[Abstract/Free FullText"

Phrase: "] Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Ancian,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Nicolas,"

Phrase: "J.-P.,"

Phrase: "Beiboer,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.424: H.W., Moinier, D., Verheij, H., and Lazdunski, M. 

Phrase: "H.W., Moinier,"

Phrase: "D."

Phrase: ","

Phrase: "Verheij,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Lazdunski,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.425: (1995) J. 

Phrase: "(1995"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.426: Biol. 

Phrase: "Biol."
Processing 00000000.tx.427: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.428: 270, 5534-5540 [Abstract/Free FullText] Nicolas, J.-P., Lambeau, G., and Lazdunski, M. 

Phrase: "270,"

Phrase: "5534-5540"

Phrase: "[Abstract/Free FullText"

Phrase: "] Nicolas,"

Phrase: "J.-P.,"

Phrase: "Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "and"

Phrase: "Lazdunski,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.429: (1995) J. 

Phrase: "(1995"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.430: Biol. 

Phrase: "Biol."
Processing 00000000.tx.431: Chem. 

Phrase: "Chem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]
Processing 00000000.tx.432: 270, 28869-28873 [Abstract/Free FullText] Ohara, O., Ishizaki, J., and Arita, H. 

Phrase: "270,"

Phrase: "28869-28873"

Phrase: "[Abstract/Free FullText"

Phrase: "] Ohara,"

Phrase: "O.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]

Phrase: "Ishizaki,"

Phrase: "J.,"

Phrase: "and"

Phrase: "Arita,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2811087:Arita [Eukaryote]

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.433: (1995) Prog. 

Phrase: "(1995"

Phrase: ")"

Phrase: "Prog."
Processing 00000000.tx.434: Lipid Res. 

Phrase: "Lipid Res."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347379:RES [Finding]
Processing 00000000.tx.435: 34, 117-138 [CrossRef][Medline] [OrderarticleviaInfotrieve] Lambeau, G., Lazdunski, M., and Barhanin, J. 

Phrase: "34,"

Phrase: "117-138"

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Lazdunski,"

Phrase: "M."

Phrase: ","

Phrase: "and"

Phrase: "Barhanin,"

Phrase: "J."
Processing 00000000.tx.436: (1991) Neurochem. 

Phrase: "(1991"

Phrase: ")"

Phrase: "Neurochem."
Processing 00000000.tx.437: Res. 

Phrase: "Res."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347379:RES [Finding]
Processing 00000000.tx.438: 16, 651-658 [Medline] [OrderarticleviaInfotrieve] Lambeau, G., and Lazdunski, M. 

Phrase: "16,"

Phrase: "651-658"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "and"

Phrase: "Lazdunski,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.439: (1996) in Venom Phospholipase A2 Enzymes: Structure, Function and Mechanism (Kini, R. M., ed), John Wiley &Sons, Chichester, UK Gandolfo, G., Lambeau, G., Lazdunski, M., and Gottesmann, C. 

Phrase: "(1996"

Phrase: ")"

Phrase: "in Venom Phospholipase A2 Enzymes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0014442:Enzymes [Enzyme,Organic Chemical]
   812   C0014445:enzymes [Functional Concept]

Phrase: ":"

Phrase: "Structure,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678594:Structure [Spatial Concept]

Phrase: "Function"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0031843:function [Physiologic Function]
  1000   C0542341:Function [Functional Concept]
  1000   C0700205:FUNCTION [Classification]
  1000   C1705273:Function [Intellectual Product]
   928 E C0205245:Functional [Functional Concept]
   928 E C2700217:Functional [Conceptual Entity]

Phrase: "and"

Phrase: "Mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0441712:Mechanism [Functional Concept]
  1000   C1706376:Mechanism [Manufactured Object]

Phrase: "(Kini,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "M."

Phrase: ","

Phrase: "ed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538926:ED [Idea or Concept]

Phrase: ")"

Phrase: ","

Phrase: "John Wiley &Sons,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0037683:Son [Family Group]

Phrase: "Chichester,"

Phrase: "UK Gandolfo,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Lazdunski,"

Phrase: "M."

Phrase: ","

Phrase: "and"

Phrase: "Gottesmann,"

Phrase: "C."
Processing 00000000.tx.440: (1996) Pharmacol. 

Phrase: "(1996"

Phrase: ")"

Phrase: "Pharmacol."
Processing 00000000.tx.441: &Toxicol. 

Phrase: "&Toxicol."
Processing 00000000.tx.442: 78, 341-347 [Medline] [OrderarticleviaInfotrieve] Fossier, P., Lambeau, G., Lazdunski, M., and Baux, G. 

Phrase: "78,"

Phrase: "341-347"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Fossier,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Lambeau,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Lazdunski,"

Phrase: "M."

Phrase: ","

Phrase: "and"

Phrase: "Baux,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.443: (1995) J. 

Phrase: "(1995"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.444: Physiol. 

Phrase: "Physiol."
Processing 00000000.tx.445: (Lond.) 

Phrase: "(Lond."

Phrase: ")"
Processing 00000000.tx.446: 489, 29-40 [Abstract] Scott, D. 

Phrase: "489,"

Phrase: "29-40"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439509:/40 [Temporal Concept]

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Scott,"

Phrase: "D."
Processing 00000000.tx.447: L., Otwinowski, Z., Gelb, M. 

Phrase: "L., Otwinowski,"

Phrase: "Z.,"

Phrase: "Gelb,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0165519:GELB [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1334523:GELB [Gene or Genome]
  1000   C1708832:GELB [Gene or Genome]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.448: H., and Sigler, P. 

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Sigler,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.449: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.450: (1990) Science 250, 1563-1566 [Medline] [OrderarticleviaInfotrieve] Dudler, T., Chen, W. 

Phrase: "(1990"

Phrase: ")"

Phrase: "Science 250,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036397:Science [Occupation or Discipline]

Phrase: "1563-1566"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Dudler,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Chen,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0999213:Chen [Bird]

Phrase: "W."
Processing 00000000.tx.451: Q., Wang, S., Schneider, T., Annand, R. 

Phrase: "Q., Wang,"

Phrase: "S."

Phrase: ","

Phrase: "Schneider,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Annand,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.452: R., Dempcy, R. 

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Dempcy,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.453: O., Crameri, R., Gmachl, M., Suter, M., and Gelb, M. 

Phrase: "O.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]

Phrase: "Crameri,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Gmachl,"

Phrase: "M."

Phrase: ","

Phrase: "Suter,"

Phrase: "M."

Phrase: ","

Phrase: "and"

Phrase: "Gelb,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0165519:GELB [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1334523:GELB [Gene or Genome]
  1000   C1708832:GELB [Gene or Genome]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.454: H. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.455: (1992) Biochim. 

Phrase: "(1992"

Phrase: ")"

Phrase: "Biochim."
Processing 00000000.tx.456: Biophys. 

Phrase: "Biophys."
Processing 00000000.tx.457: Acta 1165, 201-210 [Medline] [OrderarticleviaInfotrieve] Kim, S.(1991) Master thesis, University of Washington Ghomashchi, F., Schuttel, S., Jain, M. 

Phrase: "Acta 1165,"

Phrase: "201-210"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Kim,"

Phrase: "S.("

Phrase: "1991"

Phrase: ")"

Phrase: "Master thesis,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681489:master thesis [Intellectual Product]
   861   C0039828:thesis [Intellectual Product]

Phrase: "University of Washington Ghomashchi,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Schuttel,"

Phrase: "S."

Phrase: ","

Phrase: "Jain,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0337694:Jain [Idea or Concept]
  1000   C1998092:Jain [Population Group]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.458: K., and Gelb, M. 

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "and"

Phrase: "Gelb,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0165519:GELB [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1334523:GELB [Gene or Genome]
  1000   C1708832:GELB [Gene or Genome]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.459: H. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.460: (1991) Biochemistry 30, 9559-9569 [Medline] [OrderarticleviaInfotrieve] Bayburt, T., Yu, B.-Z., Street, I., Ghomashchi, F., Laliberte, F., Perrier, H., Wang, Z., Homan, R., Jain, M. 

Phrase: "(1991"

Phrase: ")"

Phrase: "Biochemistry 30,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005477:Biochemistry [Occupation or Discipline]

Phrase: "9559-9569"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Bayburt,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Yu,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1006780:yu [Plant]

Phrase: "B.-Z.,"

Phrase: "Street,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0442658:Street [Manufactured Object]
  1000   C1301826:Street [Finding]

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Ghomashchi,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Laliberte,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Perrier,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Wang,"

Phrase: "Z.,"

Phrase: "Homan,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Jain,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0337694:Jain [Idea or Concept]
  1000   C1998092:Jain [Population Group]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.461: K., and Gelb, M. 

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "and"

Phrase: "Gelb,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0165519:GELB [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1334523:GELB [Gene or Genome]
  1000   C1708832:GELB [Gene or Genome]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.462: H. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.463: (1995) Anal. 

Phrase: "(1995"

Phrase: ")"

Phrase: "Anal."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0003461:Anal [Body Part, Organ, or Organ Component]
  1000   C2939124:Anal [Spatial Concept]
Processing 00000000.tx.464: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.465: 232, 7-23 [CrossRef][Medline] [OrderarticleviaInfotrieve] Lehmann, A. 

Phrase: "232,"

Phrase: "7-23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450348:23 [Quantitative Concept]

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Lehmann,"

Phrase: "A."
Processing 00000000.tx.466: (1974) Atlas Strotaxique du Cerveau de la Souris, Editions du Centre National de la Recherche Scientifique, Paris, France Shipolini, R. 

Phrase: "(1974"

Phrase: ")"

Phrase: "Atlas Strotaxique du Cerveau de la Souris,"

Phrase: "Editions du Centre National de la Recherche Scientifique,"

Phrase: "Paris,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0030561:Paris [Geographic Area]
  1000   C0331677:Paris [Plant]
  1000   C1824032:PARIS [Gene or Genome]
   966 E C1824369:PARI [Gene or Genome]

Phrase: "France Shipolini,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.467: A., Callewaert, G. 

Phrase: "A.,"

Phrase: "Callewaert,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.468: L., Cottrell, R. 

Phrase: "L., Cottrell,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.469: C., and Vernon, C. 

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "and"

Phrase: "Vernon,"

Phrase: "C."
Processing 00000000.tx.470: A. 

Phrase: "A."
Processing 00000000.tx.471: (1974) Eur. 

Phrase: "(1974"

Phrase: ")"

Phrase: "Eur."
Processing 00000000.tx.472: J.

Phrase: "J."
Processing 00000000.tx.473: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.474: 48, 465-76 [Medline] [OrderarticleviaInfotrieve] Kubelka, V., Altmann, F., Staudacher, E., Tretter, V., Marz, L., Hard, K., Kamerling, J. 

Phrase: "48,"

Phrase: "465-76"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Kubelka,"

Phrase: "V.,"

Phrase: "Altmann,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Staudacher,"

Phrase: "E.,"

Phrase: "Tretter,"

Phrase: "V.,"

Phrase: "Marz,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Hard,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0018599:Hard [Qualitative Concept]

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Kamerling,"

Phrase: "J."
Processing 00000000.tx.475: P., and Vliegenthart, J. 

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "and"

Phrase: "Vliegenthart,"

Phrase: "J."
Processing 00000000.tx.476: F. 

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.477: (1993) Eur. 

Phrase: "(1993"

Phrase: ")"

Phrase: "Eur."
Processing 00000000.tx.478: J.

Phrase: "J."
Processing 00000000.tx.479: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.480: 213, 1193-1204 [Abstract] Scott, D. 

Phrase: "213,"

Phrase: "1193-1204"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Scott,"

Phrase: "D."
Processing 00000000.tx.481: L., White, S. 

Phrase: "L., White,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0007457:White [Population Group]
   861   C0043157:White [Population Group]
   861   C0220938:White [Qualitative Concept]

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.482: P., Otwinowski, Z., Yuan, W., Gelb, M. 

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Otwinowski,"

Phrase: "Z.,"

Phrase: "Yuan,"

Phrase: "W.,"

Phrase: "Gelb,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0165519:GELB [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1334523:GELB [Gene or Genome]
  1000   C1708832:GELB [Gene or Genome]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.483: H., and Sigler, P. 

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Sigler,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.484: B. 

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.485: (1990) Science 250, 1541-1546 [Medline] [OrderarticleviaInfotrieve] Annand, R. 

Phrase: "(1990"

Phrase: ")"

Phrase: "Science 250,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036397:Science [Occupation or Discipline]

Phrase: "1541-1546"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Annand,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.486: R., Kontoyianni, M., Penzotti, J. 

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Kontoyianni,"

Phrase: "M."

Phrase: ","

Phrase: "Penzotti,"

Phrase: "J."
Processing 00000000.tx.487: E., Dudler, T., Lybrand, T. 

Phrase: "E.,"

Phrase: "Dudler,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Lybrand,"

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]
Processing 00000000.tx.488: P., and Gelb, M. 

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "and"

Phrase: "Gelb,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0165519:GELB [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1334523:GELB [Gene or Genome]
  1000   C1708832:GELB [Gene or Genome]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.489: H. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.490: (1996) Biochemistry 35, 4591-4601 [CrossRef][Medline] [OrderarticleviaInfotrieve] Gomez, F., Vandermeers, A., Vandermeers-Piret, M. 

Phrase: "(1996"

Phrase: ")"

Phrase: "Biochemistry 35,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005477:Biochemistry [Occupation or Discipline]

Phrase: "4591-4601"

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Gomez,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Vandermeers,"

Phrase: "A.,"

Phrase: "Vandermeers-Piret,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.491: C., Herzog, R., Rathe, J., Stievenart, M., Winand, J., and Christophe, J. 

Phrase: "C., Herzog,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Rathe,"

Phrase: "J.,"

Phrase: "Stievenart,"

Phrase: "M."

Phrase: ","

Phrase: "Winand,"

Phrase: "J.,"

Phrase: "and"

Phrase: "Christophe,"

Phrase: "J."
Processing 00000000.tx.492: (1989) Eur. 

Phrase: "(1989"

Phrase: ")"

Phrase: "Eur."
Processing 00000000.tx.493: J.

Phrase: "J."
Processing 00000000.tx.494: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.495: 186, 23-33 [Abstract] Vandermeers, A., Vandermeers-Piret, M. 

Phrase: "186,"

Phrase: "23-33"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450348:23 [Quantitative Concept]

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Vandermeers,"

Phrase: "A.,"

Phrase: "Vandermeers-Piret,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.496: C., Vigneron, L., Rathe, J., Stievenart, M., and Christophe, J. 

Phrase: "C., Vigneron,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Rathe,"

Phrase: "J.,"

Phrase: "Stievenart,"

Phrase: "M."

Phrase: ","

Phrase: "and"

Phrase: "Christophe,"

Phrase: "J."
Processing 00000000.tx.497: (1991) Eur. 

Phrase: "(1991"

Phrase: ")"

Phrase: "Eur."
Processing 00000000.tx.498: J.

Phrase: "J."
Processing 00000000.tx.499: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.500: 196, 537-544 [Abstract] Sosa, B. 

Phrase: "196,"

Phrase: "537-544"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Sosa,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.501: P., Alagon, A. 

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Alagon,"

Phrase: "A."
Processing 00000000.tx.502: C., Martin, B. 

Phrase: "C., Martin,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.503: M., and Possani, L. 

Phrase: "M."

Phrase: ","

Phrase: "and"

Phrase: "Possani,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.504: D. 

Phrase: "D."
Processing 00000000.tx.505: (1986) Biochemistry 25, 2927-2933 [Medline] [OrderarticleviaInfotrieve] Lotan, A., Fishman, L., Loya, Y., and Zlotkin, E. 

Phrase: "(1986"

Phrase: ")"

Phrase: "Biochemistry 25,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005477:Biochemistry [Occupation or Discipline]

Phrase: "2927-2933"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Lotan,"

Phrase: "A.,"

Phrase: "Fishman,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Loya,"

Phrase: "Y.,"

Phrase: "and"

Phrase: "Zlotkin,"

Phrase: "E."
Processing 00000000.tx.506: (1995) Nature 375, 456 [Medline] [OrderarticleviaInfotrieve] Tsai, I. 

Phrase: "(1995"

Phrase: ")"

Phrase: "Nature 375,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0349590:Nature [Idea or Concept]
   861   C1262865:Nature [Functional Concept]
   789 E C0205296:Natural [Functional Concept]

Phrase: "456"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Tsai,"

Phrase: "I."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.507: H., Liu, H. 

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Liu,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.508: C., and Chang, T. 

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "and"

Phrase: "Chang,"

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]
Processing 00000000.tx.509: (1987) Biochim. 

Phrase: "(1987"

Phrase: ")"

Phrase: "Biochim."
Processing 00000000.tx.510: Biophys. 

Phrase: "Biophys."
Processing 00000000.tx.511: Acta 916, 94-99 [Medline] [OrderarticleviaInfotrieve] Rosenberg, P., Ghassemi, A., Condrea, E., Dhillon, D., and Yang, C. 

Phrase: "Acta 916,"

Phrase: "94-99"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Rosenberg,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979969:Rosenberg [Spatial Concept]

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Ghassemi,"

Phrase: "A.,"

Phrase: "Condrea,"

Phrase: "E.,"

Phrase: "Dhillon,"

Phrase: "D."

Phrase: ","

Phrase: "and"

Phrase: "Yang,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945617:yang [Idea or Concept]

Phrase: "C."
Processing 00000000.tx.512: C. 

Phrase: "C."
Processing 00000000.tx.513: (1989) Toxicon 27, 137-159 [Medline] [OrderarticleviaInfotrieve] Yang, C. 

Phrase: "(1989"

Phrase: ")"

Phrase: "Toxicon 27,"

Phrase: "137-159"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Yang,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945617:yang [Idea or Concept]

Phrase: "C."
Processing 00000000.tx.514: C., and Chang, L. 

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "and"

Phrase: "Chang,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.515: S. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.516: (1991) Biochem. 

Phrase: "(1991"

Phrase: ")"

Phrase: "Biochem."
Processing 00000000.tx.517: J. 

Phrase: "J."
Processing 00000000.tx.518: 280, 739-744 [Medline] [OrderarticleviaInfotrieve] Kini, R. 

Phrase: "280,"

Phrase: "739-744"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Kini,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.519: M., and Iwanaga, S. 

Phrase: "M."

Phrase: ","

Phrase: "and"

Phrase: "Iwanaga,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.520: (1986) Toxicon 24, 527-541 [Medline] [OrderarticleviaInfotrieve] Mollier, P., Chwetzoff, S., Bouet, F., Harvey, A. 

Phrase: "(1986"

Phrase: ")"

Phrase: "Toxicon 24,"

Phrase: "527-541"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Mollier,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Chwetzoff,"

Phrase: "S."

Phrase: ","

Phrase: "Bouet,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Harvey,"

Phrase: "A."
Processing 00000000.tx.521: L., and Menez, A. 

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "and"

Phrase: "Menez,"

Phrase: "A."
Processing 00000000.tx.522: (1989) Eur. 

Phrase: "(1989"

Phrase: ")"

Phrase: "Eur."
Processing 00000000.tx.523: J.

Phrase: "J."
Processing 00000000.tx.524: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.525: 185, 263-270 [Abstract] Curin-Serbec, V., Novak, D., Babnik, J., Turk, D., and Gubensek, F. 

Phrase: "185,"

Phrase: "263-270"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Curin-Serbec,"

Phrase: "V.,"

Phrase: "Novak,"

Phrase: "D."

Phrase: ","

Phrase: "Babnik,"

Phrase: "J.,"

Phrase: "Turk,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0337911:Turk [Population Group]

Phrase: "D."

Phrase: ","

Phrase: "and"

Phrase: "Gubensek,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.526: (1991) FEBS Lett. 

Phrase: "(1991"

Phrase: ")"

Phrase: "FEBS Lett."
Processing 00000000.tx.527: 280, 175-178 [CrossRef][Medline] [OrderarticleviaInfotrieve] Curin-Serbec, V., Delot, E., Faure, G., Saliou, B., Gubensek, F., Bon, C., and Choumet, V. 

Phrase: "280,"

Phrase: "175-178"

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Curin-Serbec,"

Phrase: "V.,"

Phrase: "Delot,"

Phrase: "E.,"

Phrase: "Faure,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Saliou,"

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Gubensek,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Bon,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1552041:Bon [Idea or Concept]
  1000   C2986536:BON [Disease or Syndrome]

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "and"

Phrase: "Choumet,"

Phrase: "V."
Processing 00000000.tx.528: (1994) Toxicon 32, 1337-1348 [Medline] [OrderarticleviaInfotrieve] Kraulis, P. 

Phrase: "(1994"

Phrase: ")"

Phrase: "Toxicon 32,"

Phrase: "1337-1348"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Kraulis,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.529: J. 

Phrase: "J."
Processing 00000000.tx.530: (1991) J. 

Phrase: "(1991"

Phrase: ")"

Phrase: "J."
Processing 00000000.tx.531: Appl. 

Phrase: "Appl."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1858559:APPL [Gene or Genome]
Processing 00000000.tx.532: Crystallogr. 

Phrase: "Crystallogr."
Processing 00000000.tx.533: 24, 946-950 [CrossRef] 1997 by The American Society for Biochemistry and Molecular Biology, Inc.

Phrase: "24,"

Phrase: "946-950"

Phrase: "[CrossRef"

Phrase: "] 1997 by The American Society"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0037455:society [Organization]
   760   C0596070:American [Population Group]

Phrase: "for Biochemistry"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005477:Biochemistry [Occupation or Discipline]

Phrase: "and"

Phrase: "Molecular Biology,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0026376:Molecular Biology [Biomedical Occupation or Discipline]
   861   C0005532:Biology [Biomedical Occupation or Discipline]
   861   C1521991:Molecular [Qualitative Concept]
   789 E C0205460:Biologic [Qualitative Concept]
   789 E C0567416:Molecule [Substance]
   789 E C2979985:BIOLOGIC [Biologically Active Substance,Pharmacologic Substance]

Phrase: "Inc."

